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Summary 
 
The identification of the molecular targets and mechanisms underpinning the beneficial or 
detrimental effects of small-molecule leads and drugs constitutes a crucial aspect of current drug 
discovery. Over the last two decades, three-hybrid (3H) systems have progressively taken an 
important position in the armamentarium of target protein profiling technologies for small 
molecules. MASPIT (mammalian small molecule-protein interaction trap) is a mammalian three-
hybrid (M3H) system that enables the identification of cytosolic target proteins of small molecules of 
interest in intact human cells. MASPIT is the 3H component of the MAPPIT (mammalian protein-
protein interaction trap) technology platform, an approach that uses the JAK-STAT pathway that 
mediates cytokine receptor (CR) signaling. MASPIT employs E. coli dihydrofolate reductase (eDHFR), 
fused to a mutated, functionally inactivated, CR to present a methotrexate (MTX) fusion compound 
(MFC) to the intracellular environment. This allows screening of a small-molecule bait against a 
collection of chimeric prey proteins. As a result of the interaction between the small-molecule bait 
and a target prey protein, the JAK-STAT pathway is activated, resulting in the expression of a reporter 
gene. 
 
A prerequisite for successful MASPIT analysis is the availability of appropriate bifunctional small-
molecule probes, capable of artificially bringing two (chimeric) proteins together to form a stable 
ternary complex. A comprehensive overview of these so-called chemical inducers of dimerization 
(CIDs) specifically applied in both yeast three-hybrid (Y3H) and M3H systems for small molecule-
target protein profiling is provided in Chapter 1. Furthermore, examples for typical components of 
chemical dimerizers for 3H systems are discussed. Additionally, a number of variations on the 
classical 3H themes as well as 3H-based screening platforms are illustrated.  
 
The aim of this thesis was to optimize the performance of MASPIT from a medicinal chemical 
perspective. Chapter 3 describes a versatile, clickable MTX reagent that allows swift -selective 
conjugation to yield MFCs appropriate for MASPIT. The general applicability of the reagent was 
demonstrated using three structurally diverse pharmacologically active compounds, i.e. tamoxifen, 
reversine, and FK506. In analytical mode, MASPIT produced concentration-dependent reporter 
signals for the established target proteins of these model baits. Furthermore, in a proof-of-concept 
experiment, the FK506 MFC was explored in a cell array screen for targets of FK506. Out of a pilot 
collection of nearly 2000 full-length human ORF (open reading frame) preys, FKBP12 was selectively 
identified as an interaction partner of FK506, thereby further validating the MASPIT system and 
showing its potential towards uncovering new intracellular targets of small molecules of interest. 
 
Two alternative chemical dimerizer approaches aimed at increasing the sensitivity of MASPIT are 
evaluated in Chapter 4. To circumvent any potential limitations related to the tight binding of MTX to 
endogenous human DHFR, trimethoprim (TMP) was explored as an alternative prokaryote-specific 
eDHFR ligand. MASPIT evaluation of TMP fusion compounds (TFCs) with tamoxifen, reversine, and 
simvastatin as model baits, resulted in dose-response curves being shifted towards lower EC50 values 
than those of their MTX congeners. Additionally, a scalable TMP-azido reagent was synthesized that 
displayed a similar improvement in sensitivity, possibly owing to increased membrane permeability 
relative to the MTX anchor. 
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Furthermore, to stabilize the ternary complex (CR-CID-Prey), the concept of covalent bonding was 
introduced into MASPIT, which hitherto relied on reversible interactions of either component of the 
dimerizers. As a starting point, a fusion compound was explored that allows selective and covalent 
immobilization to the CR by using a SNAP-tag-based system. Unexpectedly, this approach did not 
yield the hypothesized increase in sensitivity, as the O6-benzylguanine-tamoxifen heterodimerizer 
produced an inferior read-out compared to its MTX or TMP congeners.  
 
In a next step, the implementation of covalent bonding on the bait-end of the dimerizers was 
explored, as described in Chapter 5. For this purpose, the optimized TMP-azido reagent was 
equipped with a double ligation handle that enabled sequential introduction of both the tamoxifen 
pilot bait and photoactivatable crosslinkers, thereby affording heterotrimeric photoaffinity labeling 
(PAL) probes. However, evaluation of these PAL probes in MASPIT turned out to be less 
straightforward than anticipated and no clear-cut proof of effective photocrosslinking was obtained 
thus far. 
Therefore, taking a short cut, a test system based on a panel of irreversible and reversible EGFR 
kinase inhibitor TFCs was explored to assess the contribution of covalent bait-prey interactions to the 
MASPIT read-out. Unfortunately, preliminary biological experiments yielded contradictory outcomes, 
which warrant further investigation. 
 
Finally, Chapter 7 is dedicated to the discussion and critical evaluation of MASPIT, and 3H systems in 
general, within the broader context of the most frequently applied strategies to small-molecule 
target deconvolution in chemical biology and drug discovery research. Furthermore, the relevance 
and potential of 3H approaches is discussed. To conclude, future perspectives regarding anchor 
moieties and conjugation methods applicable to the synthesis of chemical dimerizers for 3H 
applications are outlined. 
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Samenvatting ─ Summary in Dutch 
 
De identificatie van de moleculaire doelwitten en mechanismen, die aan de basis liggen van de 
gunstige en schadelijke effecten van kleine therapeutische lead verbindingen en geneesmiddelen, is 
cruciaal in geneesmiddelenontdekking. In de afgelopen twee decennia hebben drie-hybride (3H) 
systemen een belangrijke positie ingenomen in het arsenaal van technologieën die het 
interactieprofiel van kleine moleculen met hun doelwiteiwitten onderzoeken. MASPIT (mammalian 
small molecule-protein interaction trap) is een zoogdier-gebaseerd 3H systeem dat de identificatie 
van cytosolische doelwiteiwitten van interessante kleine moleculen mogelijk maakt in intacte 
humane cellen. MASPIT is een 3H component van het MAPPIT (mammalian protein-protein 
interaction trap) technologieplatform, een systeem dat gebruik maakt van de JAK-STAT cascade, die 
cytokine receptor (CR) signalisatie medieert. MASPIT gebruikt E. coli dihydrofolaatreductase (eDHFR) 
dat gefuseerd is aan een gemuteerde, functioneel geïnactiveerde CR om een methotrexaat (MTX) 
fusiecomponent (MFC) aan het intracellulaire milieu aan te bieden. Dit laat toe om een kleine 
lokaasmolecule te screenen tegen een collectie van chimere prooi-eiwitten. De interactie tussen de 
kleine lokaasmolecule en een doelwit-prooiproteïne resulteert in activatie van de JAK-STAT cascade 
en daaropvolgende expressie van een reportergen. 
 
Voor succesvolle MASPIT analyse dient men te beschikken over geschikte bifunctionele synthetische 
probes, die in staat zijn om twee (chimere) eiwitten artificieel samen te brengen ter vorming van een 
stabiel ternair complex. Een uitvoerig overzicht van deze zogenaamde chemische induceerders van 
dimerisatie (CIDs) die tot op heden specifiek aangewend werden in zowel gist- als zoogdier-
gebaseerde 3H systemen voor het in kaart brengen van kleine molecuul-doelwitproteïne interacties 
is weergeven in Hoofdstuk 1. Verder worden voorbeelden van de typische componenten van 
chemische dimerizeerders voor 3H systemen besproken. Daarnaast worden enkele variaties op de 
klassieke 3H systemen, alsook 3H-gebaseerde screeningsplatformen toegelicht. 
 
De doelstelling van dit proefschrift was het optimaliseren van de performantie van MASPIT vanuit 
een medicinaal chemische invalshoek. Hoofdstuk 3 beschrijft de ontwikkeling van een veelzijdig MTX 
reagens dat via click-chemie snelle, -selectieve conjugatie toelaat ter vorming van MFCs die geschikt 
zijn voor toepassing in MASPIT. De algemene toepasselijkheid van het reagens werd aangetoond 
voor drie structureel uiteenlopende farmacologisch actieve verbindingen, namelijk tamoxifen, 
reversine, en FK506. In analytische modus produceerde MASPIT concentratieafhankelijke 
reportersignalen voor de gekende doelwiteiwitten van deze model lokaasmoleculen. Voorts werd, in 
een proof-of-concept experiment, de FK506 MFC onderworpen aan een cel array screen, op zoek 
naar doelwitten van FK506. Uit een initiële collectie van nagenoeg 2000 full-length humane ORF 
(open reading frame) prooi-eiwitten werd FKBP12 selectief geïdentificeerd als interactiepartner van 
FK506. Zo werd het MASPIT systeem verder gevalideerd, alsook zijn vermogen om nieuwe 
intracellulaire doelwitten van kleine therapeutische verbindingen te onthullen. 
 
Hoofdstuk 4 beschrijft de synthese en evaluatie van twee alternatieve CIDs, die als doel hebben de 
gevoeligheid van MASPIT te verhogen. Om de potentiële beperkingen gerelateerd aan de sterke 
binding van MTX aan endogeen humaan DHFR te omzeilen, werd trimethoprim (TMP) als alternatief 
prokaryoot-specifiek eDHFR ligand onderzocht. MASPIT evaluatie van TMP fusiecomponenten (TFCs) 
met tamoxifen, reversine, en simvastatine als model lokaasmoleculen, resulteerde in verschuiving 
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van de dosis-respons curves naar lagere EC50 waarden in vergelijking met de corresponderende MTX 
analogen. Bijkomend werd een schaalbaar TMP-azido reagens gesynthetiseerd dat een gelijkaardige 
verbetering in gevoeligheid vertoonde, mogelijks toe te schrijven aan zijn verhoogde 
membraanpermeabiliteit ten opzichte van het MTX anker. 
Met het oog op het stabiliseren van het ternaire complex (CR-CID-prooiproteïne), werd verder het 
concept van covalentie onderzocht in MASPIT, dat tot dusver gestoeld was op reversibele interacties 
van elk van de componenten van de dimerizeerders. Als vertrekpunt werd getracht de 
fusiecomponent selectief en covalent te immobiliseren op de CR door middel van een SNAP-tag-
gebaseerd systeem. Deze strategie leverde onverwachts niet de veronderstelde toename in 
gevoeligheid op, gezien de O6-benzylguanine-tamoxifen heterodimerizeerder een lagere readout 
produceerde vergeleken met zijn MTX of TMP analogen. 
 
In een volgende fase werd de implementatie van covalentie aan de kant van de lokaasmolecule van 
de dimerizeerders onderzocht, zoals uiteengezet in Hoofdstuk 5. Hiertoe werd het geoptimaliseerde 
TMP-azido reagens uitgerust met een dubbel ligatie-handvat dat sequentiële invoering van zowel het 
tamoxifen modellokaas als fotoactiveerbare crosslinkers mogelijk maakte. Deze synthesestrategie 
leverde heterotrimere fotoaffiniteitslabeling (PAL) probes op. Echter, de evaluatie van deze PAL 
probes in MASPIT bleek minder voor de hand liggend dan vooropgesteld en tot dusver werd geen 
uitgesproken bewijs van effectieve fotocrosslinking verkregen. 
Daarom werd besloten een shortcut te nemen en een testsysteem, gebaseerd op een reeks 
irreversibele en reversibele EGFR kinase inhibitor TFCs, te ontwikkelen om de bijdrage van covalente 
lokaas-prooi interacties tot de MASPIT readout te bepalen. Helaas leverden preliminaire biologische 
experimenten tegenstrijdige resultaten op, die verder onderzoek vereisen. 
 
Tot slot worden in Hoofdstuk 7 MASPIT, en 3H systemen in het algemeen, kritisch besproken en 
geëvalueerd binnen de bredere context van de meest frequent toegepaste strategieën voor target 
identificatie van kleine therapeutische verbindingen in het onderzoeksdomein van de chemische 
biologie en geneesmiddelenontdekking. Voorts worden de relevantie en het potentieel van 3H 
systemen uiteengezet. Ten slotte worden enkele toekomstperspectieven geschetst met betrekking 
tot immobiliserende groepen en conjugatiemethoden, toepasbaar voor de synthese van chemische 
dimerizeerders voor drie-hybride toepassingen. 
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Chapter I: General introduction 
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I. Chemical Dimerizers in Three-Hybrid Systems for Small Molecule-Target Protein Profiling 
 
I.1. Introduction 
 
Drug discovery research has mainly relied on two strategies to identify potential drug candidates, 
molecular and empirical approaches.[1] The latter relate to phenotypic screening, which implies the 
measurement of phenotypic responses to small bioactive modulators in complex biological systems, 
such as intact cells, isolated organs or model organisms. Traditional, unbiased phenotype-based drug 
discovery has been applied for over a century and successfully led to the development of numerous 
important drugs.[2] However, with molecular biology and biochemistry moving to the center stage 
since the genomics era in the 1990s,[3] drug discovery predominantly concentrated on molecular 
approaches. These include hypothesis-driven target-based approaches in which compounds that 
interact with a validated (protein) target are identified via high-throughput screening. Subsequently, 
these hit compounds are optimized with respect to potency, selectivity and ADME-Tox properties in 
further stages of the drug discovery process (Figure I.1). 
 
 
 
Figure I.1: Schematic diagram of phenotype-based versus target-based drug discovery. The phenotype-based 
approach is initiated by hit and lead discovery, followed by identification of the molecular targets that underlie 
their observed phenotypic effects. The target-based strategy starts from validated targets to identify hits and 
leads via extensive assays and screenings. Figure from: Nature Reviews Drug Discovery 2007, 6 (11), 891-903. 
 
Yet, many clinically approved drugs have been found to be more promiscuous than originally 
thought, with every drug interacting on average with six targets.[4] Therefore, the ‘one gene, one 
drug, one disease’ core assumption that frames target-based drug discovery is largely outdated.[5] 
Furthermore, phenotypic screening initially was suggested to be the more successful strategy for the 
discovery of small-molecule, first-in-class drugs in an era in which the major focus was on targets (i.e. 
1999-2008).[6] Indeed, target-based approaches for first-in-class drugs were postulated to be the root 
cause for high attrition rates and low productivity, which pharmaceutical R&D is currently facing. This 
was attributed to the fact that target-based screening focuses narrowly on a particular target, 
thereby inherently failing to address the molecular complexities underlying drug action.[7],[1] 
 
However, a recent analysis of the origins of all first-in-class drugs approved by the US Food and Drug 
Administration (FDA) from 1999 to 2013 significantly deviates from this previous report,[1],[6] as it 
shows that the majority (70%) were discovered through target-based approaches.[8] This discrepancy 
originates from several factors. Firstly, the important five year extension over the former analysis 
(i.e. 2013 vs. 2008) illustrates that owing to the long time frames of drug development, the relatively 
new technologies underpinning target-based approaches (such as the sequencing of the human 
genome) may only be starting to substantially affect drug approvals and some even suggest that the 
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best is yet to come.[8] Secondly, different terminologies and definitions have been used to describe 
the drug discovery approaches, phenotypic screening in particular, which influences interpretation of 
the data. Nevertheless, elucidating the exact origin of new drugs is less important to drive drug 
development than establishing the causal links between target engagement, molecular effects on cell 
biology and the desired phenotypic response.[9] Toward this end, current drug discovery programs 
should not rely on one single screening approach, but rather combine them sensibly and productively 
in order to deliver drugs with optimal efficacy/safety as recently exemplified by the introduction of 
the ‘mechanism-informed phenotypic drug discovery’ (MIPDD) paradigm in the oncology field, which 
implies a mechanistically defined, clinically relevant phenotypic screening and ensuing optimization 
approach.[9] This way phenotypic screening might contribute by expanding the discovery scope from 
a single molecular target to multiple processes, signaling pathways and complex molecular functions 
related to untreated or understudied diseases.[10] The subsequent identification of the target 
spectrum of active hits discovered in such phenotypic screens, i.e. target deconvolution, constitutes 
an important aspect of current drug discovery.[11],[12]  
 
Over the past decades, numerous case studies within the target profiling field that apply, for 
example, chemical proteomics-based methods have proved successful. However, despite these 
success stories, to date target identification often remains an important bottleneck in drug discovery, 
as a generally applicable methodology is still lacking.[13],[14] In case the target protein of interest is low 
abundant or unstable, expression-cloning-based methods, such as yeast[15] and mammalian[16] three-
hybrid systems, can be a valuable alternative to classical pulldown approaches.[12] However, a 
conditio sine qua non for successful three-hybrid analysis is the availability of appropriate 
bifunctional small-molecule probes, capable of artificially bringing two proteins together to form a 
stable ternary complex - termed chemical inducers of dimerization (CIDs),[17] or chemical dimerizers. 
Thorough reviews providing a broader overview on CID applications[18],[19],[20] as well as those 
summarizing yeast ‘N’-hybrid systems[21],[22] have been recently published. However, reports 
elaborating on a combination of these themes, more specifically the use of CIDs in three-hybrid 
systems, are scarce and go back more than a decade.[23] Therefore, in this chapter we aim to fill this 
gap, focusing on the design of CIDs and their specific application in both yeast and mammalian three-
hybrid systems for small molecule-target protein profiling within the broader scope of target 
deconvolution and drug discovery. 
 
I.2. Chemically induced dimerization 
 
The ability to bind two proteins or protein domains simultaneously represents the main 
characteristic of chemical inducers of dimerization. Homodimerizers are symmetrical bifunctional 
ligands that act to bring two identical proteins together. If two different proteins are recognized, the 
molecules are referred to as heterodimerizers.[18] Historically, mechanism of action studies on the 
immunosuppressive drugs FK506, rapamycin and cyclosporin A (CsA) initiated the development of 
the concept of chemically induced dimerization.[24] These studies revealed that the latter compounds 
act as naturally occurring heterodimerizers, since they first form a binary complex with their 
respective immunophilin, which subsequently competitively binds to and concomitantly inhibits a 
second protein enzyme. More specifically, FK506 and rapamycin both bind to FK506 binding protein 
12 (FKBP12), after which the complex recruits calcineurin[25] or the FKBP12-rapamycin-binding (FRB) 
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domain of FRAP (FKBP12-rapamycin-associated protein),[26] respectively. In the case of CsA, complex 
formation with cyclophilin is followed by interaction with calcineurin.[25] 
 
The first application of the CID technology was introduced in 1993 by the Schreiber and Crabtree 
groups, reporting on the use of cell permeable, synthetic ligands to control an endogenous signal 
transduction pathway.[17] In particular, an artificial dimer of FK506, FK1012, was constructed to 
homodimerize chimeric FKBP12 proteins fused to the cytoplasmic ζ subunit of the T-cell receptor, 
allowing ligand-regulated signal transmission and specific target gene activation. Since this seminal 
paper, the chemical toolbox to induce protein-protein interactions has been greatly expanded,[27] 
with prominent roles reserved for both FK506, rapamycin and their synthetic analogues.[28],[29] A 
comprehensive general overview of the CID field is beyond the scope of this chapter. Rather, in the 
following sections we focus on the spectrum of dimerizer systems that has been applied in yeast as 
well as mammalian three-hybrid assays over the last two decades.  
 
I.3. Yeast three-hybrid systems 
 
The yeast three-hybrid (Y3H) system[15] is an extension of the original yeast two-hybrid (Y2H) 
assay,[30] which was introduced in 1989 by Fields and Song for the identification of protein-protein 
interactions. In this genetic system the interaction between two proteins of interest (X and Y) is 
detected via the reconstitution of an active transcription factor, which has been split into a separate 
DNA binding domain (DBD) and a transcriptional activation domain (AD), and the subsequent 
activation of a reporter gene under the control of this transcription factor (Figure I.2A).[31] 
 
As the name suggests, the three-hybrid version includes a third hybrid component, i.e. a CID 
consisting of an anchor moiety which is covalently coupled to a small molecule of interest via an 
appropriate linker. Accordingly, this adaptation of the Y2H assay shifts the application scope from 
protein-protein interactions to the detection of small molecule-target protein interactions. In the 
Y3H assay, the small molecule of interest is displayed as ‘bait’ through a high affinity interaction of 
the anchor moiety of the CID with the ligand binding domain (LBD) of a LBD-DBD fusion protein. The 
latter is screened against a collection of chimeric candidate target proteins (referred to as ‘preys’; Y), 
encoded by a cDNA library fused to the AD. Positive interactions reconstitute a functional 
transcription-activating trimeric complex, which upon recruitment to specific DNA binding sites in the 
promoter region of a reporter construct results in the activation of the downstream reporter gene, 
enabling for example yeast growth on a selective medium (Figure I.2B). Finally, sequencing of the 
prey fusion gene present in these positive clones completes the target identification process. 
 
 
Chapter I: General introduction 
I.4 
 
 
 
Figure I.2: Schematic overview of the yeast two-hybrid (Y2H) and three-hybrid (Y3H) system. A) Y2H: A 
chimeric protein (DBD-X) consisting of a DNA binding domain (DBD) fused to a protein X is coexpressed with a 
second protein chimera (AD-Y) comprising a transcriptional activation domain (AD) fused to a protein Y. If 
protein X and Y bind to one another, a functional transcription factor is reconstituted, leading to transcription 
of a downstream reporter gene. B) Y3H: Successful reconstitution of a functional trimeric complex through 
interaction of three hybrid components implies small molecule-target protein binding and results in the 
expression of a reporter gene (see text for more details). These hybrids include a hybrid protein that consists of 
a DBD fused to a ligand binding domain (LBD, e.g. dihydrofolate reductase), a CID comprising an anchor moiety 
(e.g. methotrexate) linked to a small molecule of interest and a second protein chimera composed of an AD 
fused to a library of candidate target proteins (Y). 
 
The initial report describing the Y3H system was published by Licitra and Liu nearly two decades 
ago.[15] In this pioneering work, they introduced the first chemical heterodimerizer, comprising a 
dexamethasone-FK506 hybrid ligand (1, Figure I.3), for effectively bridging two fusion proteins: the 
hormone-binding domain of the rat glucocorticoid receptor (rGR) fused to the LexA DNA-binding 
domain and FKBP12 fused to the B42 transcriptional activation domain. Moreover, in a proof-of-
principle experiment using this heterodimerizer they demonstrated the potential of the Y3H system 
to uncover the target proteins of small organic compounds by identifying FKBP12 as the interaction 
partner of FK506 from a Jurkat cDNA library fused to the B42 activation domain. The application of 
Y3H as a screening tool for novel compound-binding proteins was later confirmed by identifying 
dihydrofolate reductase (DHFR) clones from a mouse cDNA library screen using the dexamethasone-
methotrexate (Dex-MTX) heterodimer as a test compound in a GAL4-AD-based system.[32] Hence, a 
major focus in the Y3H field has been the development of new ligand-receptor CID pairs, as 
systematically outlined in Table I.1. 
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Table I.1: Overview of chemical heterodimerizers used in yeast three-hybrid (Y3H) systems. 
 
Dimerizer Description DBD-
fusion 
AD-fusion Comments Ref. 
Dex-FK506 Dexamethasone and 
FK506 
rGR FKBP12 Used in Jurkat cDNA library 
screen 
[15] 
Dex-MTX Dexamethasone and 
methotrexate 
rGR mDHFR Used in mouse cDNA library 
screen 
[32] 
FK506 
Rapamycin 
Natural product 
Natural product 
FKBP12 
FKBP12 
CNA 
FRB 
Using synthetic ligands as a 
transcriptional on-off switch 
[33] 
C40-PhOPh-
FK506 
C40-p-phenoxyphenyl 
bumped FK506 analogue 
Mutant 
mCAB 
library 
FKBP12 Screening for restored binding 
of compensatory mutant 
mCABs to a calcineurin-
resistant FK506 derivative  
[34] 
Rapamycin Natural product FKBP12 FRB Towards large-scale screening 
of protein-ligand interactions 
in nanodroplets 
[35] 
Estradiol-
biotin 
7--substituted -
estradiol and biotin 
ER-/ Tetrameric SA 
(Y43A mutant) 
Enhanced potency and 
efficacy compared to Dex-
biotin 
[36] 
Estrone 
oxime-biotin 
Estrone-17-(O-
carboxymethyl)oxime 
and biotin 
ER-/ Tetrameric SA 
(Y43A mutant) 
More readily synthesized than 
estradiol congeners 
[37] 
MTX-Dex Methotrexate and 
dexamethasone 
eDHFR/ 
mDHFR 
rGR Most commonly used anchor 
moiety 
[38],[39],[40], 
[41],[42] 
MTX-SLF Methotrexate and 
synthetic ligand for 
FKBP12 
eDHFR FKBP12 
mutants 
KD of ligand-receptor 
interaction correlates with 
transcription read-out 
[43] 
MTX-PurB
1
 Methotrexate and 
purvalanol B 
eDHFR CDK First successful identification 
of novel (CDK-like/unrelated) 
kinase targets 
[44],[45] 
MTX-PurB
2
 Methotrexate and 
purvalanol B 
Cub-
eDHFR 
Nub-PCTK3 Split-ubiquitin-based Y3H 
system for small-molecule-
protein interaction analysis 
[46] 
MTX-RGB-
286147 
 
Methotrexate and a 
pyrazolopyrimidinone 
kinase inhibitor 
eDHFR CDK/CRK Application to MOA studies [47],[48] 
MTX-AA Methotrexate and 
anecortave acetate 
eDHFR PDE6D Identification of new target of 
drug with unknown MOA 
[49] 
MTX-Cmpd2 Methotrexate and an 
imidazopyridine PKG 
inhibitor 
eDHFR TgBRADIN/ 
GRA24 
 
Application to MOA studies of 
antiparasitic drug 
[50],[51] 
TMP-Dex Trimethoprim and 
dexamethasone 
eDHFR rGR No cross-reactivity with 
endogenous DHFR 
[52],[53] 
TMP-SLF Trimethoprim and 
synthetic ligand for 
FKBP12 
eDHFR FKBP12 No endogenous (mammalian) 
targets 
[54] 
BG-MTX O
6
-Benzylguanine and 
methotrexate 
hAGT eDHFR Selective covalently 
immobilizing anchor moiety 
(SNAP-tag) 
[55],[56] 
BG-Sulfa
3
 O
6
-Benzylguanine and 
sulfasalazine 
hAGT SPR Identification of known and 
novel targets of clinically 
approved drugs 
[57],[58] 
BG- 
VC490004
4
 
O
6
-Benzylguanine and an 
anti-TB drug lead 
hAGT CoxF Target deconvolution and 
validation of anti-TB drugs 
[59] 
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Abbreviations used: AD, transcriptional activation domain; CDK, cyclin-dependent kinase; CID, chemical inducer 
of dimerization; CNA, calcineurin A subunit; CoxF, carbon monoxide dehydrogenase F protein; CRK, CDK-related 
kinase; Cub/Nub, C/N-terminal half of ubiquitin; DBD, DNA binding domain; eDHFR/mDHFR, Escherichia 
coli/mammalian dihydrofolate reductase; ER, estrogen receptor; FKBP12, FK506 binding protein with a mass of 
12 kDa; FRB, FKBP12-rapamycin-binding domain of FRAP (FKBP12-rapamycin-associated protein); hAGT, human 
O
6
-alkylguanine-DNA alkyltransferase; mCAB, modular calcineurin A/B fusion protein domain; MOA, 
mechanism of action; PCTK3, PCTAIRE protein kinase 3; PDE6D, phosphodiesterase 6-delta; PKG, cGMP-
dependent protein kinase; rGR, rat glucocorticoid receptor; SA, streptavidin; SPR, sepiapterin reductase; TB, 
tuberculosis; TgBRADIN, Toxoplasma gondii bradyzoite differentiation inhibitor.  
1
 As well as (R)-roscovitine and indenopyrazole-1. 
2
 As well as dexamethasone. 
3
 As well as methotrexate, dasatinib, purvalanol B, erlotinib, atorvastatin, furosemide and indomethacin. 
4 
As well as methotrexate, fluphenazine, mefloquine, ofloxacin, clofazimine and rifampicin. 
 
Initially, the Schreiber and Crabtree laboratories exploited the use of the natural heterodimerizers 
FK506 and rapamycin to control transcription of integrated genes in yeast.[33] In an effort to 
circumvent the limitations of these dimerizers related to interference with cellular functions of their 
endogenous binding partners, novel, orthogonal dimerizer systems were engineered following a 
‘bump-hole’ strategy.[60] In this approach, an artificial cavity is introduced into the ligand-binding site 
of the protein to accommodate an additional, bulky substituent installed on the ligand and which 
inhibits binding to the wild-type protein. In the case of FK506, a Y3H screen was applied as a chemical 
genetic selection tool to identify compensatory mutant modular calcineurin A/B fusion protein 
domains (mCABs) that restored binding to a calcineurin-resistant bumped analogue.[34] Over the last 
two decades, these natural dimerizers and their synthetic derivatives found widespread use as 
powerful research tools in an investigational[29],[28] and therapeutic[61],[62],[18] context, but have only 
been scarcely applied in small molecule-target protein profiling research. An interesting yeast-based 
example is the concept of detecting protein-ligand interactions in stochastic nanodroplets on a large 
scale.[35] Here, rapamycin is coupled to TentaGel resin beads via a photocleavable linker and its time-
dependent photochemical release results in the dimerization of FKBP12-DBD and FRB-AD fusion 
proteins, which triggers transcription of a HIS3 reporter gene, allowing selective yeast growth in 
nanodroplets lacking histidine. In an extension of this initial design, the authors postulate the 
potential of the system to screen an anchored combinatorial library, consisting of large numbers of 
combinatorial small molecules covalently coupled to a constant anchor moiety, against a cDNA 
library of candidate target proteins in a single experiment. However, since this first proof of concept, 
to our knowledge no follow-up studies on this topic have been reported. 
 
Relying on the rather weak binding of dexamethasone to yeast-expressed GR proteins[63] and its 
relatively low activity in recombinant yeast systems,[64] Peterson and co-workers investigated 
steroidal estrogens as alternative immobilizing anchor moieties for profiling natural products in 
Y3H.[36] They synthesized both a hybrid 7--substituted -estradiol derivative fused to biotin, 
providing a simple model of more complex natural products, and its dexamethasone congener. To 
directly compare dimerizer-mediated activation of gene expression, yeast were engineered to co-
express tetrameric streptavidin (SA)-AD and estrogen receptor (ER) /- or GR-DBD fusion proteins, 
respectively. Markedly, this new -estradiol-based CID showed enhanced potency and efficacy 
compared to the previous Dex-GR CID pair. Though, the routine use of these 7--substituted -
estradiol derivatives as CIDs is hampered by their elaborate 14-step synthesis.[65],[36] As a dramatically 
streamlined alternative, a facile two-pot synthesis starting from estrone afforded in good overall 
yield a novel, cell-permeable CID comprising estrone-17-(O-carboxymethyl)oxime linked to biotin, 
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which displayed a dose-dependent activation of reporter gene expression in the ER-SA Y3H assay 
comparable to its estradiol congener.[37] 
 
A significant evolution in the Y3H field was the introduction of the well-established methotrexate 
(MTX)-dihydrofolate reductase (DHFR) CID pair by the Cornish group,[38] which represents the most 
commonly used anchor system to date. In an effort to characterize three-hybrid systems at the 
biochemical level, they examined the influence of the ligand-receptor pair on the transcriptional 
read-out.[39] The latter was found to be much more sensitive to the structure of the fusion proteins 
than to variations in the MTX-Dex dimerizer design. Most surprisingly, using the bacterial E. coli DHFR 
(eDHFR), consistently higher transcription activation levels were obtained compared to its 
mammalian homologue (mDHFR), despite the fact that both exhibit similar binding affinities for MTX 
(Ki = 1.0-3.4 pM).
[66] Subsequently, this initial plasmid-based system was optimized to stabilize the 
transcriptional read-out in a manner that allows the straightforward variation of the AD chimera.[40] 
Therefore, the genes encoding the DHFR anchor protein and the complementary LEU2 and lacZ 
reporters were integrated into the yeast chromosome. Given its remarkably reduced percentage of 
false negatives (from 20% to 3%) and a highly consistent reporter read-out, Cornish and colleagues 
assumed that this MTX-based integrated system would be suitable for the de novo identification of 
small molecule-target proteins in AD-fused prey cDNA library screens. 
 
In fact, in a follow-up paper they showed that the MTX-DHFR Y3H system has the requisite sensitivity 
for drug discovery.[43] For this, a systematic study was undertaken to quantitatively characterize the 
correlation between ligand-receptor affinity and the transcription read-out using a heterodimer of 
MTX and the synthetic ligand for FKBP12 (SLF), which was previously described in the context of a 
bacterial RNA polymerase small molecule three-hybrid system.[67] As a starting point, de Felipe et al. 
designed a series of FKBP12 point mutants spanning several orders of magnitude in their KD for SLF, 
as measured in vitro using a fluorescence polarization assay. Subsequently, the levels of 
transcriptional activation for these variants were determined in the Y3H assay. Interestingly, they 
observed that the strength of the SLF-FKBP12 interaction does correlate with the transcriptional 
read-out, albeit over a small range of KD’s (1 order of magnitude on log scale). Furthermore, the 
authors concluded that in this MTX-based Y3H assay it is not possible to detect interactions whose 
KD’s are over ca. 50 nM, a cutoff considered high enough to realistically use the Y3H system for drug 
discovery. A question that may be asked, however, is whether such a system would indeed be 
sufficiently sensitive for detecting medium/low-affinity interactions of different types of small 
molecules of interest with off-target proteins that contribute to unwanted side-effects or toxicity. 
 
In 2004 this major outstanding question was addressed by Kley and co-workers in a key publication 
reporting the first successful application of the Y3H assay to discover novel drug targets.[44],[45] More 
specifically, the target spectrum of cyclin-dependent kinase (CDK) inhibitors, including purvalanol B, 
was determined in a MTX-eDHFR-based system using both cDNA library and focused screening of 
yeast cell arrays displaying selected polypeptide open reading frames (ORFs). The target profile of 
the latter purine analogue proved to be significantly broader than originally anticipated, since in 
addition to a range of known targets (CDK1, CDK4, and CK1, among others) several novel candidate 
binders, such as CDC/CDK-like kinases, other types of serine/threonine kinases and even receptor 
and non-receptor tyrosine kinases were identified. In vitro, these enzymes are inhibited by 
purvalanol B with IC50 values in the higher nanomolar to low micromolar range, defining a sensitivity 
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limit of this Y3H system comparable to that of yeast two-hybrid[68] and significantly broadening the 
range of detectable interactions in the context of target deconvolution and drug discovery. As such, 
this work represents a significant step forward by enlarging the scope of Y3H towards profiling of 
small-molecule kinase inhibitors, one of the main components of drug development pipelines to 
date. 
 
 
 
Figure I.3: Chemical structures of selected dimerizers used in yeast three-hybrid systems. Dexamethasone-
FK506 (1); methotrexate-anecortave (2); trimethoprim-synthetic ligand for FKBP12 (3); and O
6
-benzylguanine-
VC490004 (4). 
 
Another interesting application of Y3H are mechanism of action studies, which are essential for 
linking phenotypic responses with molecular targets of small molecules. This was first successfully 
demonstrated in 2005 by Caligiuri et al., exploring the potential applications of compounds derived 
from a trisubstituted pyrazolopyrimidinone kinase inhibitor scaffold (such as the putative CDK 
inhibitor RGB-286147).[47],[48] Recently, Shepard et al. elucidated the MOA of anecortave acetate (AA), 
an intraocular pressure-lowering cortisene for treating glaucoma.[49] By displaying the latter in a MTX-
anchored Y3H system (2, Figure I.3), they identified phosphodiesterase 6-delta (PDE6D) as a new 
molecular target and validated it all the way from quantitative in vitro measurements to an animal 
model of the disease. 
 
So as to overcome the partial limitations of MTX-based CIDs related to their cross-reactivity with 
endogenous yeast DHFR and the ensuing potentially impaired transcriptional activation in Y3H, 
Cornish and colleagues introduced trimethoprim (TMP) as an alternative prokaryote-specific[69] DHFR 
anchor moiety.[52] This new CID pair (TMP-eDHFR) was originally established as an in vivo chemical 
protein labeling method, i.e. TMP-tag,[70] which recently has been rendered both covalent and 
fluorogenic for high-resolution intracellular live cell imaging applications[71] (for thorough reviews on 
chemical tags, see [72],[73],[74]). In the context of protein dimerization studies, TMP-based CIDs proved 
particularly useful in mammalian systems, as exemplified by the biocompatible TMP-SLF 
heterodimerizer (3, Figure I.3)[54] and further discussed in chapter 4. The latter CID 3 was successfully 
employed to activate transcription in an eDHFR-FKBP12 Y3H assay and to modulate a Golgi-resident 
glycosyltransferase in Chinese hamster ovary (CHO) cells. 
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While the spectrum of CIDs discussed so far exclusively relies on reversible interactions, some 
dimerizers have been developed to present the small molecule of interest in an irreversible, covalent 
fashion based on yet another protein labeling approach, i.e. SNAP-tag.[75] This strategy is centered 
around the human DNA-repair protein O6-alkylguanine-DNA alkyltransferase (hAGT). The Johnsson 
laboratory exploited the low substrate specificity of this enzyme to covalently label SNAP-tag-fused 
proteins in vivo with a ligand of interest by conjugating the latter to the para position of O6-
benzylguanine (BG). Extrapolating this method to the CID field, they introduced the first chemical 
inducer of hemicovalent dimerization comprising a BG-MTX bifunctional molecule.[55] In a proof-of-
principle hAGT-eDHFR Y3H system, this dimerizer induced transcriptional activation at a level 
comparable to that achieved with noncovalent CIDs.[55] By optimizing this initial concept, the 
Johnsson group established a powerful yeast-based platform that enabled the identification of both 
known and novel interaction partners of clinically approved drugs covering a wide range of 
therapeutic areas.[57] The methodology couples the identification of a candidate target to its 
subsequent unambiguous validation by combining a new, more sensitive SNAP-tag-based Y3H system 
with an effective pulldown or activity assay that utilizes the same BG drug derivative as in the Y3H 
screens. In this respect, they uncovered, for example, the first non-kinase target of erlotinib (ORP7) 
and characterized several off-targets of atorvastatin (such as PDE6D and NQO2). Most intriguingly, 
this milestone study revealed that the anti-inflammatory drug sulfasalazine and its metabolites 
inhibit sepiapterin reductase (SPR) and consequently decrease tetrahydrobiopterin (BH4) 
biosynthesis, thereby suggesting new and improved therapeutic applications for this long-standing 
drug. Finally, this SNAP-tag-based Y3H platform was recently adapted for target deconvolution of 
anti-tuberculosis drugs by screening cDNA libraries encoding mycobacterial proteins with BG-
derivatized small molecules, such as the synthetic anti-TB drug lead VC490004 (4, Figure I.3).[59] A 
comparable approach was followed by Odell et al. to identify T. gondii parasite proteins that interact 
with a MTX-functionalized imidazopyridine PKG inhibitor (‘Compound 2’).[50] Of note, both TMP- and 
SNAP-tag-based Y3H assays are being applied as compound profiling tools as part of a commercial 
drug discovery service.[76] 
 
I.4. Mammalian three-hybrid systems 
 
Analogous to the yeast three-hybrid systems described above, several classes of chemical dimerizers 
have been applied in a mammalian (human) context, as listed in Table I.2. The interest in developing 
these mammalian systems was instigated by a number of limitations of Y3H, including its restricted 
membrane permeability, primitive cellular context, and incapacity to monitor interactions outside of 
the nucleus. Starting in 1996, FK1012 homodimerizers were shown to activate gene transcription in 
Jurkat cells[33],[77] and human skin keratinocytes and fibroblasts[78]. In a next stage, wholly synthetic 
dimeric SLFs (such as AP1510) were developed by Ariad Gene Therapeutics, which combine a 
reduced complexity and greater adaptability with higher potency compared to the first generation 
natural product-derived CIDs.[79],[80],[81] Finally, in order to potentially reduce nonproductive 
interactions and further improve performance, a series of novel, homodimeric bumped AP1510 
analogues (e.g. AP1889) was designed to bind specifically to the F36V point mutant and only 
minimally to endogenous FKBP12.[82],[83] 
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Table I.2: Overview of chemical dimerizers used in mammalian three-hybrid (M3H) systems. 
 
Dimerizer Description DBD/Anchor 
protein
1
-
fusion 
AD/Prey
1
-
fusion 
Comments Ref. 
Homodimerizers 
FK1012 Dimeric FK506 FKBP12       
(3 copies) 
FKBP12       
(3 copies) 
Using synthetic ligands as a 
transcriptional on-off switch 
[33],[77], 
[78] 
AP1510 and 
congeners 
Dimeric synthetic 
FKBP12 ligands 
FKBP12       
(3 copies) 
FKBP12       
(3 copies) 
Reduced complexity, greater 
adaptability and more potent 
than natural product CIDs 
[79],[80], 
[81],[84] 
AP1889 and 
congeners 
Bumped analogues of 
AP1510 series 
FKBP12 
F36V mutant 
(3 copies) 
FKBP12 
F36V mutant 
(3 copies) 
No affinity for endogenous 
FKBP12 
 
[82],[83] 
Heterodimerizers 
FKCsA FK506 and cyclosporin A FKBP12       
(3 copies) 
CyP              
(2 copies) 
Inducible transcriptional 
activation in Jurkat cells 
[85] 
AP1867-
THOXs 
Synthetic FKBP12 ligand 
and substituted 
tetrahydrooxazepines 
FKBP12 
F36V mutant 
? Diversified library of cell-
permeable CIDs to identify 
novel ligand-receptor pairs 
[86] 
C40-PhOPh-
FK506
2
 
C40-p-phenoxyphenyl 
bumped FK506 analogue 
FKBP12       
(3 copies) 
mCAB 
VKMGC 
mutant 
No affinity for endogenous 
calcineurin 
[34] 
Rapamycin Natural product FKBP12       
(3 copies) 
FRB Pharmacological control of 
gene expression in human cells 
[87],[88], 
[89] 
C16-(R)-
methallyl
3
 
and other 
rapalogues 
C16-(R)-methallyl and 
other bumped 
rapamycin analogues 
FKBP12       
(3 copies) 
FRB 
LFP 
mutant 
No affinity for endogenous FRB [90],[62] 
Dex-Fum Dexamethasone and 
fumagillin 
rGR PfMetAP2
 
 
SAR evaluation of fumagillin 
analogues via competition 
assay 
[91],[92] 
MTX-
PD173955
4
 
Methotrexate and a 
potent ABL kinase 
inhibitor 
eDHFR ABL MASPIT cDNA library screening 
and competition assays for 
small molecule-target protein 
profiling in intact human cells 
[16] 
 
Abbreviations used: ABL, Abelson tyrosine kinase; AD, transcriptional activation domain; CID, chemical inducer 
of dimerization; CyP, cyclophilin; DBD, DNA binding domain; eDHFR, Escherichia coli dihydrofolate reductase; 
FKBP12, FK506 binding protein with a mass of 12 kDa; FRB, FKBP12-rapamycin-binding domain of FRAP 
(FKBP12-rapamycin-associated protein); MASPIT, mammalian small molecule-protein interaction trap; mCAB, 
modular calcineurin A/B fusion protein domain; PfMetAP2, Plasmodium falciparum methionine 
aminopeptidase type 2; rGR, rat glucocorticoid receptor. 
1 
In MASPIT, anchor protein (X) and prey (Y) denote the cytokine receptor (CR)-X and Y-gp130 fusion proteins, 
respectively (see Figure I.5 for details).
 
 
2
 As well as C40-phenyl-FK506. 
3
 As well as C16-(R)-isopropoxy rapamycin. 
4
 As well as AP1867, E7070, RGB-285978, RGB-285961 and RGB-286147. 
 
The first synthetic heterodimerizer implemented in a mammalian three-hybrid setting was described 
by Crabtree and Schreiber in 1996, and consists of a fusion of the natural products FK506 and 
cyclosporin A (FKCsA 5, Figure I.4).[85] By dimerizing FKBP12-DBD and cyclophilin (CyP)-AD chimeras, 
the hybrid ligand strongly stimulated the expression of a GAL4-responsive secreted alkaline 
phosphatase (SEAP) reporter gene in Jurkat cells. As for the Y3H system, initial attention was also 
Chapter I: General introduction 
I.11 
 
paid to the well-established natural heterodimerizers FK506, rapamycin and derivatives thereof. 
Having identified a set of selected mutant mCAB hits that restored binding to C40-p-phenoxyphenyl 
FK506 using a Y3H system (see Section I.3), the Schreiber group applied a reciprocally configured 
M3H assay in a subsequent validation step.[34] Toward that end, these hits were fused to an AD 
domain and evaluated for their ability to restore binding to the bumped FK506 analogue, displayed 
by FKBP12-DBD chimeras. As a result, the VKMGC mutant was shown to most optimally respond to 
the calcineurin-resistant derivative. Previously, the group had followed a similar M3H-based 
screening approach for the discovery of novel ligand-receptor CID pairs based on rapamycin.[90] As 
mentioned in Section I.3, next to their application as tool compounds for fundamental biology 
studies, rapamycin[87] and its bumped analogues[62] paved the way for the development of suitable 
systems for pharmacological control of therapeutic gene expression. 
 
 
 
Figure I.4: Chemical structures of selected dimerizers used in mammalian three-hybrid systems. FK506-
cyclosporin A (5); and methotrexate-PD173955 (6).  
 
In another study aiming at the identification of new ligand-receptor CID pairs, Koide et al. 
constructed a diversified library of heterodimerizers comprising an invariant synthetic FKBP12 ligand 
(i.e. AP1867) attached to 320 substituted tetrahydrooxazepines (THOXs).[86] The latter system was 
selected as ‘privileged scaffold’ for its structural novelty in the cyclic form and convertibility to a 
linear form through reduction of the N-O bond. Furthermore, the presence of the olefin and three 
chiral centers creates a further functionalization site and the possibility to exploit stereochemistry as 
a diversity element, respectively. Subsequently, the cell permeability of these candidate 
heterodimerizers was assessed by analyzing a representative panel of 25 library members spanning a 
broad range of hydrophobicities using an AP1889-based M3H competition assay. In this experiment, 
a cell-permeable heterodimerizer competes with the AP1889 homodimerizer for binding to FKBP12 
F36V chimeras, thereby disrupting the complex that activates SEAP expression. All of the tested 
compounds as well as an additional sample of six of the most polar library members were found to 
be freely permeable to human fibrosarcoma cells, as each gave strong inhibition of SEAP expression 
levels. Unfortunately, the authors did not report on the identification of any functional, novel CID 
pairs and only briefly referred to several initial promising ‘hits’. However, to our knowledge, no 
follow-up studies have been published ever since. In addition to the evaluation of cell permeability 
properties, M3H competition experiments with native unfused small molecules also allow for their 
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prioritization with respect to in cell target binding affinity. Accordingly, structure-activity 
relationships (SAR) can be mapped out based on the side-by-side comparison of analogue series. An 
interesting example of this strategy is provided by Chen et al., who performed dexamethasone-
fumagillin-mediated M3H assays in the absence and presence of a series of potential competitors of 
this antimalarial lead.[92],[91] 
 
The possibility to perform such competition assays in a host system that is readily permeable to a 
wide variety of small molecules, offers an important advantage of mammalian over yeast three-
hybrid systems. Namely, wild-type yeast are naturally resistant to many drugs, whose intracellular 
accumulation is hampered by constitutively active multidrug-resistance (MDR) mechanisms.[93] In 
fact, a complex network of genes, termed the pleiotropic drug resistance (PDR) network, contributes 
to this MDR phenotype. For example, three such genes, i.e. PDR5, SNQ2, and YOR1, encode plasma 
membrane ATP-binding cassette (ABC) transporters that actively mediate drug efflux, thereby 
lowering intracellular drug levels.[94],[95] On the other hand, the ERG6 gene, encoding the C-24 sterol 
methyltransferase enzyme acting in the late steps of the ergosterol biosynthetic pathway, limits the 
rate of passive drug diffusion across the fungal membrane.[96] Hence, in an effort to tackle this uptake 
issue, reporter yeast strains have been genetically modified by specific deletion of the latter genes, 
resulting in a significantly enhanced permeability to small molecules, as exemplified in both two-
hybrid[97] and three-hybrid[57],[98] studies. An alternative and complementary approach to increase the 
sensitivity of yeast to drugs consists of inducing the hexose transporters HXT11 and HXT9, which 
have been postulated to influence ABC pump function via negative feedback regulation or to allow 
the translocation of other classes of compounds across the membrane.[99] 
 
I.4.1. MASPIT and KISS 
 
An inherent limitation to both the mammalian three-hybrid systems discussed so far and Y3H in 
general is their restriction to the detection of interactions with proteins or protein domains that can 
be functionally expressed and effectively translocated into the nucleus. MASPIT (mammalian small 
molecule-protein interaction trap) circumvents this disadvantage by shifting the analysis of binding 
events between small organic compounds and their target proteins to the cytosol of living human 
cells (Figure I.5A).[16] Additionally, the intact human cellular context (HEK293T) ensures compound 
profiling in a physiological relevant environment and conserves normal protein conformation as well 
as post-translational modifications. Furthermore, this might reveal potential effects of the target’s 
association with additional proteins or other intracellular molecules on small molecule binding. 
 
MASPIT is the three-hybrid component of the MAPPIT (mammalian protein-protein interaction trap) 
technology platform,[100],[101] an approach that uses the JAK-STAT pathway which mediates cytokine 
receptor (CR) signaling. MASPIT employs E. coli dihydrofolate reductase (eDHFR), fused to a mutated, 
functionally inactivated, CR to present a methotrexate (MTX) fusion compound (MFC) to the 
intracellular environment. This allows screening of a small-molecule bait against a collection of 
chimeric prey proteins. As a result of the interaction between the small-molecule bait and a target 
prey protein, the JAK-STAT pathway is activated, resulting in the expression of a reporter gene 
(Figure I.5A). 
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Figure I.5: Outline of the MASPIT and KISS mammalian three-hybrid (M3H) systems. A) MASPIT: E. coli 
dihydrofolate reductase (D) is fused to a cytokine receptor (CR) that is rendered signaling-deficient by mutating 
STAT3 recruitment sites in its cytoplasmic tail (grey dots). A prey protein (Y) is tethered to a gp130 CR fragment 
containing functional STAT3 transcription factor docking sites (black dots). When a fusion compound consisting 
of a small molecule of interest (asterisk) coupled to methotrexate (MTX) is added to the cells, MTX binds to 
eDHFR, resulting in the compound of interest being displayed as bait. Upon administration of the appropriate 
cytokine ligand (cyt), the CR-eDHFR chimeric receptor undergoes a conformational change, activating the 
associated JAK2 kinases through crossphosphorylation (P). Interaction between the small-molecule bait and the 
prey-gp130 fusion protein brings the latter into proximity of the activated JAK kinases, reconstituting a 
functional JAK-STAT signaling pathway. Sequential phosphorylation of STAT3 docking sites on the gp130 chain 
(P), STAT3 recruitment, and STAT3 phosphorylation (P) ultimately leads to activated STAT3 dimers that induce 
the expression of a reporter gene coupled to a STAT3-dependent promoter. B) KISS: eDHFR (D) is tethered to 
the C-terminal (kinase-domain-containing) portion of tyrosine kinase 2 (TYK2) and co-expressed with a prey 
protein (Y) fused to a gp130 CR fragment. Upon physical interaction between the small molecule and the prey 
protein, TYK2 phosphorylates STAT3 docking sites on the prey chimera (P), which eventually triggers reporter 
gene activation as in the case of the MASPIT assay. 
 
The original MASPIT paper was published by Kley and coworkers in 2006, focusing on MTX-based 
CIDs incorporating diverse small-molecule chemotypes, such as the potent pyridopyrimidine ABL 
tyrosine kinase inhibitor PD173955 (6, Figure I.4).[16] The latter MFC was applied in a MASPIT cDNA 
library screen aiming at the proteome-wide de novo identification of its target proteins. Only kinases 
were detected in this screen; besides different known kinases (e.g. LYN, FYN and FGFR1), the authors 
also identified several novel kinase targets of this compound, such as various ephrin receptors and 
cyclin G-associated kinase. In contrast to classical target-based profiling, this M3H system can thus 
provide information regarding unanticipated small molecule-target protein interactions. 
Furthermore, this study also describes for the first time the use of competition assays to compare 
and rank unmodified small molecules (e.g. PD173955 and imatinib) on the basis of their relative 
ability to displace a CID (MTX-PD173955) from its target protein (ABL) in intact mammalian cells 
(analogous to SAR evaluation in [92] as discussed above). Interestingly and unlike in vitro KD or IC50 
values, such quantitative cellular targeting potencies integrate many variables associated with 
compound cell-bioavailability and intracellular targeting efficiency. However, an important limitation 
of the system is its incompatibility with (full size) transmembrane proteins. Indeed, since the small-
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molecule bait is recruited to a plasma membrane anchored cytokine receptor chimera, only 
interactions with soluble target proteins can be detected. 
 
The latter shortcoming was addressed by the introduction of KISS (kinase substrate sensor), a novel 
binary protein-protein interaction mapping approach that enables in situ analysis in living 
mammalian cells of protein interactions and additionally small molecule-target protein profiling in a 
three-hybrid setup.[102] In this assay, small molecules are displayed as baits through recruitment of 
their corresponding MFCs to an E. coli DHFR (eDHFR)-tyrosine kinase 2 (TYK2) fusion protein, and 
interactions with target protein prey fusions are detected through reporter induction as in the case 
of the MASPIT assay (Figure I.5B). Contrary to MASPIT, the KISS 3H approach allows screening for 
integral membrane target proteins as this interaction sensor is freely diffusible. 
 
I.5. Design aspects of chemical dimerizers  
 
Ideally a CID for three-hybrid applications should be accessible via a modular, versatile and practical 
synthesis in a minimal number of steps and acceptable overall yield. Furthermore, the CID should be 
readily soluble and cell permeable. In the following three subsections examples of anchor moieties, 
linkers and conjugation methodologies are discussed (Figure I.6). 
 
I.5.1. Anchor moieties 
 
For a comprehensive outline of the ligand-receptor pairs used in three-hybrid systems to date, we 
refer to Table I.1 and Table I.2. Representative examples of prominent anchor moieties based upon 
reversible or irreversible immobilization are included below (Figure I.6).  
 
 
 
Figure I.6: Typical components of chemical dimerizers for three-hybrid systems. Schematic non-
comprehensive overview of anchor moieties, linkers and conjugation methods applicable to the synthesis of 
chemical dimerizers as exemplified by the O
6
-benzylguanine-(PEG)4-dasatinib
[57]
 conjugate. Anchor proteins are 
in brackets.  
 
I.5.2. Linkers 
 
To discourage steric hindrance of fusion partners, which could cause the CID to bind suboptimally to 
its anchor protein or allow one to overlook targets that might interact with the unconjugated small-
molecule bait, a linker is introduced to allow optimal interaction with prey chimeras. Toward this 
end, the attachment position of the spacer, both on the anchor moiety and bait, must be 
meticulously chosen so as to minimize loss in binding affinity through perturbation of 
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pharmacophores or induction of conformational changes. In this respect, ‘linkerology’ studies are 
often guided by available SAR, structural, and molecular modeling data, which facilitate selection of 
the attachment site and incorporation of appropriate chemical handles. Indeed, in the case of DHFR 
ligands attachment positions are well established. For example, SAR studies of MTX derivatives have 
emphasized the importance of selective conjugation to the -carboxylic acid of the glutamate moiety 
to ensure high affinity binding to eDHFR through interaction of this enzyme with the free -
carboxylic acid.[103],[104] However, appropriate derivatization of small-molecule baits is often less 
obvious and is generally initiated from SAR information of their primary targets (as far as known). Of 
note, for comprehensive target deconvolution studies one should ideally rely on phenotypical SAR 
data, acquired from testing a panel of derivatives modified at different positions for retained activity 
in appropriate functional assays.[57] Two main factors that govern the design of a particular linker are 
its length and chemical composition. 
 
Though crucial, no hard and fast rules are available for identifying the optimal linker length, which is 
typically determined empirically. For instance, one can envision that sufficient length and flexibility 
would be necessary to effectively bridge both binding sites and successfully heterodimerize the two 
fusion proteins, while on the other hand the linker should be short enough to ensure the desired 
proximity-related dimerization event to occur. Hence, this supports the development of modular 
synthesis strategies, enabling linker length and conjugation method to be swiftly mixed and matched 
as required (Figure I.6).[51] Previously, the effect of CID linker length modifications on the 
transcription read-out in both yeast and mammalian three-hybrid systems has been investigated, yet 
yielding contradictory outcomes. Piloting work by Cornish and colleagues suggested an increase in 
Y3H sensitivity by increasing the linker length of MTX-Dex CIDs.[39] However, only subtle differences 
among five-, eight-, and ten-methylene linkers were revealed. Yet, the latter trend was later 
confirmed in several other yeast-based studies,[36],[44],[46] but contrasts sharply with the reports by 
Amara[79] and Schreiber[77], observing a clear inverse correlation between linker length and activity. 
These discrepancies might be explained by the relative strength of the interactions, as well as 
geometrical and steric effects governed by the nature of the prey chimeras and hence frequently 
underscore the need for application-specific CID optimizations. 
 
Three main classes of linker types have been applied for the construction of CIDs in the context of 3H 
systems, i.e. straight-chain aliphatic (methylene),[39] poly(ethylene glycol) (PEG),[44],[46],[51] and mixed-
type spacers (e.g., N,N'-(ethane-1,2-diyl)bis(2-hydroxyacetamide)-derived).[81],[79] The chemical 
composition of the linker might significantly influence the stability, solubility, cell permeability and 
hence overall efficiency of CIDs. Clearly, one should keep away from reactive functional groups, such 
as esters, which could be cleaved in vivo. Johnsson and co-workers have shown that a BG-based CID 
comprising an aliphatic linker proved to be more effective than its PEG congener, most probably due 
to the fact that the former spacer relatively increases the overall hydrophobicity of the CID, favoring 
its cellular uptake.[55] However, this frequently observed enhanced permeability of methylene spacer-
based CIDs is often at the expense of their solubility and too hydrophobic linkers could promote 
undesired aggregation in aqueous media.[20] PEG linkers on the other hand were reported to yield 
dimerizers with generally good water solubility properties and, remarkably, ditto yeast cell 
permeability.[44],[23]  
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I.5.3. Conjugation methodologies 
 
Various (bio)conjugation methods are available for fusing both the anchor moiety and small-
molecule bait to either end of the linker. Most synthetic strategies apply general anchor-spacer 
reagents (e.g. MTX-(PEG)5-NH2 or BG-(PEG)4-NH2)
[44],[57] for subsequent ligation to (appropriately 
functionalized) small molecules using standard peptide coupling, Mitsunobu or N-alkylation 
reactions, thereby yielding amide, ether or amine linkages, respectively.[23] Remarkably, only by 2011, 
the highly powerful, regioselective and reliable copper(I)-catalyzed azide alkyne cycloaddition ‘click’ 
reaction (CuAAC)[105] found acceptance in the Y3H field.[57] Two years later, Tran et al. reported on 
newly developed synthetic strategies, implementing ‘clickable’ MTX reagents for the straightforward 
generation of CIDs for Y3H applications.[51]  
 
I.6. Alternative three-hybrid systems 
 
I.6.1. Alternative yeast three-hybrid systems 
 
A number of variations on the classical Y3H theme, as depicted in Figure I.2, have appeared in the 
course of the past decade. One of the most notable adaptations is the chemical complementation 
assay, introduced by the Cornish group (Figure I.7).[106] The approach entails a reaction-independent, 
genetic high-throughput assay, which uses a MTX-Dex Y3H system to link enzyme catalysis of bond 
formation or cleavage reactions to transcription of an essential or repression of a toxic downstream 
reporter gene, respectively. In the bond-making direction, enzyme-mediated covalent coupling of a 
MTX-disaccharide-fluoride donor and a Dex-disaccharide acceptor reconstitutes a functional 
heterodimerizer capable of increasing transcription of a LEU2 reporter gene, which allows for a 
growth selection in the absence of leucine (Figure I.7A).[107] Hence, in this forward direction, the 
system has been mainly applied as a platform for the directed evolution of glycosynthases.[108],[109]  
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Figure I.7: Schematic overview of the chemical complementation assay. A) Bond formation: Glycosynthase-
catalyzed glycosidic bond formation between a MTX glycosyl donor (Do) and a dexamethasone glycosyl 
acceptor (Ac) is detected by reconstitution of the MTX-Dex heterodimerizer and activation of reporter gene 
expression. B) Bond cleavage: Addition of cephalosporinase to the Y3H system results in cleavage of the MTX-
Cephem-Dex substrate and disruption of reporter gene transcription. D, eDHFR; E, enzyme; G, glucocorticoid 
receptor; Su, substrate. 
 
On the other hand, to monitor enzyme-catalyzed bond cleavage reactions, specialized CIDs 
comprising the substrate for the reaction under study as alternative linker between the anchor 
moiety and small-molecule bait (i.e., MTX-substrate-Dex) are constructed (Figure I.7B). Addition of an 
active enzyme as a fourth component to the Y3H system, results in cleavage of the dimerizer and 
subsequent disruption of reporter gene transcription.[106],[110] In combination with combinatorial 
mutagenesis, this assay variant was used to investigate the mechanism of resistance to the third-
generation cephalosporin cefotaxime by the class C β-lactamase P99.[111] Alternatively, by switching 
to the toxic URA3 reporter gene, the detection of enzymatic activity was coupled to yeast cell 
survival, enabling the first high-throughput selection for cellulase catalysts.[112] Taken together, the 
generality of chemical complementation represents a fundamental asset of this approach and should 
allow its extrapolation to detect new enzymatic activities for important chemical transformations.[112]  
 
Two other modified versions of the traditional Y3H system were described by Peterson and co-
workers, which are essentially built around the phosphorylation of a universal protein tyrosine kinase 
(PTK) substrate[113] and biotinylation of a BirA biotin protein ligase substrate,[114] respectively. The 
former system was initially designed for the discovery and characterization of novel PTK enzymes.[113] 
In a successful validation experiment, v-Abl or v-Src kinase mediated phosphorylation of a tetrameric 
universal tyrosine-containing substrate linked to green fluorescent protein (GFP) and fused to the 
LexA DBD enabled recognition by the coexpressed phosphotyrosine-binding Grb2 SH2 domain-B42 
AD chimera, ultimately activating the expression of the reporter gene. In a follow-up report, the 
authors described a permeability-enhanced variant of this system, allowing analysis of PTK inhibitors 
and suggesting its application to the discovery of drug leads in high-throughput screening assays.[98] 
The second alternative and related Y3H approach involves highly specific BirA-facilitated covalent 
acylation of the key lysine-10 residue of the Avitag-GFP-B42 AD substrate by exogenous biotin.[114] 
Chapter I: General introduction 
I.18 
 
The resulting biotinylated Avitag fusion protein subsequently tightly binds the SA-LexA DBD, leading 
to reporter gene expression. Afterwards, Weber et al. exploited this specific use of biotin as a 
covalent heterodimerizer to control transgene expression in mammalian cells.[115],[116]  
 
A last alternative three-hybrid technology is based on the split-ubiquitin system, an in situ protein 
interaction sensor.[117] In the three-hybrid setup, a CID mediates the proximity of the split-ubiquitin 
sensor via interaction with its two receptors, each of which fused to the N- (Nub) or C-terminal half of 
ubiquitin (Cub).
[46] Subsequent reconstitution of quasi-native ubiquitin results in proteolytic cleavage 
by ubiquitin-specific proteases (UBPs) and ensuing degradation of the destabilized R-Ura3p reporter 
(Figure I.8). Successful proof-of-concept studies were conducted with model MTX-Dex dimerizers, 
comprising different PEG linker lengths (see Section I.5.2) and a comparison with their effectiveness 
in the classical Y3H assay was performed. The application of this alternative Y3H system was further 
extended to a pharmaceutically relevant context upon monitoring the interaction of purvalanol B 
with PCTAIRE protein kinase 3 (PCTK3). 
 
 
 
Figure I.8: Schematic representation of the split-ubiquitin-based yeast three-hybrid system. A successful 
small molecule-target protein interaction mediates reconstruction of ubiquitin, resulting in cleavage by 
ubiquitin-specific proteases (UBPs) and degradation of the R-Ura3p reporter. D, eDHFR; Nub/Cub, N/C-terminal 
half of ubiquitin; Y, target protein. 
 
I.6.2. Alternative mammalian three-hybrid systems 
 
Next to the conventional M3H system, MASPIT and KISS, several strategies have been developed to 
study small-molecule induced protein-protein interactions in a mammalian setting based on protein-
fragment complementation assays (PCAs). A first example of such an assay is the split-DHFR 
approach, which was described by Remy and Michnick and preceded the previously outlined split-
ubiquitin sensor (see Section I.6.1).[118] The strategy is based on the reassembly of two designed 
complementary fragments of the split-DHFR sensor, each fused to either of two proteins or protein 
fragments that dimerize upon small-molecule addition; in this case the well-characterized rapamycin-
induced association of FKBP to FRB is used. Correct folding of DHFR reconstitutes enzyme activity, 
which can be detected in vivo by DHFR-negative cell survival in medium depleted of nucleotides or by 
stoichiometric binding and retention of fluorescein-conjugated MTX followed by fluorescence 
microscopy/spectroscopy, or fluorescence-activated cell sorting (FACS). Since the successful 
introduction of these first test DHFR assays, there has been a veritable explosion of applications 
utilizing split-protein systems in numerous fields such as cell biology, drug discovery and chemical 
biology.[119],[120],[121] In fact, many split-protein reporters were initially validated using the FKBP-
rapamycin-FRB CID system including split -lactamase,[122],[123] split firefly luciferase,[124] split Gaussia 
luciferase,[125] and split TEV (tobacco etch virus protease).[126],[127] However, to our knowledge, these 
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various split-protein systems have not been applied in the context of small molecule-target protein 
profiling so far. 
 
A final intriguing methodology introduced by Jester et al. is the coiled-coil enabled split-luciferase 
three-hybrid system for profiling kinase inhibitors (Figure I.9).[128] Contrary to the latter split-protein 
approaches, this strategy utilizes a cell free translation system, thereby circumventing potential 
issues related to cell permeability, large-scale protein purification and off-target effects. In the initial 
design, a protein kinase of interest is coupled to the C-terminal fragment of split firefly luciferase 
whereas its N-terminal part is fused to the coiled-coil Fos peptide, which is specific for the coiled-coil 
Jun. The establishment of a ternary complex, mediated by addition of a heterodimerizer consisting of 
Jun tethered to the pan-kinase inhibitor staurosporine, results in the reassembly of active luciferase, 
allowing a straightforward luminescent read-out. Kinase inhibitors were then rapidly identified by 
competitively displacing the staurosporine-based CID with reversal of luciferase reassembly and 
concomitant loss in luminescence.  
 
 
 
Figure I.9: Design of the coiled-coil enabled split-luciferase three-hybrid system. The two halves of split-
luciferase are tethered to a kinase and coiled-coil Fos, respectively. Addition of the Jun-staurosporine CID 
results in ternary complex formation and reconstitution of active luciferase. Small-molecule kinase inhibitors 
competitively displace the CID, thereby decreasing luciferase signal. Nfluc/Cfluc, N/C-terminal half of firefly 
luciferase; SM, small molecule; ST, staurosporine. 
 
At first, the potential generality of this new three-hybrid biosensor was demonstrated by successfully 
interrogating ten representative protein kinases from six groups in competitive binding assays. 
However, in a recent follow-up paper it was found that the Fos and either of six tyrosine kinase (TK) 
fusion proteins (PTK6, EPHB3, RIPK2, ABL, SRC and EPHA2) did not show significant luminescence in 
the presence of the staurosporine warhead based CID, as anticipated from the reported low affinity 
interactions of the latter inhibitor with these TKs.[129] Hence, in an effort to expand the coiled-coil 
enabled method to the entire kinome, particularly the TK group, dasatinib based CIDs were designed 
and implemented as active site directed ligands. Most notably, the authors showed that a CID based 
on a lower affinity derivative of dasatinib was necessary for being amenable to displacement by free 
inhibitors in the three-hybrid assay. Finally, as a proof-of-principle experiment, this modified 3H split-
luciferase approach was employed to screen a broad panel of known kinase inhibitors against ABL, 
providing potential starting points for new drug design campaigns. 
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I.7. Three-hybrid screening platforms 
 
Adoption of 3H technologies in a small molecule profiling platform, aimed at de novo identification of 
(on- or off-) target proteins, requires access to a set of potential target proteins (preferably 
proteome-wide) and an approach that enables efficient screening of this collection. Essentially two 
general methodologies can be pursued in high-throughput 3H applications: cDNA library and array 
screening. 
 
Traditionally, mainly the former has been applied because this requires relatively little resources with 
respect to both building and screening extensive libraries. Moreover, since the screening format is 
essentially the same as in the case of (yeast or mammalian) two-hybrid technologies for the 
identification of protein-protein interactions, tools and libraries, which are broadly distributed within 
the research community and can be acquired commercially, can be applied as such in a 3H setup. In 
brief, a mRNA sample derived from (a) relevant cell type(s) is cloned as cDNA in a suitable prey vector 
and the resulting cDNA library is co-expressed together with the anchor protein (e.g. the LBD-DBD 
fusion protein in the case of Y3H) in the appropriate cell type. The resulting pool of cells, ideally each 
expressing a different prey protein, is treated with a CID containing the bait small molecule and cells 
harboring an interacting small molecule bait-target prey pair can be recovered through selection for 
reporter gene activity. In yeast systems, growth selection through an auxotrophic marker potentially 
combined with a β-lactamase-based colorimetric read-out is typically used.[15],[32],[44],[49] In mammalian 
cells, a wider variety of growth selection (mostly based on antibiotic resistance markers), enzymatic 
(e.g. luciferase) or fluorescent read-outs are being applied.[16],[130] Although seemingly 
straightforward, cDNA library screening is quite labor- and time-consuming: a screen for a single 
small-molecule bait typically requires several weeks, if not months, from the actual library screen up 
to the selection of validated clones. In addition, once these clones have been selected, target protein 
identity still needs to be retrieved through prey cDNA amplification and sequencing.  
 
An alternative format that accommodates higher throughputs is array screening. This entails parallel 
testing in an arrayed fashion of individual combinations of the small-molecule bait of interest with a 
(large) set of target preys, typically in microtiterplates or using (micro-)arrays. Conceptually, an 
important benefit is that, because preys are assayed individually rather than in the bulk of a cDNA 
library-expressing cell pool, there is no competitive selection among different target proteins, which 
results in a higher level of sensitivity of an array format. Compared to cDNA library screening, setting 
up an array screening platform requires much more effort in terms of generation of the library of 
cDNA clones (which need to be cloned individually) and infrastructure for printing and scanning the 
arrays. Once operational however, array replicas can be produced batch-wise (potentially in a largely 
automated way) and stored as a flexible screening resource, and an efficient arrayed 3H platform 
enables screening large collections of target proteins within days, whereby target identity is revealed 
by its position in the array. 
 
A focused yeast cell array covering a limited subset of protein kinases has been used to complement 
a cDNA library screening approach aimed at identifying novel targets of purvalanol B, as mentioned 
in Section I.3. Here, array replicas of yeast cell clones stably expressing different kinase prey fusion 
proteins were generated and screened with different concentrations of a number of small-molecule 
CIDs.[44] Over the past couple of years, the Tavernier group has invested heavily in adopting the 
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MASPIT and KISS M3H assays to a cell array format. In the current setup, functionalized mixtures 
containing individual prey-encoding plasmids are being printed at high density and screened through 
reverse transfection. In this approach, a HEK293T cell pool, bulk transfected with the CR-eDHFR 
anchor protein and treated with the small molecule-derived CID (see Figure I.5), is grown as a 
monolayer on the array, resulting in local uptake and expression of the target prey. In cells growing 
on top of a plasmid  encoding a target protein of the small molecule of interest, the reporter gene is 
activated, flagging the interaction. 
 
Although such an approach clearly exhibits vast potential as to scale and speed, besides the fact that 
it requires significant upfront investments to have such a platform in place, there are also a number 
of other points to consider. A potential disadvantage compared to cDNA library-based approaches is 
that, in particular when only full size ORFs are being used, interactions with specific subdomains that 
are not properly exposed (e.g. in cases where the small molecule binds to a subdomain of the target 
protein that is only accessible in specific protein conformers induced under particular physiologic 
conditions) might be missed. Additionally, a cDNA library might cover target protein isoforms not 
present in a full size ORF collection. These issues can be easily addressed however by growing the 
arrayed library beyond full size ORFs, by adding in additional protein isoforms and subdomains in 
order to move towards the complexity of classical cDNA libraries. 
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II. Objectives 
 
The overarching aim of this thesis is to optimize the performance of the MASPIT system from a 
medicinal chemical perspective (Figure II.1). As described in the general introduction, a prerequisite 
for successful MASPIT analysis is the availability of appropriate methotrexate fusion compounds 
(MFCs). Structure-activity relationship (SAR) studies of methotrexate (MTX) derivatives have 
emphasized the importance of selective conjugation to the -carboxylic acid of the glutamate moiety 
to ensure high affinity binding to dihydrofolate reductase (DHFR) of E. coli, since the -carboxylic acid 
significantly contributes to the overall binding by forming an ion pair with the guanidinium group of 
Arg-57, a residue that is highly conserved in prokaryotic and eukaryotic dihydrofolate reductases, 
while the -carboxylate appears to interact only with the solvent. Hence, a first objective of this work 
is to design and synthesize a versatile MTX-based reagent and explore its use for easy and 
straightforward ligation to bait small molecules of interest. In this respect, we also set out to 
determine the optimal linker length and assess different conjugation methodologies (Figure II.1, 
panel A). 
 
 
 
Figure II.1: Schematic overview of the chemical dimerizer optimization approaches for MASPIT. BG, O
6
-
benzylguanine; h, photoactivatable group; MTX, methotrexate; TMP, trimethoprim. 
 
In a next step, two alternative chemical dimerizer approaches, i.e. TMP- and SNAP-tag, will be 
investigated with the aim of increasing the sensitivity of MASPIT. First, we will try to circumvent any 
potential limitations related to the tight binding of MTX to endogenous human DHFR, which might 
titrate out a portion of the fusion compound and induce cellular toxicity through perturbation of the 
endogenous folate metabolism. As an Escherichia coli enzyme is employed in MASPIT, we will explore 
trimethoprim (TMP) as an alternative prokaryote-specific DHFR ligand (Figure II.1, panel B). 
 
Furthermore, so as to stabilize the ternary complex (cytokine receptor-fusion compound-prey 
chimera) in order to improve the system’s sensitivity, we will introduce the concept of covalent 
bonding into the MASPIT assay, which hitherto relies on reversible interactions of either component 
of the dimerizers. As a starting point, we aim to selectively and covalently immobilize the fusion 
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compound to the cytokine receptor (CR) by using a SNAP-tag-based system, which is centered 
around the human O6-alkylguanine-DNA alkyltransferase (hAGT) enzyme. Previously the low 
substrate specificity of this enzyme has been exploited to covalently label SNAP-tag-fused proteins in 
vivo with a ligand of interest by conjugating the latter to the para-position of O6-benzylguanine (BG) 
(Figure II.1, panel B). Therefore, by fusing hAGT to the cytoplasmic domain of the CR and synthesizing 
the appropriate BG fusion compound (BGFC), we plan to present a covalently coupled bait small 
molecule. 
 
Our final optimization efforts will be aimed at introducing covalent bonding on the bait-end of the 
dimerizer. For this purpose, we envision that photoactivatable crosslinkers will be particularly 
suitable for capturing transient and low-affinity bait-prey interactions. Indeed, such 
photocrosslinkers convert upon photoactivation to highly reactive species, capable of introducing 
covalent bonds between interacting molecules. In the context of the MASPIT assay, this strategy thus 
might give rise to increased signal output. Hence, we will equip the anchor-spacer reagent with a 
double ligation handle, enabling introduction of both bait small molecules of interest and suitable 
photophores, to yield heterotrimeric photoaffinity labeling (PAL) probes (Figure II.1, panel C). 
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III. A ‘Clickable’ MTX Reagent as a Practical Tool for Profiling Small-Molecule–Intracellular 
Target Interactions via MASPIT 
 
III.1. Small-molecule baits 
 
To optimize the CIDs for use in MASPIT, we selected four structurally diverse, pharmacologically 
active compounds as model baits: tamoxifen, reversine, FK506, and simvastatin. In the following 
subsections some background on their mechanism of action (MOA) as well as the specific motivation 
for our interest in these baits is provided. Furthermore, we discuss available structure-activity 
relationship (SAR), structural, and molecular modeling data underlying our rationale for choosing a 
particular attachment position, which tolerates the incorporation of appropriate chemical handles 
necessary for the derivatization of these small-molecule baits into MASPIT-compatible CIDs. 
 
III.1.1. Tamoxifen 
 
III.1.1.1. MOA and motivation  
 
Tamoxifen (TAM) is a selective estrogen receptor (ER) modulator, which displays antagonistic effects 
on the ERs of breast tissue, accounting for its ability to inhibit tumor growth.[1] Hence, tamoxifen has 
been part of the standard therapy for ER-positive breast cancer treatment since the 1970s.[2] The 
drug is extensively metabolized, predominantly by the liver cytochrome P450 (CYP) enzymes 2D6 and 
3A4, yielding several active metabolites such as (Z)-4-hydroxytamoxifen (4-OH-TAM) and (Z)-4-
hydroxy-N-desmethyltamoxifen (endoxifen) (Figure III.1).[3] The latter exhibit both a much higher 
antiestrogenic potency in breast cancer cells and a greater affinity for ER compared to the parent 
drug (e.g., Ki(4-OH-TAM) = 0.25 nM vs. Ki(TAM) = 12 nM),
[4] emphasizing their contribution in 
mediating the overall clinical outcome.[5] Of note, the Z-configuration of the double bond of 
tamoxifen and its metabolites is required for high affinity ER binding; the E isomers have low binding 
affinity.[6] 
 
 
 
Figure III.1: Chemical structures of tamoxifen and its main active metabolites, (Z)-4-hydroxytamoxifen (4-OH-
TAM) and (Z)-4-hydroxy-N-desmethyltamoxifen (endoxifen). The functional group selected as conjugation site 
is highlighted in red. 
 
In humans, two ER isoforms are found, ER and ER, each encoded by separate genes and exhibiting 
different affinities for certain ligands.[7],[8] The vast majority of breast carcinomas, i.e. 80%, are 
positive for and driven by ERα. The latter is a master transcription factor and belongs to the steroid 
hormone receptor superfamily.[9] ER can be activated in a ligand-dependent as well as independent 
fashion, via modulation by its natural ligand 17-estradiol or by a number of posttranslational 
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modifications, such as direct phosphorylation by several protein kinases, respectively.[10] In the 
classical ligand-dependent signaling pathway estradiol diffuses into the cell and binds ER, located in 
the cytosol, triggering its dissociation from the stabilizing heat shock protein 90 (HSP90) and 
subsequent homodimerization. Next, activated ER dimers translocate into the nucleus and bind the 
DNA at estrogen response elements (ERE), resulting in the recruitment of the transcription complex. 
Ultimately this cascade leads to a downregulation of anti-proliferative and pro-apoptotic genes, 
while upregulating responsive genes involved in cell cycle progression.[11] 
 
Tamoxifen functions as a competitive antagonist, which upon binding to ER alters the conformation 
of the ligand-binding domain (LBD), thereby preventing the formation of an active transcription 
complex.[10] Consequently, tamoxifen inhibits the expression of estrogen-regulated genes, including 
growth and angiogenic factors, resulting in a block of the cell cycle, a slowing of cell proliferation and 
eventually tumor regression.[1] Alternatively, tamoxifen may also directly induce apoptosis, even in 
ER-negative cancer cells, suggesting that it can also operate by modulating alternative targets.[12],[13] 
In this respect, prominent roles have been proposed for discrete signaling proteins, such as protein 
kinase C (PKC), calmodulin, transforming growth factor- (TGF-);[14] the proto-oncogene c-MYC;[15] 
oxidative stress and NF-B[16]; mitogen-activated protein kinases (MAPK), including c-Jun N-terminal 
protein kinase (JNK) and p38 kinase;[17] and mitochondria and caspases.[18] However, no unique signal 
transduction pathway has been unambiguously attributed to TAM’s pro-apoptotic effects. As yet, the 
exact overall MOA underlying the apparent promiscuity of this blockbuster drug remains elusive. 
Clearly, a better understanding of this complexity would enable the development of new and 
potentially more effective analogues that retain all of the beneficial effects but are devoid of toxicity 
and could bypass the emergence of resistance often seen with TAM.[10],[13] Taking this together, we 
judged this bait would be a particularly interesting test case for MASPIT. 
 
III.1.1.2. SAR and conjugation site 
 
Since, to our knowledge, no crystallographic data of tamoxifen in complex with ER is available, we 
focused on the cocrystal structure of one of its main active metabolites, 4-OH-TAM, bound to the 
LBD of human ER, as described by Shiau and colleagues (Protein Data Bank (PDB) code: 3ERT).[19] 
The overall architecture of the ER LBD comprises a wedge-shaped molecular scaffold consisting of 
three layers of 12 -helices and a small two-stranded antiparallel -sheet.[20] The orientation of 4-
OH-TAM within the binding pocket is principally governed by the positioning of the phenolic A ring 
and the bulky side chain (Figure III.2A). 
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Figure III.2: A) The interactions of (Z)-4-hydroxytamoxifen (‘OHT’) with the LBD of human ER (PDB code: 
3ERT). The residues that form van der Waals contacts with the ligand are depicted as labeled arcs. Hydrogen 
bonding residues are shown in ball-and-stick representation, with individual hydrogen bonds represented as 
dashed cyan lines; the distance of each bond is indicated in Å. Figure from: Cell 1998, 95 (7), 927-937. B) Space-
filling model of the cocrystal structure of 4-OH-TAM bound to the LBD of ER. The ligand is shown in ball-and-
stick representation. Figure from: Journal of Medicinal Chemistry 2004, 47 (5), 1193-1206. 
 
The A ring of 4-OH-TAM is bound near helices 3 and 6, and its hydroxyl function forms three 
hydrogen bonds with the side chains of Glu-353, Arg-394 and a structurally conserved water 
molecule (W), respectively. The tertiary amine group of the flexible 2-(dimethylamino)ethoxy side 
chain, on the other hand, is stabilized by an electrostatic interaction with the -carboxylate of Asp-
351 (3.8 Å), while the rest of the chain has van der Waals contacts with Thr-347, Ala-350, and Trp-
383. Furthermore, this side chain projects out of the binding pocket between helices 3 and 11, 
thereby providing the structural basis of tamoxifen antagonism. Indeed, early SAR explorations 
already emphasized the importance of the bulky side chain of TAM analogues with respect to ER 
antagonism.[21],[22] More specifically, this extension of steric bulk from the rigid triphenylethylene 
framework promotes a conformation of the LBD, which imposes helix 12 to reposition over the 
coactivator recognition groove, thus preventing recruitment of coactivators and subsequent 
transcriptional activation.[23] 
 
Closer examination of a space-filling model of this cocrystal structure revealed that the methyl 
groups of the dimethylamino function of 4-OH-TAM are solvent exposed, providing an optimal 
conjugation site for derivatization without disruption of binding affinity (Figure III.2B).[24] Henceforth, 
this particular structural information has been exploited to successfully tether tamoxifen to a variety 
of scaffolds, such as doxorubicin-formaldehyde conjugates,[24] gold nanoparticles,[25] histone 
deacetylase (HDAC) inhibitors,[26] and bile acids,[27] for targeted breast cancer therapy. Guided by 
these structural and experimental data, we decided to explore the dimethylamino moiety of the 
tamoxifen bait as starting point for our conjugation efforts. 
 
 
 
 
 
Chapter III: A ‘clickable’ MTX reagent 
 
III.4 
 
III.1.2. Reversine 
 
III.1.2.1. MOA and motivation  
 
Reversine, a 2,6-disubstituted purine analogue (Figure III.3), was discovered in 2004 from a library of 
50 000 heterocyclic compounds designed around a large number of kinase-directed scaffolds in a 
search for small molecules which induce dedifferentiation of somatic cells.[28] In particular, reversine 
was found to promote the reversion of myogenic lineage-committed cells to multipotent 
mesenchymal progenitor cells, which can proliferate and redifferentiate into osteoblasts and 
adipocytes under lineage-specific inducing conditions. Additionally, it was shown that reversine 
treatment converts primary murine and human dermal fibroblasts into myogenic-competent cells, 
which can be induced to differentiate into skeletal muscle at high frequency both in vitro and in 
vivo.[29] As such, this small molecule holds great therapeutic potential related to its ability to 
reprogram somatic cells to a state of increased plasticity that can be manipulated to direct 
differentiation in different types of functional cells for repairing damaged tissues in e.g. 
cardiovascular or musculoskeletal diseases.[30]  
 
 
 
Figure III.3: Chemical structure of reversine, 2-(4-morpholinoanilino)-N
6
-cyclohexyladenine. The functional 
group selected as conjugation site is highlighted in red. 
 
Initial mechanism of action studies by Schultz and coworkers suggest that reversine acts as a dual 
inhibitor of nonmuscle myosin II (NM II) and MAPK and ERK kinase 1 (MEK1), and that inhibition of 
both is required for its activity.[31] The former is a cytoskeleton protein that plays a major role in 
processes that require cellular reshaping, such as cytokinesis.[32],[33] By blocking this protein, reversine 
leads to accumulation of cells in G2/M phase, which might contribute to the increase in cellular 
plasticity. MEK1, on the other hand, is part of the evolutionary conserved ERK/MAPK pathway (ERK, 
extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase), which is involved in 
the control of many fundamental cellular processes including cell proliferation, survival, 
differentiation, apoptosis, and stem cell fate determination.[34] Moreover, this signaling pathway also 
regulates histone acetylation, either via direct phosphorylation of histone acetyltransferase (HAT), or 
via indirect modulation of its activity.[31] It was shown that reversine treatment resulted in decreased 
acetylation of histone H3 by inhibition of MEK-dependent signaling, thereby potentially suppressing 
cell-fate-determining genes. Furthermore, the authors postulate that yet other factors might 
contribute to the activity of reversine, including activation of the phosphatidylinositol 3-kinase (PI3K) 
signaling pathway, which is implicated in the regulation of functions as diverse as cell metabolism, 
proliferation, cell cycle and survival.[35]  
 
In an effort to provide a molecular explanation for the function of reversine, D’Alise et al. tested its 
activity on a broad panel of protein kinases, the majority of which are involved in cell cycle regulation 
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and cytokinesis.[36] The small molecule was initially shown to specifically inhibit Aurora kinases, 
predominantly Aurora B (IC50 = 98.5 nM),
[37] both in vitro and in cell-based assays. The Aurora B 
protein kinase is involved in multiple mitotic functions, and its inhibition produces various effects 
including chromosome segregation failure, spindle checkpoint override and impairment of 
cytokinesis.[38],[39] Collectively, these outcomes result in polyploidy and suggest the direct 
involvement of Aurora B on reversine-induced dedifferentiation. However, a follow-up paper from 
the same group showed that the inhibition of these mitotic functions per se is not sufficient for 
dedifferentiation.[40] Rather, these authors suggest a model wherein inhibition of Aurora B-mediated 
histone H3 phosphorylation results in chromatin remodeling and ensuing restoration of the 
multipotent state. Furthermore, they performed in vitro inhibition assays on a battery of human 
mitotic kinases to ascertain whether reversine is a selective Aurora B inhibitor. Interestingly, their 
analysis indicated that reversine is a very potent (IC50 = 2.8 nM) and relatively selective ATP-
competitive inhibitor of human TTK (threonine and tyrosine kinase; also known as monopolar spindle 
1, MPS1, kinase).[37],[41] In fact, TTK was attributed to act as a primary target kinase for reversine in 
mitosis, operating downstream from Aurora B. 
 
Aurora kinases have also emerged as promising targets in cancer therapy, as they are frequently 
amplified and overexpressed in human tumors and as their inhibition is associated with the potential 
to induce cell-cycle arrest or apoptosis in a range of tumor cell types.[39],[42] In this respect, reversine 
was reported to display potent antitumor effects with concomitant good therapeutic selectivity in 
human acute myeloid leukemia cells,[36] and three human thyroid cancer cell lines.[43] However, as for 
its dedifferentiation capability, the exact molecular mechanism of reversine’s tumor suppression 
effect remains to be elucidated. Hence, this spurred our interest in profiling this bait in MASPIT, not 
least given its potential as a useful agent in regenerative medicine and cancer chemotherapy. 
 
III.1.2.2. SAR and conjugation site 
 
Preliminary SAR studies on reversine indicated the necessity of both the N9 hydrogen and the NH 
substitution at the C2 position of the purine ring, as activity completely plummeted upon removal of 
either.[28] Yet, a wide variety of oxygen- or sulfur-linked substituent groups were tolerated at C6 
without loss of activity, suggesting that a H-bond donor at this position is not essential. Furthermore, 
the scope of substituents accepted on the aniline moiety at the C2 position turned out to be rather 
restricted. These observations are consistent with the crystal structure of reversine in the active site 
of the Aurora B protein kinase (PDB code: 2VGO) (to our knowledge, no cocrystal structure of 
reversine bound to its primary target kinase, TTK, has been published).[36] The purine ring of reversine 
is positioned in the ATP-binding pocket via stacking interactions with the side chains of Ala-120, Leu-
170, Ala-173, Leu-99, and Leu-223 (Figure III.4.). More important, both its N3 and N9 hydrogen bond 
to Ala-173 and Glu-171, respectively. Moreover, in agreement with earlier suggestions from the SAR 
data, the NH substituent at C2 was shown to donate an additional hydrogen bond to the carbonyl 
group of the latter alanine residue. 
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Figure III.4: Ball-and-stick representation of the interaction of reversine with selected residues in the ATP-
binding pocket of X. laevis Aurora B (PDB code: 2VGO). A semitransparent molecular surface of reversine is 
shown. Hydrogen bonds are represented as dashed red/blue lines. Figure from: Molecular Cancer Therapeutics 
2008, 7 (5), 1140-1149.   
 
Hence, so as not to perturb this crucial H-bonding network, we selected the accessible morpholine 
moiety of reversine as the conjugation site, taking the liberty to exchange it for a piperazine in order 
to be able to attach an appropriate ligation handle. This strategy was based on earlier work by the 
Schultz group, successfully conjugating reversine to an agarose matrix for subsequent target 
identification studies by affinity chromatography.[31] Interestingly, these authors also synthesized a 
negative control probe comprising an inactive reversine analogue bearing an N9-methyl substituent. 
Indeed, later crystallographic data established the structural basis for this observed drop in activity, 
i.e. the presence of a substituent at N9 proved incompatible with the orientation of the purine ring 
within the Aurora B binding pocket since it would clash with the kinase main chain near Glu-171 
(Figure III.4.).[36]  
 
III.1.3. FK506[44] 
 
III.1.3.1. MOA and motivation  
 
FK506, or tacrolimus (Figure III.5.), is an immunosuppressant macrolide produced by Streptomyces 
tsukubaensis, which has found widespread use in organ transplantations as a means to lower the risk 
of organ rejection.[45] The cellular target of FK506 was identified as FK506 binding protein 12, FKBP12 
(‘12’ refers to the originally discovered 12 kDa isoform), a peptidyl-prolyl cis-trans isomerase 
(rotamase) that catalyzes the interconversion of the cis- and trans-rotamers of the peptidyl-prolyl 
amide bond of peptide and protein substrates.[46] As a naturally occurring heterodimerizer (see 
Section I.2), FK506 is known to first form a high affinity binary complex (Kd = 0.4 nM)
[47] with its 
principal cytoplasmic target FKBP12, which subsequently competitively binds to and concomitantly 
inhibits a second protein enzyme, calcineurin.[48] The latter is a heterodimeric (A/B) Ca2+- and 
calmodulin-dependent serine/threonine phosphatase essential for T cell activation and interleukin-2 
production. 
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Figure III.5: Chemical structure of FK506, or tacrolimus. The functional group selected as conjugation site is 
highlighted in red. 
 
MASPIT profiling of FK506 was pursued to evaluate whether this system would be applicable to the 
analysis of natural products or biologically active compounds that are not limited in molecular size 
and/or complexity. Furthermore, the well-established FK506-FKBP12 ligand-receptor pair has been 
frequently applied in proof-of-concept studies, as exemplified by the pioneering yeast three-hybrid 
work by Licitra and Liu (see Section I.4).[49] Hence, analogous to this landmark report, we selected this 
bait to validate the MASPIT cell-array screening platform for small molecule-target protein profiling. 
 
III.1.3.2. SAR and conjugation site 
 
An extensive amount of structure-activity data is available regarding the binding of FK506 to its 
receptors, which facilitates selection of the conjugation site. FK506 has been shown to comprise two 
distinct protein binding surfaces, an immunophilin-binding domain (binding element) and a 
calcineurin-binding one (effector element) (Figure III.6A).[47] 
 
Schreiber demonstrated that the allyl group within the calcineurin-binding domain of FK506 can be 
converted into a hydroxyethyl handle without significant loss in affinity for FKBP12.[50] Indeed, X-ray 
analysis of the FKBP12-FK506-calcineurin inhibitory complex confirmed that the terminal olefin (C39-
C40) of FK506 protrudes into an interface between calcineurin A and calcineurin B,[51] making this an 
attractive moiety for derivatization (Figure III.6B).[52] 
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Figure III.6: A) Structure of FK506 with indication of its FKBP12-binding domain (bracket) and calcineurin-
binding surface (circle). Figure from: Science 1991, 251 (4991), 283-287. B) Close-up of the binding interface of 
FKBP12 (magenta), FK506 (white), calcineurin A (green), and calcineurin B (blue) (PDB code: 1TCO). The 
terminal olefin (C39-C40) of FK506 is shown in space-filling representation. Figure from: Chemistry & Biology 
2002, 9 (1), 49-61.  
 
III.1.4. Simvastatin 
 
III.1.4.1. MOA and motivation  
 
Simvastatin is a semisynthetic derivative (bearing an additional methyl group in the acyl chain) of 
lovastatin, a fermentation product of the fungus Aspergillus terreus (Figure III.7). This hypolipidemic 
blockbuster drug is a member of the statin class of cholesterol-lowering agents that act through 
competitive inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) (Ki = 0.1 nM),
[53] the 
rate-limiting enzyme in the cholesterol biosynthetic pathway. Accordingly, the levels of HMGCR’s 
product, mevalonate, are reduced, which ultimately leads to upregulation of HMGCR, other enzymes 
of cholesterol biosynthesis, and most importantly induction of the hepatic low-density lipoprotein 
(LDL) receptor. As such, the hepatic reuptake of LDL via this receptor is increased, overall resulting in 
a lowering of plasma LDL cholesterol levels. Simvastatin was initially approved for marketing in 
Sweden in 1988 and subsequently worldwide prescribed for the primary and secondary prevention 
of cardiovascular diseases such as myocardial infarction, angina pectoris and other coronary events 
associated with elevated plasma cholesterol.[54] 
 
 
 
Figure III.7: Chemical structures of lovastatin and simvastatin. The functional group of simvastatin selected as 
conjugation site is highlighted in red. 
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A first motive to profile this bait in MASPIT is an attempt to map potential off-targets that may 
contribute to the adverse effects of the statin class of drugs. An important example of such an 
undesired class effect is myopathy or, in its more severe form, rhabdomyolysis.[55],[56],[57] Myopathy is 
characterized by a creatine kinase level greater than 10 times the upper limit of normal with 
accompanying symptoms including generalized muscle pain, fatigue, or weakness. Rhabdomyolysis 
results from a progress of this condition to severe and widespread injury to skeletal muscle and the 
subsequent accumulation of toxic degradation products in the blood and urine that can lead to acute 
renal failure. Although the typical incidence in controlled trials is less than 1%, in clinical practice 
statin therapy is associated with muscle problems in approximately 10-25% of treated patients.[55] 
For example, the risk for these adverse events increases significantly upon high dosage, long-term 
therapy in the elderly population or patients with renal insufficiency.[57] Moreover, the risk of statin-
induced myopathy is considerably increased by drug-drug interactions resulting from concomitant 
administration of other myotoxic drugs (particularly the fibrate gemfibrozil)[58],[59] or agents that may 
increase the plasma concentration of statins by potently inhibiting or sharing key metabolic 
pathways (e.g. CYP 3A4, in the case of lovastatin, simvastatin and atorvastatin).[60] Most notably, in 
2001, cerivastatin was voluntarily withdrawn from the global market by its manufacturer (Bayer) 
since the drug had been linked to a large number of fatal cases of rhabdomyolysis,[61],[62] thereby 
raising concerns regarding the safety of the entire statin class.[63] Remarkably, although more than 25 
years have elapsed since its initial report, the molecular mechanism underlying the pathogenesis of 
statin-mediated muscular adverse effects remains ambiguous.[64] 
 
In addition to their primary cholesterol lowering effect, statins have been shown to also exert 
cholesterol-independent or so-called pleiotropic effects, which contribute to their observed overall 
clinical outcome.[65],[66] By inhibiting the formation of mevalonate, statins also prevent the synthesis 
of important downstream isoprenoids, including farnesyl pyrophosphate (FPP) and geranylgeranyl 
pyrophosphate (GGPP). The latter serve as the source of the lipid moiety that is attached to proteins, 
such as Ras, Rho, and Rac, upon prenylation.[67] Hence, interference of statins with this post-
translational modification, which controls diverse cellular events, might account for their additional 
effects beyond lipid lowering. For example, inhibition of geranylgeranylation of Rho proteins has 
been suggested as an important anticancer effect of statins,[68] and selective inhibition of GTPases 
has been associated with reduced amyloid- production, thereby potentially reducing Alzheimer’s 
disease pathogenesis.[69] On the other hand, lovastatin has been shown to function as a 
chemopreventive agent independently of the mevalonate pathway through inhibition of the 
proteasome, leading to suppression of cell proliferation and apoptosis.[70]  
 
Apart from these biochemical effects statins have several other lipid-independent actions at the 
cellular and physiological level, including improvement of endothelial function, inhibition of cellular 
senescence, anti-inflammatory and antiatherogenic effects;[65] immunomodulatory properties;[71] 
bone anabolism;[72],[73] and the recently disclosed, somewhat unexpected, improvement of overall 
health and function of skeletal muscles in Duchenne muscular dystrophy (DMD) mice.[74] Although 
the involvement of certain signaling cascades, such as the Rho/Rho kinase and phosphatidylinositol-3 
kinase/Akt pathway, has been suggested, the actual mechanisms by which these and other 
pleiotropic effects are obtained have not yet been fully clarified,[66] thereby providing the second 
motive for our interest in this bait. 
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III.1.4.2. SAR and conjugation site 
 
Functioning as competitive inhibitors of HMGCR, all statins share a common HMG-like moiety as 
central pharmacophore, which mimics the natural substrate HMG-CoA.[75] In the case of the prodrug 
simvastatin this moiety is initially present in an inactive -hydroxy--valerolactone form, which is 
enzymatically hydrolyzed in vivo to the active ring-opened -hydroxy-acid form (Figure III.8).[53]  
 
 
 
Figure III.8: Chemical structures of the inactive (‘lactone’) and active (‘acid’) form of the HMG-like moiety 
(green) of simvastatin as well as the natural substrate HMG-CoA. ‘R’ denotes the substituted decalin system of 
simvastatin (see Figure III.7.) 
 
The active hydrolyzed HMG-like moiety of simvastatin occupies the HMG-binding pocket of the 
enzyme’s active site, thereby blocking access of the substrate HMG-CoA. Accordingly, the orientation 
of this moiety clearly resembles that of the substrate complex and is mainly governed by an intricate 
network of electrostatic and hydrogen bonding interactions (Figure III.9).[75] The terminal carboxylate 
forms an electrostatic interaction with Lys-735 and two hydrogen bonds with Ser-684 and Lys-692. 
Furthermore, the -hydroxyl group hydrogen bonds to Asp-690 and twice to Arg-590, whereas the -
hydroxy forms hydrogen bonds with Lys-691, Asn-755, and Glu-559. Additionally, this cocrystal 
structure reveals that simvastatin is kinked at the -OH of the HMG-like moiety, with its rigid 
hydrophobic substituted decalin ring system being accommodated in a shallow hydrophobic groove 
between helices L1 and L10. In this region the hydrophobic moiety of the statin makes van der 
Waals contacts with the hydrophobic side chains of Leu-562, Leu-853, Ala-856, and Leu-857. 
 
 
 
Figure III.9: Mode of binding of simvastatin (purple) to the catalytic portion of human HMGCR (PDB code: 
1HW9). Selected side chains of residues that contact the statin are depicted in ball-and-stick representation. 
Individual electrostatic and hydrogen bonds are represented as dotted black lines; the distance of each bond is 
indicated in Å. Figure from: Science 2001, 292 (5519), 1160-1164. 
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Consequently, we assumed that the acyl side chain would provide a suitable site for derivatization 
without significant interference with the ensemble of bonding interactions outlined above. Indeed, 
early SAR studies on statin-like analogues by Stokker et al. already indicated the necessity of the 
terminal carboxylate in the ring-opened HMG-like moiety, as its replacement with a carboxamido 
group ablated activity.[76] Likewise, Chidley et al. recognized that derivatization of atorvastatin at its 
carboxyl group interferes with binding to HMGCR. Nevertheless, the authors did prepare an O6-
benzylguanine-atorvastation conjugate in such a fashion, speculating that this derivative could allow 
the identification of off-targets using a SNAP-tag-based Y3H assay (Figure III.10).[77] Recently, the 
importance of the free carboxylate was once more confirmed by Hsieh et al.[73] This study described 
an anabolic polyaspartate-simvastatin analogue, which was constructed via amidation of the latter 
carboxyl, thereby displaying a more than 1000-fold drop in inhibitory activity against HMGCR (IC50 > 
30 μM) compared to the parent compound (IC50 = 11 nM)
[75] (Figure III.10).[73]  
 
 
  
Figure III.10: Comparison of different conjugation sites for the HMGCR inhibitors atorvastatin and 
simvastatin. 
 
In conclusion, since our primary aim was to uncover protein targets that may contribute to some of 
the obscure beneficial or detrimental effects of the statin class of drugs (rather than elucidating 
compound-specific effects), we decided to keep the central HMG-like pharmacophore intact and to 
focus our ligation efforts on the acyl side chain (Figure III.10). Remarkably, to our knowledge, no prior 
literature data regarding the conjugation of simvastatin at this specific site has been published. 
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III.2. Introduction 
 
As we move toward systems biology and personalized medicine, it will become increasingly 
important to profile small molecule-target interactions and to map this information with metabolic 
and signaling pathways. Indeed, many clinically used drugs have been found to be more promiscuous 
than originally thought. However, modulation of multiple targets can also cause harmful side effects, 
and another considerable challenge is to uncover the mechanisms of toxicities that are not directly 
related to the desired pharmacological effects of drugs (‘off-target pharmacology’). As classical in 
vitro target profiling requires time- and budget-consuming expression, purification, and assay setup 
for each individual target, it usually involves testing of a compound against a limited panel of related 
targets and is thus not comprehensive.  
 
The number of ‘tried-and-true’ drug targets is quite small.[78],[79] The emergence of molecular biology 
and the completion of the human genome project have hitherto failed to produce the expected flood 
of compounds acting on new targets. Unbiased, phenotype-based screens represent a promising 
approach to uncover drugs with a novel mechanism of action. For small molecules discovered in such 
screens, identifying the biological targets remains largely an ad hoc affair. Traditional approaches 
using affinity pull-down reagents[80] have been successful for the identification of new targets and 
have, for example, been recently employed to uncover targets involved in the teratogenic effects of 
thalidomide.[81] However, sensitivity can be limited, particularly for compounds that exhibit low 
binding affinity toward their target or for targets expressed at low levels. In these cases, the target 
protein may be lost during the washing steps, or its binding is obscured by the presence of highly 
abundant (non-specifically binding) proteins.[82] A systematic, widely applicable, and robust approach 
is badly needed. 
 
MASPIT (mammalian small molecule-protein interaction trap) is a three-hybrid trap variant of the 
original MAPPIT concept[83],[84] for the detection of small molecule-protein interactions. MASPIT 
makes use of a signaling-deficient cytokine receptor lacking STAT3 recruitment sites, which is fused 
to dihydrofolate reductase (DHFR) (Figure III.11). Fusion compounds consisting of an organic 
molecule of interest tethered to methotrexate (MTX) bind DHFR with very high affinity, allowing 
presentation of the organic molecule as ‘bait’. Binding of a chimeric ‘prey’ protein containing 
functional STAT3 binding sites on the MTX fusion compound (MFC) complements the STAT3 signaling 
cascade. Hence, ligand binding to the receptor will lead to activation of receptor-associated JAK2 
kinases, followed by tyrosine phosphorylation of the STAT3 recruitment motifs of the prey chimeras. 
Subsequent binding and activation of STAT3 is then easily measured using a STAT3-responsive 
reporter gene. 
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Figure III.11: Outline of the MASPIT system. Mammalian cells express a signaling-deficient cytokine receptor 
containing mutated STAT3 recruitment sites (grey dots), which is fused to DHFR (D). Upon addition of an MFC, 
which is readily taken up by the cells, the MTX moiety binds to DHFR with high affinity, resulting in the small 
organic molecule being displayed as bait. A second hybrid polypeptide expressed in the cells consists of a prey 
protein (Y) coupled to a gp130 cytokine receptor fragment that contains functional STAT3 docking sites (black 
dots). Physical interaction between the bait small molecule and the prey protein brings the cytokine receptor 
fragments into close proximity, reconstituting a functional cytokine receptor system. When these cells are 
stimulated with the appropriate cytokine ligand (cyt), constitutively associated JAK2 kinases are activated, 
leading to phosphorylation of tyrosine molecules in the gp130 moiety (P) and resulting in the recruitment of 
STAT3 transcription factors. Subsequently, these STATs are activated through phosphorylation (P) by the 
activated JAKs. Finally, activated STAT3 complexes migrate to the nucleus as dimers, where they induce 
expression of a STAT3-dependent reporter gene. 
 
MASPIT can be used both analytically, to study designated small molecule-protein interactions, and 
in searches for interaction partners. Since 2006, our research group has been involved in a large-scale 
human interactome mapping program.[85],[86] As a consequence, a large portion of the human 
ORFeome is being transferred into MASPIT prey vectors, currently encompassing more than 12 000 
ORFs.[87] To optimize screening, a cellular array screening platform was developed.[88] In brief, each 
prey plasmid from the collection, together with a luciferase reporter construct, was mixed with a 
transfection reagent to generate prey arrays in 384-well plates. After reverse transfection with a cell 
pool expressing the receptor-DHFR chimera and addition of the bait MFC, followed by ligand-induced 
activation of the system, positive interactors were detected simply by measuring the activity of a 
STAT3-dependent luciferase reporter gene. 
 
In contrast to classical target-based profiling, this mammalian three-hybrid system can provide 
information regarding unanticipated small molecule-target protein interactions. Another important 
advantage of MASPIT is the fact that the interactions between small molecules and target proteins 
occur in living mammalian cells rather than in vitro. Consequently, this might reveal potential effects 
of post-translational modifications of the target or of the target’s association with additional proteins 
or other intracellular molecules on small molecule binding.  
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A necessary component of successful MASPIT applications, however, is the synthesis of appropriate 
MFCs. Structure-activity relationship (SAR) studies of MTX derivatives have emphasized the 
importance of selective conjugation to the -carboxylic acid of the glutamate moiety to ensure high 
affinity binding to DHFR through interaction of this enzyme with the free -carboxylic acid.[89] Hence, 
an objective of this study was to synthesize a versatile MTX-based building block and explore its use 
for easy and straightforward ligation to bait small molecules of interest. 
 
III.3. Results and Discussion 
 
To swiftly access a wide variety of MFCs with minimal effort, we envisaged the synthesis of a general 
MTX conjugate appropriately equipped with a ligation handle. It was estimated that a copper-
catalyzed 3+2 azide alkyne cycloaddition (CuAAC)[90] would be a suitable method for the attachment 
of the small molecule baits to the MTX-linker conjugates, given the high chemoselectivity, mild 
reaction conditions, and high tolerance for a wide diversity of reaction solvents.  
 
A terminal azido group was selected as a ligation handle. To discourage steric hindrance of fusion 
partners, which could cause the MFC to bind suboptimally to DHFR or allow one to overlook targets 
that might interact with the unconjugated bait, a poly(ethylene glycol) (PEG) linker was introduced 
between the -carboxylic acid and the ligation handle to allow optimal interaction with prey chimeras 
(Scheme III.1). The synthesis was commenced with the generation of an amino/azido bifunctionalized 
PEG linker. To this end poly(ethyleneglycols) were treated with methanesulfonyl chloride. Treatment 
of the formed bismesylates 2 with sodium azide yielded diazides 3. Desymmetrization of these 
compounds towards the corresponding azidoamines 4 was carried out in a biphasic system using 
triphenylphosphine and dilute hydrochloric acid.[91] 
 
 
 
Scheme III.1: Regioselective synthetic approach to a general MTX reagent with a terminal azido ligation 
handle. [i] MsCl, Et3N, CH2Cl2, 0°C; [ii] NaN3, DMF, 60°C, (a 92%; b 98%; c 93% two steps); [iii] first PPh3, 2.0M 
HCl, toluene; then NaOH, (a 81%; b 88%; c 89%); [iv] 5, TPTU, Et3N, DMF, (a 80%; b 49%; c 42%). 
 
With the azido-PEG spacers in hand, attention was focused to the -selective condensation of MTX to 
4. Initial condensations using EDC or other standard peptide coupling reagents in DMF consistently 
provided an intractable mixture of the - and the -amide. Variation of temperature, coupling 
reagent and solvent had negligible effect on the product distribution. This can be explained by the 
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initial formation of an acid anhydride intermediate in the glutamoyl moiety of MTX, which is 
subsequently opened by the amine of 4 (Scheme III.2). To circumvent the formation of this 
regioisomeric mixture, we condensed -tert-butylmethotrexate 5[92] with the PEG azidoamines using 
TPTU reagent to obtain satisfactory yields (Scheme III.1). Three different MTX-azido reagents (6a-c) 
were thus synthesized which differed with regard to the number of PEG units. 
 
 
 
Scheme III.2: Formation of a regioisomeric mixture of methotrexylamides via an anhydride intermediate. 
 
The utility of these MTX-based ligation reagents to form MFCs was demonstrated for three 
structurally diverse baits of interest, beginning with tamoxifen. The desired tamoxifen-MTX fusion 
compounds 8a-c were prepared via click reaction with N-desmethyl-N-propargyltamoxifen (7), which 
was obtained by propargylation of N-desmethyltamoxifen hydrochloride[25] under alkaline conditions 
(Scheme III.3, III.4). 
 
 
 
Scheme III.3: Synthesis of alkyne-functionalized tamoxifen. [i] first ACE-Cl, DCE, ; then MeOH, , 94%; [ii] 
propargyl bromide, K2CO3, MeCN, 60°C, 57%. 
 
 
 
 
Chapter III: A ‘clickable’ MTX reagent 
 
III.16 
 
 
 
Scheme III.4: Synthesis of click-coupled tamoxifen-MFCs. [i] TFA, CH2Cl2; [ii] 7, CuSO4, Na ascorbate, TBTA, 
H2O/tBuOH, 80°C, (a 50%; b 52%; c 63% two steps). 
 
To investigate the possible influence of the triazole ring on the MASPIT signal, we also prepared an 
amide-coupled MFC. Toward this end, the required carboxylate functionalized analogue of tamoxifen 
was generated in two steps from N-desmethyltamoxifen hydrochloride. Alkylation with methyl 
bromoacetate followed by saponification of the ester with concomitant neutralization provided the 
acid (10) (Scheme III.5). 
 
 
 
Scheme III.5: Synthesis of carboxylate-functionalized tamoxifen. [i] Methyl bromoacetate, DIPEA, CH2Cl2, 0°C, 
91%; [ii] first NaOH, MeOH, 50°C; then HCl,  quant. 
 
With the acid in hand, the MFC was constructed. Methotrexate derivative 6a was deprotected with 
trifluoroacetic acid and subsequently reduced under Staudinger conditions. Purification of the crude 
amine followed by PyBOP-mediated condensation to acid 10 yielded MFC 11 in 33% after HPLC 
purification (Scheme III.6). 
 
 
 
Scheme III.6: Synthesis of amide-coupled tamoxifen-MFC. [i] TFA, CH2Cl2; [ii] Me3P, THF, H2O; [iii] 10, PyBOP, 
DIPEA, DMF, 33%. 
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To evaluate tamoxifen-MTX conjugates 8a-c and 11 in MASPIT, estrogen receptor alpha (ER1), the 
established primary target of tamoxifen, was selected as a prey protein. Hence, HEK293T cells were 
transiently transfected with receptor-DHFR chimera, ER1 prey constructs, and a STAT3-dependent 
luciferase reporter gene. Reporter activity was shown to be dependent on MFC concentration, with a 
similar pattern for all evaluated tamoxifen MFCs and a maximal signal within the 0.1-1 µM range 
(Figure III.12). Although the optimal spacer length may be determined by the nature of the prey, we 
decided to use a PEG6 linker for the synthesis of two additional MFCs. 
 
 
 
Figure III.12: Comparison of different tamoxifen MFCs. Cells were transiently transfected with a pCLG-eDHFR 
receptor-DHFR plasmid, an ER1 prey construct, and a luciferase reporter plasmid. They were then treated with 
combinations of leptin and the indicated concentration of either of the different MTX-tamoxifen fusion 
compounds: click-coupled through a tetra- (PEG4), hexa- (PEG6), or octa(ethylene glycol) linker (PEG8), or 
amide-coupled through a hexa(ethylene glycol) linker (amide). The graph shows average luciferase activity of 
triplicate samples. Error bars represent the standard deviation. 
 
Reversine, a small molecule found to promote dedifferentiation of committed cells into multipotent 
progenitor-type cells,[28] was selected as a second bait of interest. In vitro inhibition assays on a 
battery of human mitotic kinases recently indicated that TTK (also known as MPS1) acts as a primary 
target kinase for reversine (IC50 = 2.8 nM).
[37] A click-coupled MFC with reversine (18) was obtained 
by CuAAC between the hydrolyzed 6a and the alkynylated reversine derivative 17 (Scheme III.7). To 
obtain the latter analogue, first N-(4-nitrophenyl)piperazine was propargylated under alkaline 
conditions. Tin(II)-mediated reduction[93] of the nitro moiety gave access to aniline 14, which could be 
reacted with N6-cyclohexyl-2-fluoroadenine[28] at elevated temperature under microwave irradiation 
to obtain alkyne-functionalized reversine 17 as a solid. 
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Scheme III.7: Synthesis of alkyne-functionalized reversine. [i] propargyl bromide, K2CO3, MeCN, 60°C, 95%; [ii] 
SnCl2, EtOH, , 87%; [iii] cyclohexylamine, DIPEA, nBuOH, 80°C, 64%; [iv] EtOH, 130°C (µW), 36%.  
 
Using TTK as a prey plasmid, stimulation with a combination of leptin and MFC 18 gave maximal 
luciferase activity at a MFC concentration of 5 µM (Figure III.13). 
 
 
 
 
 
Figure III.13: Evaluation of reversine MFC. Cells transfected with a pCLL-eDHFR receptor-DHFR construct, a 
luciferase reporter plasmid, and a TTK prey plasmid were stimulated with a combination of leptin and the 
indicated concentration of MFC. The graph shows average luciferase activity of triplicate samples. Error bars 
represent the standard deviation. 
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Tacrolimus (FK506), an immunosuppressant macrolide produced by Streptomyces tsukubaensis, was 
selected as a third model bait. FK506 has found widespread use in organ transplantations as a means 
to lower the risk of organ rejection. The cellular target of FK506 was identified as peptidyl-prolyl cis-
trans isomerase FKBP12. Binding of FK506 to FKBP12 inhibits calcineurin, a protein phosphatase 
essential for T cell activation and interleukin expression.[48] FK506 is known to bind to its principal 
intracellular target, FKBP12, with high affinity,[47] and an extensive amount of structure-activity data 
is available regarding the binding of FK506 to its receptors, which facilitates selection of the 
attachment site. FK506 has been modified to create affinity reagents for the isolation and 
identification of its receptors.[46] 
 
Successful MASPIT profiling of FK506, a highly complex natural product, was pursued to provide 
clear-cut proof that this system is not confined to evaluation of biologically active compounds that 
are limited in molecular size and/or complexity. We additionally used this bait to show that selective 
conjugation of MTX to FK506 via the -carboxylic acid offers advantages in readout sensitivity in 
comparison with the non-regiomeric conjugate mixture previously used. Our final goal was to 
demonstrate the feasibility of FK506 MFC in identifying protein targets of small molecules using 
MASPIT in the cellular array assay by screening for proteins that bind to FK506. 
 
In order to attach FK506 to the azido-functionalized MTX to form the desired MFC, a terminal 
acetylene had to be grafted onto the macrolide (Scheme III.7). The attachment position of this 
acetylene was meticulously chosen so as to minimize the loss in affinity for FKBP12. Schreiber 
demonstrated that the allyl moiety of FK506 can be converted into a hydroxyethyl handle (as with 
compound 19) without significant loss of activity.[50] Simple alkylation of the primary hydroxy with 
propargyl bromide under alkaline conditions proceeded with poor regioselectivity, presumably due 
to the lower pKa of the hydroxyl group of the ketal functionality. Significantly better regioselectivity 
was achieved upon reaction of compound 19 with TMS-ethynylphenol[94] under Mitsunobu 
conditions.[95] Subsequent treatment with TBAF/HOAc and hydrofluoric acid[96] cleanly removed all 
silyl protecting groups to give acetylene 22. After removal of the remaining tert-butylester of MTX-
azide 6a, CuAAC with 22 afforded the desired MFC (23). 
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Scheme III.7: Synthesis of alkyne-functionalized FK506 and its corresponding MFC.  
 
Evaluation of MTX-FK506 conjugate 23 in MASPIT showed that reporter activity was induced only in 
cells that were treated with both the bait MFC and the cytokine ligand that activates the assay 
(Figure III.14A). No luciferase activity was measured in cells transfected with a combination of the 
receptor-DHFR chimera with an empty control prey construct. Co-transfection of the receptor-DHFR 
chimera with a positive control prey that binds to the receptor chimera itself (EFHA1) resulted in bait 
MFC-independent reporter gene induction. 
 
Next, performance of the -substituted MTX-FK506 conjugate was compared with that of a non-
regiomeric conjugate mixture.[97] HEK293T cells expressing receptor-DHFR chimera and FKBP12 prey 
were treated with the cytokine ligand and a concentration gradient of either of the two bait MFCs 
(Figure III.14B). Clearly, stronger signals were obtained with the regioselective -substituted MTX-
FK506 fusion compound. This observation was anticipated, as the -substituted fusion compound, 
which constituted roughly half of the non-regiomeric conjugate mixture, inhibits formation of the 
three-hybrid complex necessary for restoration of the functional MASPIT receptor complex, due to its 
inability to bind to DHFR. 
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Figure III.14: A) Evaluation of the MTX-FK506 conjugate 23 in MASPIT. Cells transfected with a pCLL-eDHFR 
receptor-DHFR construct, a luciferase reporter plasmid, and either an empty, EFHA1, or FKBP12 prey construct 
were treated with leptin and/or 1 µM MTX-FK506. Luciferase activity was expressed as relative light units (RLU) 
and calculated as the average signal of triplicate samples. Error bars represent the standard deviation. B) 
Comparison of the regioselective and a non-regiomeric MTX-FK506 conjugate mixture. Cells transfected with 
a receptor-DHFR construct (pCLL-eDHFR), FKBP12 prey plasmid, and a luciferase reporter plasmid were treated 
with leptin and the indicated concentration of either MTX-FK506 conjugate. The graph shows the average 
luciferase activity of triplicate samples. Error bars represent the standard deviation. 
 
Having confirmed the functionality of the MTX-FK506 fusion compounds in MASPIT, we next 
evaluated whether the regioselective MFC 23 could be applied in a cellular array screen for targets of 
FK506. A pilot collection of nearly 2000 full-length human ORF preys, spotted as transfection 
mixtures in 384-well microtiter plates,[88] was reverse-transfected with a pool of HEK293T cells 
transiently transfected with the receptor-DHFR plasmid. Duplicate wells were treated with either 
MTX-FK506 alone or in combination with the cytokine ligand. The results are shown as a dot plot of 
normalized luciferase readings for both treatments (Figure III.15). Applying a cutoff of tenfold 
induced luciferase activity for MTX-FK506/ligand-treated over MTX-FK506-treated, the only prey that 
scored positive corresponds to FKBP12. Importantly, no other previously reported FK506 target 
proteins were present in the screened collection. 
 
This arrayed screening approach nicely complements the MASPIT cDNA library screening protocol[98] 
that has previously been used to search for targets of the kinase inhibitor PD173955. The 
complementarity of the latter assay lies mainly in the fact that, in contrast to the full-length ORF 
collection screened by the cellular array assay, a cDNA library also contains partial ORFs encoding 
protein fragments or domains. Interacting sub-modules in proteins, when isolated from regulatory 
domains, can allow an interaction to be identified that does not occur in the presence of the 
regulatory domains. In addition, a cDNA library generally covers a larger portion of the proteome, 
including multiple protein isoforms for many genes. However, the increased complexity of cDNA 
libraries, along with the fact that such collections are pooled and not arrayed, makes the screening 
process much more complicated and time-consuming. 
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Figure III.15: MASPIT cellular array screen with the MTX-FK506 conjugate 23. An array containing 1879 
distinct preys was reverse transfected with cells transfected with a receptor-DHFR plasmid (pCLL-eDHFR), and 
duplicate wells were treated with either 1 µM MTX-FK506 alone or with 1 µM MTX-FK506 combined with 
leptin. The dot plot shows normalized average luciferase values for each prey. The dashed line indicates the 
threshold of tenfold induced luciferase activity for MTX-FK506- and leptin-treated over MTX-FK506-treated 
values. The position of the FKBP12 prey in the plot is indicated. 
 
III.4. Conclusions 
 
In conclusion, we have presented a scalable synthesis of a versatile MTX reagent that allows for the 
rapid synthesis of MFCs compatible with MASPIT from any acetylene-functionalized compound using 
‘click chemistry’. The conjugation methodology, however, is not limited to click chemistry but is also 
applicable for Staudinger-type ligations or standard peptide coupling conditions. This allows easy and 
fast access to various MFCs, thereby minimizing the number of chemical manipulations for each 
construct. The results presented here clearly demonstrate the versatility of the new MTX reagent to 
generate an MFC of interest for use in MASPIT. Furthermore, we demonstrated the clear benefit of -
selective functionalization of methotrexate with respect to the signal output. In a cellular array 
screen, FKBP12 was selectively identified as an interaction partner of FK506, thereby validating the 
MASPIT system and showing its potential for the identification of the molecular targets responsible 
for the beneficial or detrimental effects of small molecule drugs. 
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III.5. Experimental Section 
 
III.5.1. Synthesis 
 
A thorough NMR analysis of compounds 6a, 8a, 11, 18 and 22 has been carried out by the NMR and 
Structure Analysis Unit, Department of Organic Chemistry, Faculty of Sciences, Ghent University (Prof. 
José Martins, Dr. Davy Sinnaeve, Dr. Freya Van den Broeck). 
 
General: All reactions were performed under nitrogen and at ambient temperature, unless stated 
otherwise. FK506 (Tacrolimus) was purchased from LC laboratories. All other reagents and solvents 
were purchased from Sigma-Aldrich, Acros Organics, or TCI Europe, and used as received. Reactions 
were monitored by thin-layer chromatography on TLC aluminum sheets (Macherey-Nagel, Alugram 
Sil G/UV254) with detection by spraying with a solution of (NH4)6Mo7O24·4H2O (25 g/L) and 
(NH4)4Ce(SO4)4·2H2O (10 g/L) in H2SO4 (10%) followed by charring or Ninhydrin (2% in ethanol). 
Column chromatography was performed with 60 Å silica gel (Biosolve, 32-63 μm). LC-MS analyses 
were carried out on a Waters Alliance 2695 XE separation Module by using a Phenomenex Luna 
reversed-phase C18 column (1002.00 mm, 3 μm) and a gradient system of HCOOH in H2O (0.1 %, 
v/v)/HCOOH in CH3CN (0.1 %, v/v) at a flow rate of 0.4 mL/min. High-resolution spectra were 
recorded on a Waters LCT Premier XE Mass spectrometer. 1H and 13C NMR spectra were measured 
on a Varian Mercury-300BB (300/75 MHz) spectrometer, an Avance III Bruker (500/125 MHz) 
spectrometer equipped with a BBI probe, or an Avance II Bruker (700/176 MHz) spectrometer 
equipped with a 1H/13C/15N TXI-Z probe. Chemical shifts () are given in ppm relative to 
tetramethylsilane (1H NMR) or CDCl3, CD3OD or SO(CD3)2 (
13C NMR) as internal standards. Coupling 
constants are given in Hz. Preparative HPLC purifications were carried out by using a Laprep 
preparative RP-HPLC system equipped with a Xbridge Prep C18 column (19250 mm, 5 μm) or a 
Phenomenex Luna C18 column (21.20250 mm, 5 μm) with a gradient system of HCOOH in H2O (0.2 
%, v/v)/CH3CN at a flow rate of 17.5 mL/min. Microwave experiments were performed using a 
Milestone Microsynth under fiberoptic internal temperature control. 
 
,-Diazido,,-dideoxy-hexa(ethylene glycol) (3a): To an ice cooled solution of hexa(ethylene 
glycol) (5.0 g, 17.7 mmol) in anhydrous CH2Cl2 (30 mL), triethylamine (7.7 mL, 55 mmol) and MsCl (3.1 
mL, 40 mmol) were added. The resulting solution was stirred overnight letting the temperature rise 
to RT. The reaction mixture was subsequently poured in 0.5N HCl (100 mL) and after separation of 
both phases, the aqueous layer was washed with CH2Cl2 (3 x 50 mL). The combined organic phases 
were next washed with sat. NaHCO3 (50 mL) and dried over Na2SO4. After filtration and removal of all 
volatiles under reduced pressure, the crude bismesylate was taken up in DMF (200 mL). Sodium azide 
(4.0 g, 61.5 mmol) was added and the reaction mixture was stirred overnight at 60°C. The reaction 
mixture was concentrated in vacuo. To the residue were added water (100 mL) and EtOAc (100 mL) 
and the biphasic mixture was agitated until the residue was completely dissolved and transferred to 
a separation funnel. The organic layer was separated and the aqueous fraction was washed 
repeatedly with EtOAc (3 x 100 mL). All EtOAc fractions were pooled, dried on Na2SO4 and taken to 
dryness. The residue was purified by silica gel chromatography (hexane/EtOAc, 1:3 v/v) yielding the 
title compound (5.4 g, 16.2 mmol, 92%) as a colorless oil. 1H NMR (300 MHz, CDCl3)  = 3.70-3.65 (m, 
20H), 3.38 (t, 4H, J = 5.0 Hz); 13C NMR (75 MHz, CDCl3)  = 70.4-70.3 (wide peak), 69.7, 50.4; HRMS: 
calcd. for C12H24N6O5Na [M+Na]
+: 355.1700, found: 355.1709. 
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,-Diazido,,-dideoxy-tetra(ethylene glycol) (3b): Tetra(ethylene glycol) (4.9 g, 25.0 mmol) was 
transformed into the corresponding diazide using the procedure described for compound 3a. Silica 
gel chromatography (toluene/EtOAc, 1:1 v/v) yielded the title compound (6.0 g, 24.4 mmol, 98%) as a 
slightly yellow liquid. 1H NMR (300 MHz, CDCl3)  = 3.70-3.67 (m, 12H), 3.39 (t, 4H, J = 5.0 Hz); 
13C 
NMR (75 MHz, CDCl3)  = 70.8 (wide peak), 70.1, 50.7; HRMS: calcd. for C8H16N6O3Na [M+Na]
+: 
267.1176, found: 267.1177. 
 
,-Diazido,,-dideoxy-octa(ethylene glycol) (3c): Octa(ethylene glycol) (904 mg, 2.4 mmol) was 
transformed into the corresponding diazide using the procedure described for compound 3a. Silica 
gel chromatography (toluene/EtOAc, 15:85 v/v) yielded the title compound (950 mg, 2.3 mmol, 93%) 
as a colorless liquid. 1H NMR (300 MHz, CDCl3)  = 3.70-3.65 (m, 28H), 3.39 (t, 4H, J = 5.0 Hz); 
13C NMR 
(75 MHz, CDCl3) δ = 70.7-70.6 (wide peak), 70.1, 50.7; HRMS: calcd. for C16H32N6O7K [M+K]
+: 
459.1964, found: 459.1933. 
 
-Amino,-azido,,-dideoxy-hexa(ethylene glycol) (4a): A solution of 3a (5.4 g, 16.2 mmol) in 
toluene (130 mL) was treated with 2.0M HCl (130 mL) followed by addition of a solution of PPh3 (4.28 
g, 16.3 mmol, 1 eq.) in toluene (15 mL) and the resulting biphasic mixture was vigorously stirred 
overnight at RT. After separation of both phases, the aqueous layer was washed with toluene (3 x 
100 mL). The aqueous layer was next cooled to 0°C and the pH was adjusted to pH 10 by slow 
addition of 3N NaOH. The alkaline solution was concentrated in vacuo and coevaporated once with 
toluene. The semisolid residue was extracted with EtOAc (3 x 150 mL). After drying of the combined 
organic layers over Na2SO4, the residue was purified by column chromatography (CH2Cl2/MeOH, 4:1 
v/v with 0.25% NH4OH) affording the title compound (4.2 g, 13.2 mmol, 81%) as a colorless oil. 
1H 
NMR (300 MHz, CD3OD)  = 3.68-3.61 (m, 18H), 3.53 (t, 2H, J = 5.4 Hz), 3.37 (t, 2H, J = 5.0 Hz), 2.81 (t, 
2H, J = 5.4 Hz); 13C NMR (75 MHz, CD3OD)  = 72.7, 71.3-71.2 (wide peak), 71.0, 70.8, 51.5, 41.7; 
HRMS: calcd. for C12H27N4O5 [M+H]
+: 307.1976, found: 307.1953. 
 
-Amino,-azido,,-dideoxy-tetra(ethylene glycol) (4b): Desymmetrization of diazide 3b (5.9 g, 
24.0 mmol) towards the corresponding azidoamine was carried out analogously to the procedure 
described for compound 4a. Silica gel chromatography (CH2Cl2/MeOH, 9:1 v/v with 1.0% NH4OH) 
yielded the title compound (4.6 g, 21.2 mmol, 88%) as a pale yellow oil. 1H NMR (300 MHz, CD3OD)  
= 4.83-4.80 (m, 2H), 3.68-3.61 (m, 10H), 3.51 (t, 2H, J = 5.3 Hz), 3.37 (t, 2H, J = 5.0 Hz), 2.78 (t, 2H, J = 
5.3 Hz); 13C NMR (75 MHz, CD3OD)  = 73.4, 71.6-71.1 (wide peak), 51.8, 42.1; HRMS: calcd. for 
C8H19N4O3 [M+H]
+: 219.1452, found: 219.1405. 
 
-Amino,-azido,,-dideoxy-octa(ethylene glycol) (4c): Desymmetrization of diazide 3c (927 mg, 
2.2 mmol) towards the corresponding azidoamine was carried out analogously to the procedure 
described for compound 4a, affording the title compound (778 mg, 2.0 mmol, 89%) as a pale yellow 
liquid. 1H NMR (300 MHz, CD3OD)  = 4.79-4.77 (m, 2H), 3.69-3.61 (m, 26H), 3.53 (t, 2H, J = 5.4 Hz), 
3.37 (t, 2H, J = 5.0 Hz), 2.80 (t, 2H, J = 5.4 Hz); 13C NMR (75 MHz, CD3OD)  = 73.1, 71.6-71.1 (wide 
peak), 51.8, 42.0; HRMS: calcd. for C16H35N4O7 [M+H]
+: 395.2500, found: 395.2406. 
 
MTX-PEG6-N3 reagent (6a): A solution of methotrexate--tert-butylester 5
[92] (1.02 g, 2.0 mmol) and 
aminoazide 4a (1.28 g, 4.2 mmol, 2.1 eq.) in DMF was treated with triethylamine (560 μL, 4.0 mmol, 
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2 eq.) and TPTU (600 mg, 2.0 mmol, 1 eq.) and the resulting reaction mixture was stirred for 48 h at 
RT. After removal of the solvent under reduced pressure, the residue was purified by silica gel 
chromatography (CH2Cl2/MeOH, 93:7 v/v with 0.4% NH4OH). A co-eluting contaminant could be 
removed by precipitation from MeOH:Et2O yielding the title compound (1.29 g, 1.6 mmol, 80%) as an 
ochre-yellow solid. HRMS calcd. for C36H55N12O9 [M+H]
+: 799.4210, found: 799.4211. 
 
Nearly complete assignment of the 1H and 13C resonances visible in the spectra could be achieved 
(see Table III.1).  
 
 
 
Figure III.16: Labeling scheme of MTX-N3 6a and its PEG6 tail. 
 
The methyl resonance of the tBu ester group is easily identified from its integration value; the 
quaternary carbon is located via HMBC from the tBu protons. This leaves the N-methyl as the only 
remaining methyl group to be assigned. The N-Me protons correlate to one Cq of the benzene-like 
ring, one aromatic CH carbon and the CH2 carbon on the other side of the N-Me group. In the 
aromatic region three doublets are visible, only two of which correlate mutually in the COSY, 
identifying these as belonging to the benzene-like aromatic ring. The third doublet has no directly 
attached carbon and is therefore the amide of the glutamate moiety (amide-1). The only triplet in the 
aromatic region belongs to the other amide (amide-2; no correlation in the HSQC, triplet expected 
from the neighbouring CH2 group). The remaining singlet in the aromatic region is attributed to the 
only proton directly attached to the pteridine heterocycle. These assigned resonances gave sufficient 
starting points for further assignment as follows. 
 
The amide carbons C18=O (amide-1) and C23=O (amide-2) were identified at 166.20 and 171.61 ppm, 
respectively, from nJCH correlations to their respective amide proton. Amide-1 also correlates to 
another Cq at 171.51 ppm, which itself correlates to the C20H proton from the glutamate moiety in 
MTX-N3. This identifies the latter Cq as the ester carbonyl carbon C26. The aromatic CH units were 
discriminated using a set of nJCH correlations from which both benzene Cq’s could be identified, and 
later assigned via connections to the N-Me and N-CH2 protons and the amide-1 proton. The 
assignment of the aromatic protons was independently confirmed from the relative intensity and 
pattern of NOE cross-peaks in the NOESY spectrum. Assignment of the pteridine heterocycle was less 
straightforward and remains incomplete. This is due in part to the appearance of the NH2 protons, 
which are considerably broadened due to intramolecular exchange phenomena (rotation along the 
C-NH2 bond), as well as intermolecular exchange with water. As a result, no correlations can be 
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developed to the directly attached or remote carbons from the NH2 groups. A broadened Cq carbon 
at 148.71 ppm was tentatively assigned (see Table III.1). 
 
In all, the above assignments allow to identify all 13C resonances observed above 100 ppm in the 13C 
APT spectrum. With the exception of the N-Me resonance, all proton resonances between 3 and 4 
ppm are contributed by CH2 type groups, as evidenced by the multiplicity editing in the 
1H-13C HSQC 
spectrum. Only four CH2 units, labeled a, b, c and d (from left to right) can be separated in this area. 
Two of these (b and c) are partially overlapping in the 1H spectrum, but can be clearly discriminated 
in the HSQC. Based on the 13C chemical shifts of these 4 CH2 moieties, two can be attributed to CH2-O 
type units (a, c), as in the PEG chain, and two to CH2-X type units (b, d), with X designating either the 
azide or amide function terminating the PEG chain. From the COSY a is seen to couple with b, while c 
couples with d, indicating that (a,b) and (c,d) are part of the same ethylene unit. Since the amide-2 
NH correlates with the carbon directly bound with d, the (c,d) ethylene unit is on the amide side of 
the PEG-chain, while the (a,b) unit is on the azide side. Thus, the (a,b) unit is identical to the -
ethylene fragment, while the (c,d) unit is identical to the -ethylene segment (see labeling scheme). 
Both CH2 groups within each of these ethylene moieties were assigned based on chemical shift 
arguments (CH2–O  highest ppm value).  
 
The remaining proton and carbon resonances are contributed by the PEG chain extending in between 
the - and -ethylene segments. They extend from 3.54 to 3.44 pm in the 1H spectrum and 69.80 to 
69.07 in the 13C spectrum. While some resolution is offered along the 13C dimension, it is insufficient 
to attempt an assignment of the 4 remaining PEG-repeat units.  
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Table III.1: 1H and 13C NMR assignment of MTX-PEG6-N3 6a in DMSO-d6 at 298K (700/176 MHz). 
 
Label 1H (ppm) 13C (ppm) Multiplicity 
1 + 12 
(8.49/8.27); 
(7.55/7.09) 
- br s 
2 - n.a. 
 4 - n.a. 
 5 - n.a. 
 6 - 148.71 
 9 8.63 148.92 s 
10 - n.a. 
 13 4.82 54.48 s 
14 - 150.77 
 15 6.81 111.06 d  
16 7.72 128.9 d  
17 - 121.27 
 18 - 166.2 
 19 8.26 - d  
20 4.21 52.99 m 
21 a 1.99 / b 1.89 31.77 m 
22 2.19 26.46 m 
23 - 171.61 
 24 7.89 - t  
25 3.22 52.99 s 
26 - 171.51 
 27 - 80.27 
 28 1.38 27.67 s 
1 3.16 (d) 38.55 m 
2 3.36 (c) 69.09 t 
- 3.54 to 3.44 69.80 to 69.07  
1 3.58 (a) 69.22 t 
2 3.37 (b) 49.97 t 
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MTX-PEG4-N3 reagent (6b): A solution of methotrexate--tert-butylester 5
[92] (300 mg, 0.59 mmol) 
and aminoazide 4b (274 mg, 1.26 mmol, 2.1 eq.) in DMF (10 mL) was treated with triethylamine (1.7 
mL, 12.2 mmol, 20.7 eq.) and TPTU (299 mg, 1.01 mmol, 1.7 eq.) and the resulting reaction mixture 
was stirred for 66 h at RT. After removal of the solvent under reduced pressure, the residue was 
purified by silica gel chromatography (CH2Cl2/MeOH, 93:7 v/v with 0.5% Et3N). A co-eluting 
contaminant could be removed by precipitation from MeOH:Et2O yielding the title compound (209 
mg, 0.29 mmol, 49%) as an ochre-yellow solid. LC-HRMS: tR = 6.34 min (10-100% MeCN, 15 min run); 
HRMS: calcd. for C32H47N12O7 [M+H]
+: 711.3685, found: 711.3740. 
 
MTX-PEG8-N3 reagent (6c): A solution of methotrexate--tert-butylester 5
[92] (300 mg, 0.59 mmol) 
and aminoazide 4c (548 mg, 1.39 mmol, 2.4 eq.) in DMF (9 mL) was treated with triethylamine (1.7 
mL, 12.2 mmol, 20.7 eq.) and TPTU (354 mg, 1.19 mmol, 2.0 eq.) and the resulting reaction mixture 
was stirred for 71 h at RT. After removal of the solvent under reduced pressure, the residue was 
purified by silica gel chromatography (CH2Cl2/MeOH, 93:7 v/v with 0.5% Et3N). A co-eluting 
contaminant could be removed by precipitation from MeOH:Et2O yielding the title compound (222 
mg, 0.25 mmol, 42%) as an ochre solid. LC-HRMS: tR = 6.52 min (10-100% MeCN, 15 min run); HRMS: 
calcd. for C40H63N12O11 [M+H]
+: 887.4734, found: 887.4756. 
 
N-Desmethyltamoxifen hydrochloride: The synthetic procedure was adapted from Dreaden et al.[25] 
In brief, to an ice cooled solution of tamoxifen (1.12 g, 3.0 mmol) in anhydrous 1,2-dichloroethane 
(31 mL), -chloroethyl chloroformate (ACE-Cl) (0.49 mL, 4.5 mmol) was added. The resulting reaction 
mixture was stirred for 15 min at 0°C and subsequently refluxed for 40 h. After cooling to RT, the 
mixture was concentrated in vacuo. The residue was taken up in methanol (21 mL) and refluxed for 4 
h. After cooling to RT, the mixture was concentrated in vacuo and the residue was purified by silica 
gel chromatography (MeOH/CH2Cl2, 1:9 v/v) to yield the title compound (1.11 g, 2.82 mmol, 94%) as 
a white solid. 1H NMR (300 MHz, CDCl3)  = 7.40 (br s, 2H), 7.35-7.04 (m, 10H), 6.76 (d, 2H, J = 8.7 Hz), 
6.55 (d, 2H, J = 8.7 Hz), 4.02 (t, 2H, J = 5.1 Hz), 3.04 (t, 2H, J = 5.1 Hz), 2.51 (s, 3H), 2.44 (q, 2H, J = 7.5 
Hz), 0.92 (t, 3H, J = 7.5 Hz); 13C NMR (75 MHz, CDCl3)  = 155.9, 143.7, 142.4, 141.8, 138.2, 136.5, 
132.0, 129.8, 129.5, 128.2, 128.0, 126.7, 126.2, 113.7, 63.9, 48.8, 34.1, 29.2, 13.7; HRMS: calcd. for 
C25H28NO [M]
+: 358.2165, found: 358.2189. 
 
N-Desmethyl-N-propargyltamoxifen (7): To a suspension of N-desmethyltamoxifen hydrochloride 
(236 mg, 0.6 mmol) and K2CO3 (191 mg, 1.38 mmol) in MeCN (6 mL) was added propargyl bromide 
(81 μL, 80% in toluene, 0.75 mmol). The reaction mixture was heated to 60°C with vigorous stirring 
for 18 h. After cooling to RT, the mixture was concentrated in vacuo. The residue was purified by 
silica gel chromatography (MeOH/CH2Cl2, 1:99 v/v) to yield the title compound (136 mg, 0.34 mmol, 
57%) as a yellow oil. 1H NMR (300 MHz, CDCl3)  = 7.37-7.07 (m, 10H), 6.76 (d, 2H, J = 8.8 Hz), 6.56 (d, 
2H, J = 8.8 Hz), 3.93 (t, 2H, J = 5.8 Hz), 3.40 (d, 2H, J = 2.3 Hz), 2.79 (t, 2H, J = 5.8 Hz), 2.45 (q, 2H, J = 
7.4 Hz), 2.36 (s, 3H), 2.20 (t, 1H, J = 2.3 Hz), 0.92 (t, 3H, J = 7.4 Hz); 13C NMR (75 MHz, CDCl3)  = 
156.8, 143.9, 142.5, 141.5, 138.4, 135.8, 132.0, 129.8, 129.6, 128.2, 128.0, 126.7, 126.1, 113.5, 78.5, 
73.5, 65.8, 54.5, 46.1, 42.3, 29.1, 13.7; HRMS: calcd. for C28H30NO [M+H]
+: 396.2322, found: 
396.2319. 
 
Click-coupled (PEG6) tamoxifen-MFC (8a): Azide 6a (180 mg, 0.23 mmol) was taken up in a mixture 
of TFA and CH2Cl2 (6 mL, 1:1, v/v) and stirred for 40 min at RT. The reaction mixture was then taken 
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to dryness, coevaporated twice with toluene and concentrated under high vacuum for 1 h. The 
residue was taken up in a mixture of water and tert-butanol (2 mL, 1:1, v/v) and alkyne 7 (40 mg, 0.1 
mmol), CuSO4 (40 μL, 0.5M, 0.2 eq.) and Na ascorbate (200 μL, 0.5M, 1.0 eq.) were added. Finally, the 
resulting reaction mixture was charged with a catalytic amount of TBTA[99] and heated to 80°C under 
vigorous stirring. Upon completion of the reaction (96 h), the solution was cooled to RT and 
concentrated in vacuo. The residue was purified by preparative RP-HPLC (10-100% MeCN) yielding 
the title compound (57 mg, 50 μmol, 50%) as a pale yellow amorphous solid. LC-HRMS: tR = 6.98 min 
(10-100% MeCN, 15 min run); HRMS: calcd. for C60H77N13O10 [M+2H]
2+: 569.7953, found: 569.7931. 
 
For the NMR assignment of the MTX-PEG part of 8a, we refer to the assignment of reversine-MFC 18 
(see further). The labeling scheme of the tamoxifen part of 8a is depicted below: 
 
 
 
Figure III.17: Labeling scheme of the tamoxifen part of 8a. 
 
From the 2 CH2 protons in the PEG chain, there is an HMBC correlation to a CH at 124.0 ppm. With 
HSQC this is seen to correlate to a 1H singlet at 7.92 ppm, this is H-5. Another HMBC correlation to C-
5 comes from a CH2 singlet at 3.60 ppm, this is H-6. Starting from H-6, two more HMBC correlations 
are seen, one to a Cq at 143.2 ppm which is assigned to be C-4 and one to a CH3 at 42.0 ppm that has 
an HSQC correlation to a 1H at 2.17 ppm and is assigned to Me-8. From Me-8, there are NOESY 
correlations visible to H-6, a CH2 triplet at 2.63 ppm and a CH2 triplet at 3.91 ppm; these can be 
assigned to H-9 and H-10, respectively. H-10 has an HMBC correlation to a Cq at 156.4 ppm, which is 
assigned to C-12. Another HMBC correlation to C-12 is visible from a CH that integrates for 2 at 6.72 
ppm; this is assigned to H-14. From this signal, there is a COSY correlation to a CH that integrates for 
2 at 6.59 ppm, this is H-13. From H-13 an HMBC to 156.3 ppm is visible, this is C-15. Thus a consistent 
picture emerges for the first aromatic moiety.  
 
In the HSQC there is one more CH3 signal visible, this is a triplet at 0.84 ppm and can be assigned to 
the Me-23. It shows a COSY correlation to a CH2 quadruplet at 2.36 ppm, which is H-22. An HMBC 
correlation is visible from H-23 and H-22 to a Cq at 140.6 ppm, this is C-17. Another HMBC correlation 
to C-17 comes from the left part of a CH type resonance at 7.12 ppm that integrates for 3 1H’s and 
comes from, according to the HSQC spectrum, two carbons. The left part can be assigned to H-19. 
The right part shows an HMBC correlation to the left part and vice versa, we can thus assign the right 
part to be H-21. This also agrees with the sum of 3 for this resonance. From these two resonances 
there is a COSY correlation to the right part of a CH signal at 7.18-7.20 ppm that in total integrates for 
4 1H’s; this can be assigned to H-20. This signal also shows an HMBC correlation to a Cq at 141.7 ppm, 
C-18. Thus a consistent picture emerges for the second aromatic moiety. 
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Also, an HMBC to C-18 is visible from H-22. Another HMBC correlation from H-22 goes to a Cq at 
137.8 ppm, this is C-16. The left part of the signal at 7.18-7.20 ppm shows an HMBC correlation to C-
16 as well and can thus be assigned to H-25. H-25 has a COSY correlation to a CH at 7.37 ppm that 
integrates for 2 protons and is assigned to H-26. From this signal, an HMBC correlation is visible to a 
Cq at 143.2 ppm, this is C-24. Also from H-26 a COSY correlation is visible to a CH signal at 7.28 ppm 
that integrates for 1 proton and is assigned to H-27. Thus a consistent picture emerges for the third 
aromatic moiety. 
 
Table III.2: 1H and 13C NMR assignment of tamoxifen-MFC 8a in DMSO-d6 at 298K (700/176 MHz). 
 
Label 1H (ppm) 13C (ppm) Multiplicity 
4 - 143.2  
5 7.92 124.0 s 
6 3.62 52.0 s 
8 2.17 42.0 s 
9 2.63 54.7 t 
10 3.91 65.6 t 
12 - 156.4  
13 6.59 113.4 d 
14 6.72 131.4 d 
15 - 156.3  
16 - 137.8  
17 - 140.6  
18 - 141.7  
19 7.12 129.4* m 
20 7.18 128.0* m 
21 7.11 126.3* m 
22 2.36 28.5 q 
23 0.84 13.3 t 
24 - 143.2  
25 7.20 129.0* m 
26 7.37 128.3 m 
27 7.28 126.7 m 
* tentative assignment only 
 
Click-coupled (PEG4) tamoxifen-MFC (8b): Azide 6b (164 mg, 0.23 mmol) was deprotected and 
subsequently conjugated to alkyne 7 (40 mg, 0.1 mmol) using the procedure described for conjugate 
8a. Upon completion of the reaction (18 h) and workup, the material was purified by preparative RP-
HPLC (10-100% MeCN), yielding the title compound (55 mg, 52 μmol, 52%) as a pale yellow 
amorphous solid. LC-HRMS: tR = 7.04 min (10-100% MeCN, 15 min run); HRMS: calcd. for C56H69N13O8 
[M+2H]2+: 525.7691, found: 525.7696. 
 
Click-coupled (PEG8) tamoxifen-MFC (8c): Azide 6c (204 mg, 0.23 mmol) was deprotected and 
subsequently conjugated to alkyne 7 (40 mg, 0.1 mmol) using the procedure described for conjugate 
8a. Upon completion of the reaction (18 h) and workup, the material was purified by preparative RP-
HPLC (10-100% MeCN), yielding the title compound (78 mg, 63 μmol, 63%) as a pale yellow 
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amorphous solid. LC-HRMS: tR = 7.11 min (10-100% MeCN, 15 min run); HRMS: calcd. for C64H85N13O12 
[M+2H]2+: 613.8215, found: 613.8204. 
 
Methyl (N-desmethyltamoxifen-N-yl)acetate (9): To an ice cooled solution of methyl bromoacetate 
(39 μL, 0.42 mmol) in CH2Cl2 (1.3 mL), N-desmethyltamoxifen hydrochloride (165 mg, 0.42 mmol) and 
DIPEA (183 μL, 1.05 mmol) were added. The resulting solution was stirred overnight letting the 
temperature rise to RT. The mixture was diluted with CH2Cl2 (6.5 mL), washed with sat. NaHCO3 (2 x 
10 mL), dried over Na2SO4 and concentrated in vacuo. The residue was purified by silica gel 
chromatography (MeOH/CH2Cl2, 1:99 v/v) yielding the title compound (161 mg, 0.38 mmol, 91%) as a 
pale white oil. 1H NMR (300 MHz, CDCl3)  = 7.37-7.07 (m, 10H), 6.76 (d, 2H, J = 8.7 Hz), 6.53 (d, 2H, J 
= 8.7 Hz), 3.95 (t, 2H, J = 5.7 Hz), 3.64 (s, 3H), 3.37 (s, 2H), 2.90 (t, 2H, J = 5.7 Hz), 2.45 (q, 2H, J = 7.5 
Hz), 2.45 (s, 3H), 0.92 (t, 3H, J = 7.5 Hz); 13C NMR (75 MHz, CDCl3)  = 171.6, 156.7, 143.9, 142.5, 
141.5, 138.4, 135.7, 132.0, 129.8, 129.6, 128.2, 128.0, 126.6, 126.1, 113.5, 66.1, 58.6, 55.7, 51.6, 
43.2, 29.1, 13.7; HRMS: calcd. for C28H32NO3 [M+H]
+: 430.2377, found: 430.2372. 
 
(N-Desmethyltamoxifen-N-yl)acetic acid (10): A solution of compound 9 (249 mg, 0.58 mmol) in 
MeOH (13 mL) was treated with NaOH (0.96 mL, 4.0M). The resulting reaction mixture was stirred for 
6 h at 50°C. After cooling to RT, the mixture was neutralized by addition of HCl (1.31 mL, 3.0M), 
concentrated in vacuo and coevaporated twice with toluene. The residue was purified by silica gel 
chromatography (MeOH/CH2Cl2, 12:88 v/v) yielding the title compound (342 mg) as a white 
amorphous solid. The additional weight could be explained by a significant amount of silica gel 
present in the material. 1H NMR (300 MHz, CDCl3)  = 7.31-7.06 (m, 10H), 6.72 (d, 2H, J = 8.0 Hz), 6.44 
(d, 2H, J = 8.0 Hz), 4.07 (m, 2H), 3.86 (br s, 2H), 3.46 (m, 2H), 2.77 (br s, 3H), 2.43 (q, 2H, J = 7.3 Hz), 
0.92 (t, 3H, J = 7.3 Hz); LC-HRMS: tR = 8.87 min (10-100% MeCN, 15 min run); HRMS: calcd. for 
C27H30NO3 [M+H]
+: 416.2220, found: 416.2065. 
 
Amide-coupled tamoxifen-MFC (11): Azide 6a (160 mg, 0.2 mmol) was taken up in a mixture of TFA 
and CH2Cl2 (7 mL, 1:1, v/v) and stirred for 40 min at RT. The reaction mixture was then taken to 
dryness, coevaporated twice with toluene and concentrated under high vacuum for 1 h. The residue 
was taken up in THF (4 mL), treated with a solution of Me3P in THF (2 mL, 1.0M) and stirred overnight 
at RT. Subsequently, H2O (100 μL) was added and stirring was continued for 1 h. The solution was 
concentrated in vacuo and the resulting residue was taken up in a mixture of tert-butanol and H2O (4 
mL, 1:1, v/v) and lyophilized. The presence of a significant contaminant bearing an additional methyl 
group, as judged by LC-HRMS (calcd. for C33H52N10O9 [M+Me+2H]
2+: 366.1954, found: 366.1926), 
necessitated an additional purification. Therefore the crude dry material was purified by preparative 
RP-HPLC (5-100% MeCN) yielding the pure amine (41 mg, 57 μmol, 29%) as an ochre semi solid. LC-
HRMS: tR = 11.40 min (5-15% MeCN, 18 min run); HRMS: calcd. for C32H50N10O9 [M+2H]
2+: 359.1876, 
found: 359.1852. Acid 10 (90 mg, ≈ 153 μmol)[100] was taken up in DMF (1.85 mL) and preactivated 
for 5 min using PyBOP (60 mg, 115 μmol) and DIPEA (150 μL, 861 μmol). The MTX-amine (41 mg, 57 
μmol) was taken up in DMF (0.5 mL) and combined with the preactivation mixture and stirred for 4 h. 
The solution was concentrated in vacuo and the residue was purified by preparative RP-HPLC (10-
100% MeCN) yielding the title compound (21 mg, 19 μmol, 33%) as a pale yellow amorphous solid. 
LC-HRMS: tR = 7.00 min (10-100% MeCN, 15 min run); HRMS: calcd. for C59H77N11O11 [M+2H]
2+: 
557.7897, found: 557.7875. 
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The NMR characterization of tamoxifen-MFC 11 was split into two parts, beginning with its MTX-PEG 
moiety. The labeling is depicted below: 
 
 
Figure III.18: Labeling scheme of the MTX-PEG part of MFC 11. 
 
For the descriptive assignment of the MTX part of 11 (identical to that of 8a), we refer to the analysis 
of reversine-MFC 18 (see further). Nearly complete assignment of the 1H and 13C resonances visible in 
the spectra could be achieved (see Table III.3). 
 
Table III.3: 1H and 13C NMR assignment of the MTX-PEG part of tamoxifen-MFC 11 in DMSO-d6 at 
298K (700/176 MHz). 
 
Label 1H (ppm) 13C (ppm) Multiplicity 
1 + 12 n.a. -  
2 - n.a.  
4 - n.a.  
5 - n.a.  
6 - 155.21*  
9 8.55 148.7 s 
10 - 145.9  
13 4.76 54.8 s 
14 - 150.9  
15 6.81 111.1 d  
16 7.69 128.6 d 
17 - 121.4*  
18 - 165.8*  
19 8.08 - d 
20 4.18 52.7 m 
21 a 2.00 / b 1.88 27.15 m 
22 2.16 32.0 m 
23 - 171.9  
24 7.91 - t 
25 3.19 39.05 s 
26 - 173.5  
27 n.a. -  
1 3.16 38.5 m 
2 3.35 69.0 t 
-1 3.4-3.55 69.0-70.4  
2 3.18 38.0 m 
* tentative assignment only 
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The labeling scheme of the tamoxifen part of tamoxifen-MFC 11 is depicted below: 
 
 
 
Figure III.19: Labeling scheme of the tamoxifen part of MFC 11. 
 
Me-4 is easily found at 2.26 ppm because it is the only remaining CH3 group that is a singlet. Starting 
from this singlet, there are two HMBC correlations, one to a CH2 at 55.8 ppm and one to a CH2 at 61.0 
ppm. The CH2 at 55.8 ppm correlates to a proton resonance at 2.68 ppm that is a triplet and can thus 
be assigned to H-5. The other CH2 has a proton resonance at 2.98 ppm that is a singlet and can be 
assigned to H-3. From H-3 an HMBC correlation is visible to a Cq at 169.7 ppm that is assigned to C-2. 
From H-3 and H-4 a NOESY correlation is visible to a triplet at 7.66 ppm that has no HSQC correlation 
and can be assigned to H-1. 
 
From H-5 there is a COSY correlation visible to a triplet at 3.91 ppm that can be assigned to H-6. In 
the HMBC spectrum, a correlation from H-6 to a Cq at 156.6 ppm is visible, this is assigned to C-7. 
Another two proton resonances have an HMBC correlation to this last one, an aromatic doublet at 
6.60 ppm and one at 6.73 ppm. These also have a COSY correlation to each other and can thus be 
assigned to H-8 and H-9, respectively. Another CH3 group is present in this part of the molecule, a 
triplet at 0.82 ppm; this is assigned to H-18. From this resonance, a COSY correlation is visible to a 
quadruplet at 2.36 ppm, which is assigned to H-17. From both H-18 and H-17 an HMBC correlation is 
visible to a Cq at 140.7 ppm, this is C-16.  
 
In the aromatic region there are still 4 signals left that integrate all together for 10 protons. The 
resonance at 7.37 ppm integrates for 2 protons and is assigned to H-14. H-14 has an HMBC 
correlation to a Cq at 143.2 ppm, which is assigned to C-12. From H-14 there are two COSY 
correlations, one to the resonance at 7.28 ppm, which is assigned to H-15 and one to the multiplet at 
7.19 ppm, from which the left part can be assigned to H-13. The latter has an HMBC correlation to a 
Cq at 137.9 ppm, C-11. The right part of the multiplet at 7.19 ppm is assigned to H-21 and has an 
HMBC correlation to a Cq at 141.8 ppm, C-19. H-21 also has a COSY correlation to the remaining 
aromatic resonance at 7.11 ppm that integrates for 3 protons and is assigned to both H-22 and H-20, 
which also shows an HMBC correlation to C-16.   
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Table III.4: 1H and 13C NMR assignment of the tamoxifen part of tamoxifen-MFC 11 in DMSO-d6 at 
298K (700/176 MHz). 
 
Label 1H (ppm) 13C (ppm) Multiplicity 
1 7.66 - t 
2 - 169.7  
3 2.98 61.0 s 
4 2.26 43.0 s 
5 2.68 55.9 t 
6 3.91 65.4 t 
7 - 156.6  
8  6.60 113.4 d 
9 6.73 131.3 d 
10 - 156.6*  
11 - 137.9  
12 - 143.2  
13 7.19 128.9 m 
14 7.37 128.3 m 
15 7.28 126.6 m 
16 - 140.7  
17 2.36 28.5 q 
18 0.82 13.3 t 
19 - 141.8  
20 7.12 129.4 m 
21 7.18 127.9 m 
22 7.11 126.2 m 
* tentative assignment only 
 
N-(4-Nitrophenyl)-N'-propargylpiperazine (13): To a suspension of N-(4-nitrophenyl)piperazine 12 
(1.0 g, 4.8 mmol) and K2CO3 (868 mg, 6.3 mmol) in MeCN (24 mL) was added propargyl bromide (651 
μL, 80% in toluene, 6.04 mmol). The reaction mixture was heated to 60°C with vigorous stirring for 18 
h. After cooling to RT, the mixture was concentrated in vacuo. The residue was purified by silica gel 
chromatography (MeOH/CH2Cl2, 3:97 v/v) to yield the title compound (1.13 g, 4.6. mmol, 95%) as an 
amorphous yellow solid, which upon crystallization (CH2Cl2/hexane) gave fine needles. 
1H NMR (300 
MHz, CDCl3)  = 8.12 (d, 2H, J = 9.5 Hz), 6.83 (d, 2H, J = 9.5 Hz), 3.47 (t, 4H, J = 5.3 Hz), 3.39 (d, 2H, J = 
2.5 Hz), 2.72 (t, 4H, J = 5.3 Hz), 2.29 (t, 1H, J = 2.5 Hz); 13C NMR (75 MHz, CDCl3)  = 154.8, 138.6, 
126.0, 112.8, 78.1, 73.8, 51.3, 47.0, 46.8; HRMS: calcd. for C13H16N3O2 [M+H]
+: 246.1237, found: 
246.1250. 
 
N-(4-Aminophenyl)-N'-propargylpiperazine (14): Compound 13 (4.2 g, 17.3 mmol) and SnCl2 (18.4 g, 
96.8 mmol) were taken up in EtOH (62 mL). The resulting reaction mixture was refluxed at 70°C 
under vigorous stirring for 9 h. After cooling to RT, the pH was made slightly basic (pH 7-8) by slow 
addition of sat. NaHCO3. The alkaline solution was transferred to a separation funnel and the 
aqueous fraction was extracted thrice with EtOAc (60 mL). All EtOAc fractions were pooled, dried 
over Na2SO4 and taken to dryness. The residue was purified by silica gel chromatography 
(MeOH/CH2Cl2, 6:94 v/v) yielding the title compound (1.9 g, 8.9 mmol, 87%) as a beige amorphous 
solid. 1H NMR (300 MHz, CDCl3)  = 6.80 (d, 2H, J = 8.7 Hz), 6.62 (d, 2H, J = 8.7 Hz), 3.41 (br s, 2H), 
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3.34 (d, 2H, J = 2.4 Hz), 3.08 (t, 4H, J = 5.0 Hz), 2.72 (t, 4H, J = 5.0 Hz), 2.28 (t, 1H, J = 2.4 Hz); 13C NMR 
(75 MHz, CDCl3)  = 144.3, 140.2, 118.6, 116.1, 78.8, 73.4, 52.0, 50.8, 46.8; HRMS: calcd. for C13H18N3 
[M+H]+: 216.1495, found: 216.1489. 
 
N6-Cyclohexyl-2-fluoroadenine (16): The synthetic procedure was adapted from Chen et al.[28] In 
brief, to a solution of 6-chloro-2-fluoropurine (600 mg, 3.48 mmol) in n-butanol (35 mL), 
cyclohexylamine (398 µL, 3.48 mmol) and N,N-diisopropylethylamine (DIPEA) (728 µL, 4.18 mmol) 
were added. The resulting reaction mixture was heated to 80°C for 16 h under vigorous stirring. After 
cooling to RT, the mixture was concentrated in vacuo and the residue was purified by silica gel 
chromatography (MeOH/CH2Cl2, 3:97 v/v) to yield the title compound (519 mg, 2.21 mmol, 64%) as a 
white solid. 1H NMR (300 MHz, CD3OD)  = 8.00 (s, 1H), 4.04 (m, 1H), 2.13-1.98 (m, 2H), 1.89-1.75 (m, 
2H), 1.74-1.62 (m, 1H), 1.56-1.20 (m, 5H); HRMS: calcd. for C11H15N5F [M+H]
+: 236.1306, found: 
236.1284. 
 
N6-Cyclohexyl-2-(4-(4-propargylpiperazin-1-yl)-N-anilinyl)-adenine (17): N6-Cyclohexyl-2-fluoroade-
nine (235 mg, 1.0 mmol) and compound 14 (431 mg, 2.0 mmol) were taken up in EtOH (3 mL) and 
the resulting reaction mixture was heated (μW) to 130°C for 5 h. After cooling to RT, the mixture was 
transferred directly into a silica gel column (MeOH/CH2Cl2, 6:94 v/v). The thus obtained semi pure 
product was purified further by precipitation (CH2Cl2/hexane) yielding the title compound (157 mg, 
0.36 mmol, 36%) as a beige amorphous solid. (More product could be isolated from the mother 
liquor, albeit in a significantly lower purity as the first crop.) 1H NMR (300 MHz, CDCl3)  = 12.82 (br s, 
1H), 7.42 (d, 2H, J = 8.9 Hz), 6.91 (d, 2H, J = 8.9 Hz), 6.74 (s, 1H), 6.65 (s, 1H), 5.56 (d, 1H, J = 6.3 Hz), 
4.09 (m, 1H), 3.36 (d, 2H, J = 2.1 Hz), 3.18 (t, 4H, J = 4.8 Hz), 2.74 (t, 4H, J = 4.8 Hz), 2.28 (t, 1H, J = 2.1 
Hz), 2.13-2.02 (m, 2H), 1.83-1.71 (m, 2H), 1.70-1.59 (m, 1H), 1.50-1.14 (m, 5H); 13C NMR (75 MHz, 
CDCl3)  = 157.3, 154.5, 150.6, 147.9, 135.9, 132.6, 123.3, 117.5, 114.6, 78.8, 73.5, 52.0, 50.0, 49.3, 
47.0, 33.4, 25.8, 25.1; HRMS: calcd. for C24H31N8 [M+H]
+: 431.2666, found: 431.2689. 
 
Reversine-MFC (18): Azide 6a (160 mg, 0.2 mmol) was taken up in a mixture of TFA and CH2Cl2 (5 mL, 
1:1, v/v) and stirred for 40 min at RT. The reaction mixture was then taken to dryness, coevaporated 
twice with toluene and concentrated under high vacuum for 1 h. The residue was taken up in a 
mixture of water and tert-butanol (3 mL, 1:1, v/v) and alkyne 17 (43 mg, 0.1 mmol), CuSO4 (20 μL, 
0.5M, 0.1 eq.) and Na ascorbate (100 μL, 0.5M, 0.5 eq.) were added. Finally, the resulting reaction 
mixture was charged with a catalytic amount of TBTA[99] and Et3N and heated to 80°C under vigorous 
stirring for 72 h. After cooling to RT, the solution was concentrated in vacuo and the residue was 
purified by preparative RP-HPLC (10-100% MeCN) yielding the title compound (36 mg, 31 μmol, 31%) 
as a pale yellow amorphous solid. LC-HRMS: tR = 5.17 min (10-100% MeCN, 15 min run); HRMS: calcd. 
for C56H79N20O9 [M+3H]
3+: 391.8774, found: 391.7788. 
 
The NMR characterization of reversine-MFC 18 was split into two parts, beginning with its MTX-PEG 
moiety. Nearly complete assignment of the 1H and 13C resonances visible in the spectra could be 
achieved (see Table III.5).  The labeling is depicted below: 
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Figure III.20: Labeling scheme of the common MTX-PEG part of MFCs 18 and 8a. 
 
Since there is only one CH3 group in conjugate 18, Me-25 can, with its integration value, easily be 
assigned to the singlet at 3.19 ppm. Starting from this singlet there are two HMBC correlations, one 
to a CH2 at 54.8 ppm and one to a Cq at 150.6 ppm, which is C-14. The CH2 signal has a proton 
resonance at 4.76 ppm and is a singlet, thus it can be assigned to be H-13. It also shows a NOESY 
correlation to both Me-25 and a signal in the aromatic region which can be assigned to H-9. Also, H-
13 shows an HMBC correlation to a Cq at 145.9 ppm, this is C-10. There is also a HMBC correlation 
visible from H-9 to a Cq, which is thus tentatively assigned to C-6. 
 
From Me-25 and H-13 there is a NOESY correlation to an aromatic doublet at 6.83 ppm, which can be 
assigned to the two H-15 protons. From this resonance, a COSY correlation to a doublet at 7.71 ppm 
is visible, this is H-16. H-15 has an HMBC correlation to 121.1 ppm, which is assigned to C-17, and H-
16 has an HMBC correlation to 150.6 ppm which was already assigned as C-14. H-16 additionally has 
a small HMBC to a Cq at 166.0 ppm that is tentatively assigned to C-18. 
 
From H-16 there is a NOESY correlation to a resonance at 8.18 ppm that does not have an HSQC 
correlation and can therefore be assigned to the H-19 amine. From this position, a COSY correlation 
is visible to a resonance at 4.25 ppm, which is according to the HSQC a CH and can be assigned to H-
20. From H-20 there are two COSY correlations to 2.04 and 1.90 ppm, respectively. Looking at the 
integrations and the HSQC spectrum, these can be assigned to the two protons H-21. From these 
resonances, a COSY correlation is visible towards a resonance at 2.18 ppm, which is assigned to H-22 
based on HSQC and the integral value. Both resonances from H-21 and H-22 have a NOESY 
correlation to the amine H-19. From H-22 there is also a NOESY correlation to a triplet at 7.88 ppm, 
which has an integral of 1 and no HSQC correlation and can be assigned to the H-24 amine. 
 
From H-24 a COSY correlation to a multiplet at 3.16 ppm is visible that has an HSQC correlation to a 
CH2 and an integral value of two and can be assigned to H-1. From this one, a COSY correlation to a 
triplet at 3.35 ppm with an HSQC correlation to a CH2 is visible, that can be assigned to H-2. From H-
24, H-21 and H-1 an HMBC correlation is visible towards a Cq at 171.81 ppm, that can be assigned to 
C-23. From H-2, HMBC correlations to 69.6 ppm are visible; these correlate to multiple CH2’s 
between 3.40 and 3.55 ppm and are thus assigned to the CH2’s  to . Another resonance at 3.82 
ppm (triplet) also shows an HMBC to these CH2 carbons; this resonance is a CH2 and can be assigned 
to H-1. From the latter, there is a COSY correlation to a triplet at 4.50 ppm that has a HSQC 
correlation to a CH2, which is H-2. 
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The H-1 and H-12 amines are present in the region 6.5-8 ppm; this is in agreement with the 
integrations. However, they cannot be distinguished. O27H is assigned at 12.29 ppm. Finally, a small 
HMBC correlation is visible from H-20 and H-21 to a Cq at 173.7 ppm; this is assigned to C-26.   
 
Table III.5: 1H and 13C NMR assignment of the MTX-PEG part of reversine-MFC 18 in DMSO-d6 at 
298K (700/176 MHz). 
 
Label 1H (ppm) 13C (ppm) Multiplicity 
1 + 12 n.a. -  
2 - n.a.  
4 - n.a.  
5 - n.a.  
6 - 155.21*  
9 8.55 148.9 s 
10 - 145.9  
13 4.76 54.54 s 
14 - 150.8  
15 6.82 110.72 d   
16 7.71 128.53 d 
17 - 121.2*  
18 - 166.0*  
19 8.18 - d 
20 4.25 52.11 m 
21 a 2.04 / b 1.90 26.41 m 
22 2.18 31.7 m 
23 - 171.7  
24 7.88 - t 
25 3.19 38.83 s 
26 - 173.7  
27 12.29 - s 
1 3.16 38.21 m 
2 3.35 68.76 t 
- 3.4-3.55 69.6  
1 3.82 68.5 t 
2 4.50 48.9 t 
* tentative assignment only 
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The labeling scheme of the reversine part of reversine-MFC 18 is depicted below: 
 
 
 
Figure III.21: Labeling scheme of the reversine part of MFC 18. 
 
From the 2 CH2 protons in the PEG chain, there is an HMBC correlation to a CH at 123.7 ppm. With 
HSQC this is seen to correlate to a 1H singlet at 7.98 ppm, this is H-5. Another HMBC correlation to C-
5 comes from a CH2 singlet at 3.60 ppm, this is H-6. Starting from H-6, two more HMBC correlations 
are seen: one to a Cq at 143.1 ppm which is assigned to be C-4; and one to a CH2 at 52.11 ppm that 
has an HSQC correlation to 2.54 ppm and integrates for 4 protons, and can be assigned to the 
isochronous H-8 and H-12. From this position there is a COSY correlation to a signal at 3.01 ppm that 
integrates for 4 protons and can be assigned to the isochronous H-9 and H-11. From this last 
resonance, a NOESY correlation is visible to two CH doublets, each integrating for two protons, at 
6.80 and 7.63 ppm, which can be assigned to H-14 and H-15, respectively. An HMBC correlation is 
visible from H-14 to a Cq at 134.4 ppm that is assigned to C-16. Also from H-15 an HMBC correlation is 
visible to a Cq at 145.1 ppm that is assigned to C-13. A NOESY correlation is visible from H-15 to a NH 
at 8.48 ppm that is assigned to the H-17 amine. 
 
Because of the large amount of nitrogen atoms and quaternary carbons, assignment from this point 
onwards was difficult. A TOCSY correlation was found between 5 CH2 resonances that integrated 
together for 10 protons and a CH resonance at 4.05 ppm, which is assigned to H-28 (the resonance is 
however broadened and no HSQC correlation was found). Distinction between the 5 CH2 signals to 
assign them to 29-33 is difficult and only done tentatively. A NOESY correlation is visible from H-28 
and the CH2 at 1.33 ppm to a NH signal at 7.04 ppm that is assigned to the H-27 amine.   
 
H-25 is only assigned tentatively by means of exclusion; there is only one singlet left in the aromatic 
region and this is therefore very likely to be H-25. The remaining quaternary carbons C-22, C-21, C-20 
and C-18 are not assigned due to lack of HMBC correlations. Also the amine H-26 is not assigned. 
Nevertheless, the integrity of the chemical link between the PEG chain and the clicked moiety could 
be established without ambiguity. 
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Table III.6: 1H and 13C NMR assignment of the reversine part of reversine-MFC 18 in DMSO-d6 at 
298K (700/176 MHz). 
 
Label  1H (ppm) 13C (ppm) Multiplicity 
4 - 143.1  
5 7.98 123.7 s 
6 3.60 52.34 s 
8+12 2.54 52.11 br t 
9+11 3.01 49.1 br t 
13 - 145.1  
14 6.80 115.7 d 
15 7.63 119.0 d 
16 - 134.4  
17 8.48 - br s 
18 - n.a.  
20 - n.a.  
21 - n.a.  
22 - n.a.  
25 8.16* n.a. s 
26 n.a. -  
27 7.04 - m 
28 4.05   m 
29 1.33* 24.9 m 
30 1.33* 24.9 m 
31 1.15+1.63* 25.0 m 
32 1.76* 24.9 m 
33 1.33+1.93* 32.3 m 
* tentative assignment only 
 
4-((trimethylsilyl)ethynyl)phenol (20): To a solution of 4-iodophenol (2.2 g, 10.0 mmol) in 
triethylamine (30 mL) were added PdCl2(PPh3)2 (70 mg, 0.1 mmol, 1 mol%), CuI (19 mg, 0.1 mmol, 1 
mol%) and trimethylsilylacetylene (2.82 mL, 20.0 mmol) and the solution was heated to 80°C under 
vigorous stirring. After 6 h, the reaction mixture was cooled to RT, filtered and concentrated in 
vacuo. The dark colored residue was purified by silica gel chromatography (MeOH/CH2Cl2, 1:99 v/v) 
to yield the title compound (1.83 g, 9.6 mmol, 96%) as a light brown solid, which upon 
recrystallization (heptanes) gave off white needles. 1H NMR (300 MHz, CDCl3)  = 7.35 (d, 2H, J = 8.7 
Hz), 6.74 (d, 2H, J = 8.7 Hz), 5.13 (s, 1H), 0.23 (s, 9H); 13C NMR (75 MHz, CDCl3)  = 155.7, 133.7, 
115.5, 115.3, 105.1, 92.6, 0.1; HRMS calcd. for C11H13OSi [M-H]
-: 189.0741, found: 189.0733. 
 
Alkyne-functionalized FK506 (22): Alcohol 19[50] (104 mg, 0.1 mmol) and p-(TMS-ethynyl)phenol (20) 
(38 mg, 0.2 mmol) were placed in a flask under a nitrogen atmosphere. To the dry material was 
added a solution of PPh3 in toluene (1.3 mL, 0.1M, 1.3 eq.). The solution was cooled on ice and 
dropwise a solution of DEAD in toluene (1.3 mL, 0.1M, 1.3 eq.) was added and the solution was 
stirred overnight. The reaction mixture was transferred directly into a silica gel column and the 
product (106 mg, 87.7 μmol, 88%) was obtained after elution (EtOAc/toluene 0-25%, v/v). HRMS 
calcd. for C66H113N2O13Si3 [M+NH4]
+: 1225.7545, found: 1225.7505. The product is taken up in MeCN 
(4 mL) and cooled on ice. To the solution are added acetic acid (30 μL, 526 μmol, 6 eq.) and TBAF 
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(525 μL, 1.0M in THF, 525 μmol, 6 eq.) and the mixture was stirred overnight. The solution was 
cooled on ice again and HF·pyridine (100 μL) was added and stirring was continued for 6 h. The 
solution was poured into sat. NaHCO3 (20 mL) and transferred to a separation funnel. The aqueous 
fraction was extracted with EtOAc (4 x 25 mL) and the organic fractions were pooled, dried over 
Na2SO4 and concentrated in vacuo. The residue was purified by silica gel chromatography 
(MeOH/CH2Cl2 0-10%, v/v) to yield the title compound (73 mg, 80.4 μmol, 80% based on 19) as an off 
white foam. 1H NMR (700 MHz, SO(CD3)2) (mixture of rotamers)  = 7.38 (2H, d), 6.87 (2H, d), 6.54 
(0.5H, s), 5.25 (0.5H, d), 5.11 (1H, m), 5.07 (0.5H, d), 5.04 (0.5H, dd), 4.80 (1.5H, br m), 4.70 (0.5H, d), 
4.63 (1H, t), 4.42 (0.5H, m), 4.21 (0.5H, d), 4.00 (1H, d), 3.93-3.78 (3H, m), 3.74 (0.5H, dt), 3.68 (0.5H, 
m), 3.57-3.36 (2.5H, m), 3.34-3.13 (15H, br m), 2.91 (1.5H, m), 2.74 (0.5H, m), 2.62 (0.5H, m), 2.44 
(0.5H, m), 2.36 (0.5H, dd), 2.29-0.9 (36.5H, br m), 0.9-0.7 (9H, m), 0.62 (1.5H, d); HRMS calcd. for 
C51H73NO13Na [M+Na]
+: 930.4974, found: 930.5010.  
 
The NMR spectra are quite complex and a full assignment has not been attempted, given that the 
synthesis of 22 starts from commercially available FK506. A lot of resonances are apparent. The 
labeling scheme for 22 is presented hereafter. 
 
 
 
Figure III.22: Labeling scheme for the relevant part of alkyne-functionalized FK506 (22) 
 
Analysis starts by noting the alkyne proton to carbon correlations in the HSQC, which have a typical 
position and appearance due to the unusual 1JCH (250 Hz) and 
2JCH (50 Hz) scalar coupling constant. 
As a result of the large size of the latter, a cross-peak is visible in the HSQC spectrum representing a  
–CqΞC–H correlation. The corresponding carbons are at 83.79 (Cq) and 79.17 (C-H) ppm. Their identity 
is further confirmed by noting the residual 1J scalar coupling doublet artefacts that occur at the 
frequency positions of the alkyne Cq (Figure III.23). Because it is correlated to the alkyne proton via 
2JCqH coupling of 51.4 Hz, the 
2JCH splitting is not removed by the low-pass filter set at 140 Hz. Thus 
both the chemical shift and the appearance confirm the assignment to the alkyne functionality in 22. 
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Figure III.23: Superposition of a detail of the 
1
H-{
13
C} HSQC spectrum (red/blue for -/+ intensity) with the 
1
H-
{
13
C} HMBC spectrum (black) showing the residual 
2
JCH splitting artefact at the level of the Cq(2) carbon. The 
antiphase nature of the correlation in the HSQC results from the large mismatch between the set and actual 
n
JCH couplings. 
 
Continuing from the alkyne proton unit, an additional nJCH correlation involving a Cq and CH carbon 
can be identified at 113.61 and 133.19 ppm, respectively. These correspond to carbon 3 and 4 of the 
benzene-like moiety introduced on the FK506 basic structure. The associated proton shift of H-4 is 
7.38 ppm, and features a triplet multiplicity. The latter at first appears odd, since only a doublet is 
expected. A strong COSY correlation is visible to the aromatic proton centered at 6.88 ppm, which 
therefore corresponds to proton 5, the second proton of the aromatic cycle. The latter signal shows a 
double doublet-like structure, which is also not expected (Figure III.24, left). 
 
 //             //   
Figure III.24: Details of the 
1
H (left) and 
13
C APT (right) spectra showing the proton and carbon resonances 
corresponding to positions 4 and 5 in 22. In the 
1
H spectrum, the bottom spectra represent a resolution 
enhanced version of the top spectra, obtained through Gaussian window multiplication.  
 
Gaussian resolution enhancement of the 1D proton spectrum shows the presence of two equally 
intense doublets with overlapping lines, causing the apparent triplet in the regularly processed 1D 
proton spectrum. Also, the 13C APT shows that the carbon resonances associated with H-4 and H-5 
each consist of two equally intense CH type resonances (Figure III.24, right). Because the lines are 
equally intense, one could conclude that the proton and carbon resonances at position 4 and 5 of 22 
are non-equivalent, for instance as a result of hindered rotation which results in slow or no exchange 
on the NMR time scale. However, the carbon at C-6 also appears as two equally intense resonances 
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ruling out the possibility of slow rotation around the C6-O7 bond as the origin of the non-
equivalence. 
We noticed that splitting of the expected resonances in two equally intense ones, both in the 1H and 
13C spectrum, occurred frequently and that the chemical shift separation between both increased as 
one progressed towards the macrocycle. Based upon literature reports describing the assignment of 
FK506, we propose that this phenomenon is explained by the presence of cis-trans isomers around 
the tertiary amide bond, causing two stereoisomers in slow or no exchange.[101] For FK506 in CDCl3, 
for example, the cis-trans ratio comprises 2:1. FK506 was reported as insoluble in DMSO-d6, thus 
there is no information on the expected cis-trans ratio in DMSO. It would appear that the 
modification to the FK506 structure as in 22 results in solubility in DMSO-d6 and a 1:1 ratio of both 
stereoisomers. However, this needs confirmation via a complete conformational analysis of 22, 
which was not attempted here. Unless mentioned otherwise, chemical shifts reported hereafter 
generally correspond to the midpoint or only one of the closely spaced resonances in the proton and 
carbon spectra.  
 
Both H-4 and H-5 are connected to a quaternary carbon at 158.85 ppm which represent the Cq at the 
foot of the alkoxy fragment, i.e. position 6. In the NOESY spectrum H-5 shows strong nOe correlations 
to protons at 3.95 and 3.85 ppm. These two protons correlate to a single CH2 type carbon at 65.37 
ppm in the multiplicity edited HSQC, identifying the CH2 at position 8. This assignment is confirmed 
by long range nJCH correlations to Cq(6) at 158.85 ppm. 
 
The area of the proton spectrum in the vicinity of the -CH2-O at position 8 is heavily overlapped, 
complicating analysis. The TOCSY suggests additional correlations to four other protons at 4.71, 3.69, 
2.08 and 1.71 ppm, respectively. Cross-peaks connect the CH2 at position 8 directly with the 
resonances at 2.08 and 1.71, identifying the latter as the CH2 unit at position 9, with its carbon at 
30.26 ppm. This carbon also correlates to the protons at position 8. Both CH2’s (8 and 9) are found to 
correlate in the HMBC to two CH units located at 49.19/3.69 and 49.29/3.73 ppm, respectively. 
Again, both protons together integrate for a single 1H compared to the aromatic signals, indicating 
that these should be considered as the same proton at position 10, but in separate isomers. This is 
confirmed from the TOCSY and COSY. Finally, the -C(9)H2-C(10)H- fragment shows 
nJCH to the keto-
carbonylregion, with two peaks at 209.30 and 210.24 ppm, respectively, corresponding to C-11. With 
this, the macrocycle of the FK506 structure has been reached.  
 
Based upon the analysis, the identity of the modification to the FK506 basic structure could be 
unambiguously determined, supporting the structure of 22 as presented. 
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Table III.7: Partial 1H and 13C NMR assignment of alkyne-functionalized FK506 (22) in DMSO-d6 at 
298K (700/176 MHz) according to the labeling scheme above. 
 
Label 1H (ppm) 13C (ppm) Multiplicity 
1 4.00 79.17 d  
2 - 83.79 
 
3 - 113.61 
 
41 7.39 133.21 d  
42 7.38 133.18 d  
51 6.89 114.65 d  
52 6.87 114.59 d  
61 - 158.89  
62 - 158.82  
8 3.93/3.84 65.37 m/m 
9 2.08/1.71 30.26 m/m 
101 3.73 49.29 dt  
102 3.69 49.19 ddd  
111 - 210.24  
112 - 209.30  
121 4.80 122.17 d  
122 4.70 121.32 m (overlapped) 
* the subscripts 1 and 2 refer to the two different rotamers present in solution. The label was 
attributed based upon the relative position of the peaks (highest ppm first), not by assignment to a 
specific rotamer. 
 
FK506-MFC (23): Azide 6a (47 mg, 59 µmol) was taken up in a mixture of TFA and CH2Cl2 (1.5 mL, 1:1, 
v/v) and stirred for 40 min at RT. The reaction mixture was then taken to dryness, coevaporated 
twice with toluene and concentrated under high vacuum for 1 h. The residue was taken up in a 
mixture of water and tert-butanol (1 mL, 1:1, v/v) and alkyne 22 (30 mg, 33 µmol), CuSO4 (33 μL, 
1.0M, 1.0 eq.) and Na ascorbate (165 μL, 1.0M, 5.0 eq.) were added. The resulting reaction mixture 
was stirred for 16 h at RT. The solution was concentrated in vacuo and the residue was purified by 
preparative RP-HPLC (10-90% MeCN) yielding the title compound (18 mg, 11 μmol, 33%) as a pale 
yellow amorphous solid. HRMS calcd. for C83H120N13O22 [M+H]
+: 1650.8665, found: 1650.9032. 
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III.5.2. Molecular biology 
 
Performed by the Cytokine Receptor Laboratory, Department of Medical Protein Research, VIB, Ghent 
& Department of Biochemistry, Faculty of Medicine and Health Sciences, Ghent University (Prof. Jan 
Tavernier, Dr. Sam Lievens). 
 
The pCLL-eDHFR receptor-DHFR vector was cloned by transferring the E. coli DHFR insert from pSEL-
eDHFR[84] into the pCLL backbone[102] using SacI and NotI restriction sites. The pCLG-eDHFR receptor-
DHFR plasmid was similarly produced by transferring the E. coli DHFR insert into the pCLG 
backbone.[103] The empty prey construct pMG2 has been previously described.[88] The FKBP12 prey 
construct pMG2-FKBP12 was generated by amplifying the FKBP12 coding sequence and cloning it 
into the EcoRI and NotI restriction sites of pMG2.[104] The prey plasmids pMG1-EFHA1, pMG1-ESR1 
and pMG1-TTK were created by Gateway transfer of the full size EFHA1, ESR1 and TTK ORFs, 
obtained as an entry clone in the hORFeome collection,[105] into the Gateway compatible pMG1 prey 
destination vector as described earlier.[88] 
 
Cells were transfected using a standard calcium phosphate protocol as previously described.[88] In 
binary MASPIT assays, HEK293T cells were seeded in black tissue-culture treated 96-well plates at 
10.000 cells/well in 100 μL culture medium (DMEM supplemented with 10% fetal calf serum), and 
grown at 37°C, 8% CO2. Twenty-four hours later, cells were transfected with combinations of 
receptor-DHFR and prey constructs and the pXP2d2-rPAP1-luciferase reporter. Twenty-four hours 
after transfection, cells were either left unstimulated or treated with 100 ng/mL leptin, with or 
without addition of bait fusion compound. Another twenty-four hours later, luciferase activity was 
assayed using the Luciferase Assay System kit (Promega). 
 
Microtiterplates (384-well) for array screening, containing dried mixtures of prey and pXP2d2-rPAP1-
luciferase reporter plasmids together with transfection reagent and additional components, were 
prepared as described, providing quadruplicate wells for each prey.[88] The collection used in this 
chapter contained a subset of 1879 full-length human ORF preys selected from the human ORFeome 
collection (Full list available in Supporting Information Table 1 of reference [105]). To screen the 
plates, HEK293T cells were first seeded in T175 flasks at a density of 7·106 cells/flask in 35 mL culture 
medium. After twenty-four hours, cells were transfected with the pCLL-eDHFR plasmid. Twenty-four 
hours after transfection, cells were detached and added to the array screening plates at 5.000 
cells/well in 15 μL medium. After twenty-four hours, duplicate wells were supplemented with 15 μL 
MTX-FK506 containing medium (final concentration 1 μM) or with 15 μL medium containing MTX-
FK506 and leptin (final concentration 1 μM and 100 ng/mL, respectively). Non-regiomeric MTX-FK506 
conjugate was used in this experiment. Twenty-four hours after stimulation, luciferase activity was 
measured. Average values of the duplicate wells were normalized for the plate median value. Filters 
for data cleanup and to remove aspecifically binding preys were set as earlier described.[88] 
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IV. Alternative Reagents for Methotrexate as Immobilizing Anchor Moieties in the 
Optimization of MASPIT: Synthesis and Biological Evaluation 
 
IV.1. Introduction 
 
Methods that allow high-throughput identification of the cellular targets of bioactive small molecules 
are invaluable assets in pharmaceutical research. They are useful in mechanism-of-action studies of 
hits identified by phenotypic screening, which is increasingly being applied in both academic and 
industrial programs.[1] Additionally, they can uncover unexpected targets of established drugs that 
could contribute to their therapeutic efficacy or cause unwanted side effects (polypharmacology).[2] 
Finally, such methods can also lead to the identification of new therapeutic applications of existing 
drugs within the scope of drug repositioning projects.[3] Over the past decade, numerous case studies 
within the target profiling field that apply, for example, activity-based protein profiling (ABPP)[4] or 
compound-centric chemical proteomics methods (CCCP)[5] have proved successful. However, despite 
these success stories, target deconvolution often remains an important bottleneck in drug discovery 
research, as a generally applicable methodology is still lacking.[6] 
 
MASPIT (mammalian small molecule-protein interaction trap) is the three-hybrid component of the 
MAPPIT technology platform,[7],[8] which enables the identification of interactions between small 
organic compounds and their cytosolic target proteins in living human cells (Figure IV.1).[9] A 
prerequisite for successful MASPIT analysis is the availability of appropriate synthetic probes. We 
previously presented a scalable synthesis of a versatile methotrexate (MTX) reagent that allows the 
rapid -selective conjugation to alkyne-functionalized bioactive small molecules to yield MTX fusion 
compounds (MFCs) appropriate for MASPIT.[10] Here, we take the next step and discuss our efforts to 
optimize the MASPIT system’s sensitivity based on chemical dimerizers with tamoxifen (TAM) as the 
model ‘bait’. The latter is a selective estrogen receptor (ER) modulator that has been part of the 
standard therapy for ER-positive breast cancer treatment since the 1970s.[11] However, TAM has 
been reported to induce apoptosis even in ER-negative cancer cells, thus suggesting that it can also 
operate by modulating alternative targets.[12] As yet, the exact mechanism of action underlying the 
apparent promiscuity of this blockbuster drug remains elusive. Taking this together and building on 
prior experience in constructing and evaluating various TAM-MFCs,[10] we judged this bait would be a 
particularly interesting test case for our optimization work. 
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Figure IV.1: Outline of the MASPIT system. E. coli dihydrofolate reductase (eDHFR) is fused to a cytokine 
receptor (CR) that is rendered signaling-deficient by mutating STAT3 recruitment sites in its cytoplasmic tail 
(grey dots). A prey protein is tethered to a gp130 CR fragment containing functional STAT3 transcription factor 
docking sites (black dots). When a fusion compound consisting of a small molecule of interest (asterisk) 
coupled to methotrexate (MTX) is added to the cells, MTX binds to eDHFR, resulting in the compound of 
interest being displayed as bait. Upon administration of the appropriate cytokine ligand (cyt), the CR-eDHFR 
chimeric receptor undergoes a conformational change, activating the associated JAK2 kinases through 
crossphosphorylation (P). Interaction between the small-molecule bait and the prey-gp130 fusion protein 
brings the latter into proximity of the activated JAK kinases, reconstituting a functional JAK-STAT signaling 
pathway. Sequential phosphorylation of STAT3 docking sites on the gp130 chain (P), STAT3 recruitment, and 
STAT3 phosphorylation (P) ultimately leads to activated STAT3 dimers that induce the expression of a luciferase 
reporter gene coupled to a STAT3-dependent promoter. 
 
First, we tried to circumvent any potential limitations related to the tight binding of MTX to 
endogenous human dihydrofolate reductase (DHFR), which might titrate out a portion of the fusion 
compound and induce cellular toxicity through perturbation of the endogenous folate metabolism. 
As an Escherichia coli enzyme is employed in MASPIT, we explored trimethoprim (TMP; Figure IV.2A) 
as an alternative prokaryote-specific DHFR ligand. Whereas MTX binds both prokaryotic and 
mammalian DHFR with similar affinity, TMP displays a 12 000-fold binding preference for E. coli over 
human DHFR (Ki = 80 pM vs. 960 nM), thus reflecting its use as a selective antibiotic in the clinic.
[13] 
Cornish and Sheetz have previously demonstrated the compatibility of the TMP-tag with mammalian 
systems for intracellular live-cell imaging.[14] 
 
Furthermore, so as to stabilize the ternary complex (CR-fusion compound-prey chimera) in order to 
improve the system’s sensitivity, we introduced the concept of covalent bonding into the MASPIT 
assay, which currently relies on reversible interactions on both ends of the MFCs. As a starting point, 
we selectively and covalently immobilized the fusion compound to the CR by using a SNAP-tag-based 
system.[15] This strategy is centered around the human DNA-repair protein O6-alkylguanine-DNA 
alkyltransferase (hAGT). Johnsson and co-workers have exploited the low substrate specificity of this 
enzyme to covalently label SNAP-tag-fused proteins in vivo with a ligand of interest by conjugating 
the latter to the para position of O6-benzylguanine (BG).[15] By fusing hAGT to the cytoplasmic domain 
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of the CR and synthesizing the appropriate BG fusion compound (BGFC), we planned to present a 
covalently coupled bait small molecule (Figure IV.2B). 
 
 
 
Figure IV.2: A) Chemical structures of folic acid (FA) and the DHFR inhibitors methotrexate and trimethoprim. 
B) Mechanism of hAGT-mediated covalent immobilization of the O
6
-benzylguanine fusion compound (BGFC) to 
the cytokine receptor (CR). 
 
IV.2. Results and Discussion 
 
IV.2.1. TMP-tag approach 
 
We sought to develop a scalable synthesis of a versatile TMP reagent with an azide ligation handle as 
an alternative for the earlier MTX congener. A synthetic route towards a first-generation TMP-azido 
reagent is depicted in Scheme IV.1. The synthesis began with the generation of a tosyl/azido 
bifunctionalized hexa(ethylene glycol) linker (26).[16] This spacer was used to alkylate phenol 28, 
which was obtained by acidic hydrolysis of TMP,[17] to afford the desired ligation handle 27. However, 
purification of 27 required RP-HPLC to remove a side product formed by alkylation at the benzhydrilic 
position. Presumably, this double alkylated TMP analogue was formed by oxidative conversion of 
phenol 28 to a reactive pyrimidine iminoquinone methide intermediate.[18] The latter can be 
converted through resonance stabilization to the corresponding para-quinone methide form, which 
has a prochiral activated exocyclic methylene group. This side reaction rendered this alkylation 
unsuitable for scale-up. Therefore, we examined alternative alkylation conditions, varying the base 
(DBU, Na2CO3), leaving group (I, OMs), solvent (DMF), temperature (RT) and reaction time (16-48 h), 
but none yielded a more favorable regioselectivity profile. 
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Scheme IV.1: Synthesis of the first-generation TMP-N3 reagent. [i] TsCl, Et3N, CH2Cl2, 0°C; [ii] NaN3, DMF, 60°C, 
64% two steps; [iii] TsCl, Et3N, CH2Cl2, 0°C, 91%; [iv] 28, K2CO3, acetone, , 39%; [v] first aq. HBr (48%), ; then 
NaOH (50%), 30%. 
 
Subsequently, first-generation trimethoprim fusion compounds (TFCs) 29a-c were prepared by 
ligating azido reagent 27 via CuAAC[19] to the alkyne-functionalized tamoxifen,[10] reversine[10] and 
simvastatin,[20] respectively (Figure IV.3). The synthesis of the first two alkynylated bait analogues 
was previously described in Chapter 3. The latter was prepared in several steps from lovastatin 
(Scheme IV.2). tert-Butyldimethylsilyloxymonacolin J (31) and the required 2,2-dimethylpent-4-ynoic 
acid 37 were obtained according to a protocol by Sorensen et al.[21] and Welsch et al.,[22] respectively. 
Analogously to a procedure by Hong et al.[23] the latter acid was converted in situ to the 
corresponding acid bromide, which was used to acylate 31 to afford alkyne 33 after desilylation. 
 
 
 
Scheme IV.2: Synthesis of alkyne-functionalized simvastatin and its corresponding MFC. [i] first LiOH, ; then 
CaH2, toluene,  (Soxhlet), 44%; [ii] TBDMSCl, imidazole, DMF, 93%; [iii] 37, PPh3, NBS, PhNMe2, CH2Cl2, 0°C to 
RT, 80%; [iv] HCl, THF, dioxane, 0°C to RT, 76%; [v] first 6a, TFA, CH2Cl2; then 33, CuSO4, Na ascorbate, Et3N, 
TBTA, DMF, H2O, 150°C (µW), 44%; [vi] first LDA, THF, -78°C; then propargyl bromide, -78°C to RT, 71%; [vii] 
first NaOH, MeOH, 50°C; then HCl, 94%. 
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MASPIT evaluation of these TMP conjugates (29a-c) against their established primary target preys 
showed decreased EC50 values with respect to the corresponding MFCs (Figure IV.3). These data 
imply a successful improvement in the system’s sensitivity by introducing TMP as an alternative 
immobilizing anchor moiety, despite the fact that it exhibits lower affinity for eDHFR than MTX (Ki = 
1.0 pM).[13] 
 
 
 
Figure IV.3: Evaluation of small-molecule TFCs 29a-c (TMP I) and 41 (TMP II) against the corresponding MFCs 
(MTX) for binding to their primary target protein in MASPIT. A) Tamoxifen-ER1; B) reversine-TTK; C) 
simvastatin-HMGCR. Luciferase signals are expressed as fold induction relative to a control sample treated with 
cytokine without fusion compound. In A), the signal decrease at the highest concentrations is due to the 
cellular toxicity of the tamoxifen fusion compound. 
 
In a next step, we explored a different alkylation strategy starting from phenol 28 (Scheme IV.3). 
Initial alkylations using ethyl 5-bromovalerate in combination with K2CO3 consistently provided an 
intractable mixture of overalkylated products. Varying the solvent (DMF, acetone), temperature 
(40°C, ) and reaction time (6-60h) had negligible effects on the regioselectivity and reaction 
progress/yield. However, encouraged by the significant positive trend we observed earlier for 27 
upon switching to a softer counterion for the carbonate base (K2CO3 vs. Na2CO3) and further guided 
by a procedure by Chen et al.,[24] we ultimately opted for Cs2CO3 which successfully gave access to 
acid 39. The latter was subsequently condensed with PEG4 azidoamine 4b
[10] in the presence of 2-(2-
pyridon-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TPTU) to obtain a second-generation 
TMP-azido reagent in satisfactory yield on a multigram scale. This reagent has the same spacer 
length, with respect to the number of atoms and chemical bonds, as the original 27 and was 
analogously click-coupled to the tamoxifen model bait to generate the second-generation TAM-TFC 
41. 
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Scheme IV.3: Synthesis of the second-generation TMP-N3 reagent and TAM-TFC. [i] Ethyl 5-bromovalerate, 
Cs2CO3, DMF, 70°C, 66%; [ii] first NaOH, MeOH; then HCl, 92%; [iii] 4b, TPTU, Et3N, DMF, 78%; [iv] alkyne-
functionalized tamoxifen,
[10]
 CuSO4, Na ascorbate, TBTA, H2O/tBuOH, 80°C, 56%. 
 
Both generations of TAM-TFCs in MASPIT yielded approximately coinciding curves, again shifted 
towards lower EC50 values compared to the original MFC (Figure IV.3A). Hereby, we demonstrated 
the biological equivalence of the scalable 40 to 27, and confirmed the increase in sensitivity for TFCs. 
Moreover, next to its superior behavior in the MASPIT assay, the newly developed second-generation 
TMP reagent offers a number of important advantages over the existing MTX anchor from a chemical 
perspective. The TMP reagent lacks chirality and shows increased solubility, thus making it in general 
more practical. Furthermore, the reagent has enhanced stability in CuAAC reactions, whereas, under 
typical conditions, the MTX-azido reagent suffered from significant degradation to the corresponding 
amine. This is possibly due to residual trifluoroacetic acid in the material from cleavage of the -tert-
butylester precursor.[10] In the case of TMP, which does not require these protecting-group 
manipulations, CuAACs can be performed without the formation of degradation or by-products, 
thereby facilitating purification of the final conjugates. 
 
Previously, Cornish[25] and Bertozzi[26] obtained contradictory outcomes when comparing the 
effectiveness of MTX- and TMP-based chemical inducers of dimerization (CIDs) in the same yeast 
three-hybrid system. For the dexamethasone ligand, Cornish found that the TMP-based CID did not 
induce transcription activation as efficiently as the corresponding MTX probe, whereas Bertozzi 
concluded exactly the opposite for the SLF bait (a synthetic analogue of FK506). They postulated that 
the disparity in activity between the two CID anchors might be attributed, for example, to different 
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cell-permeability properties. To our knowledge, this aspect has not been experimentally clarified in 
the context of compound profiling strategies so far. Hence, in an effort to elucidate the origin of the 
superior performance of TMP fusions in the assay, we studied the uptake of MTX- versus TMP-linked 
fluorophores in HEK293T cells, the cell line employed in MASPIT. The known MTX-azido and 
optimized TMP-azido reagents were fused to an alkyne-functionalized BODIPY analogue[27] by CuAAC 
to yield 42 and 43, respectively (Figure IV.4). 
 
 
 
Figure IV.4: Evaluation of the membrane permeability of BODIPY conjugates of MTX (42) and TMP (43). A) 
Dose-response curves showing the inherent fluorescence of the conjugates. B) Dose-response curves of the 
cellular uptake of the BODIPY conjugates. The graph shows the mean fluorescence as measured by FACS 
analysis of cells stained with increasing concentrations of the conjugates. C) Kinetic analysis of cellular staining 
with the MTX- or TMP-BODIPY fusion molecules. Mean fluorescence measured by FACS is plotted against time 
after the addition of 1 µM of either conjugate. 
 
Subsequently, the permeability of both conjugates was tracked in a fluorescence-activated cell-
sorting (FACS) experiment. First, we measured the fluorescence intensity of both fusion molecules in 
solution in order to exclude the possibility that the inherent fluorescence of the BODIPY fluorophore 
was affected by fusion to MTX or TMP. As the concentration-fluorescence curves of both BODIPY 
fusions closely overlap, this does not seem to be the case (Figure IV.4A). Next, HEK293T cells were 
incubated for a fixed time (15 min) with increasing concentrations of either BODIPY fusion molecule. 
The mean fluorescence of the viable cell subset was measured by FACS, and showed a dose-
dependent increase that was significantly higher for the TMP-linked fluorophore than for the MTX 
fusion molecule (Figure IV.4B). Additionally, the rate of dye fusion molecule uptake was followed as a 
function of time at a set concentration of 1 µM. Cells turned out to take up the BODIPY conjugates 
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rapidly, with maximal fluorescence being reached within 30 s (Figure IV.4C). Consistent with the 
dose-response analysis, both the rate of conjugate uptake and the plateau level of fluorescence were 
markedly higher for the TMP-BODIPY fusion. These results indicate that the increased sensitivity 
obtained when using TMP fusion compounds in MASPIT can be attributed, at least partly, to a 
significantly higher membrane permeability than for MTX-linked compounds, although we cannot 
exclude that this trend might be affected by the nature of the bait. 
 
IV.2.2. SNAP-tag approach 
 
To implement the SNAP-tag strategy, we needed a general O6-benzylguanine (BG) reagent, para-
substituted with a PEG linker and with a terminal azide ligation handle. Therefore, the azido spacer 
25 was first benzylated and then purinated with 46[28] and 50,[29] respectively (Scheme IV.4). 
Subsequent CuAAC between the resulting BG-based building block 51 and alkyne-functionalized 
tamoxifen readily afforded the desired TAM-BGFC 52. However, the BG-PEG6-N3 reagent suffers from 
intrinsic thermal degradation issues that result in the elimination of the terminal azidoethyl group 
and make it less attractive than the optimized TMP reagent. In order to enable BGFC incorporation in 
the MASPIT system, in the plasmid encoding the CR fusion protein, the eDHFR coding sequence was 
replaced by a DNA fragment encoding a hAGT mutant that exhibits increased activity towards BG and 
which has been optimized with regard to mammalian codon usage. 
 
 
 
Scheme IV.4: Synthesis of the BG-PEG6-N3 reagent. [i] TBDMSCl, imidazole, DMF, 42%; [ii] PPh3, I2, imidazole, 
Et2O/MeCN, 79%; [iii] 25, NaH, DMF, 0°C, 59%; [iv] HF.pyr, THF, 80%; [v] 1-methylpyrrolidine, DMF, 63%; [vi] 
KOtBu, DMF, 25%. 
 
The SNAP-tag MASPIT version was evaluated for the interaction between tamoxifen and its primary 
target, ER1. Cells expressing both the CR-hAGT and ER1 prey fusion proteins and treated with the 
cytokine ligand and increasing concentrations of the tamoxifen-BGFC 52 exhibited a dose-dependent 
increase in luciferase reporter activity (Figure IV.5). This indicated that a ternary complex containing 
the hAGT and ER1 fusion proteins and the tamoxifen-BGFC is indeed formed, likely involving a 
covalent bond between hAGT and the BG conjugate. However, the induction window turned out to 
be significantly lower (sixfold vs. 177-fold) and the EC50 markedly higher (2.410
-7 M vs. 2.510-8 M) 
than in the case of the TMP-tag setup. Note, we tested a variety of experimental conditions (varying 
CR-hAGT and ER1 prey expression levels and time between BGFC addition and luciferase readout) for 
the interaction between the tamoxifen-BGFC and the ER1 prey, as well as several other tamoxifen 
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(off- or on-) target proteins recently identified by our group, and in none of these cases did the SNAP-
tag approach perform better than the MTX- or TMP-tag-based assay. There might be a number of 
reasons for this, including titration of the supplied BGFC by endogenous AGT[15] and CR-hAGT fusion 
protein degradation upon alkyl transfer.[30] 
 
 
 
Figure IV.5: Evaluation of the interaction of TAM-BGFC 52 with ER1 in the SNAP-tag MASPIT setup. The graph 
shows the fold change in luciferase activity for a concentration gradient of TAM-BGFC relative to a control 
treated with the cytokine ligand without TAM-BGFC. The signal decrease at the highest concentration is due to 
the cellular toxicity of the tamoxifen fusion compound. 
 
IV.3. Conclusions 
 
In this chapter, we evaluated two approaches, i.e. TMP- and SNAP-tag, to increase the sensitivity of 
MASPIT. Unexpectedly, the implementation of the SNAP-tag approach, in which the bait fusion 
molecule is coupled covalently to the CR chimera, did not yield the hypothesized increase in 
sensitivity. On the other hand, we have demonstrated a clear improvement in the system’s sensitivity 
by introducing trimethoprim as an alternative immobilizing anchor moiety. This improvement is 
possibly due to its significantly higher membrane permeability than that of MTX-based fusion 
compounds. In addition, we presented a scalable synthesis of a versatile TMP reagent that proved 
superior to the original MTX probe with respect to solubility and stability under various reaction 
conditions.  
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IV.4. Experimental Section 
 
IV.4.1. Synthesis 
 
General: All reactions were performed under nitrogen and at ambient temperature, unless stated 
otherwise. Reagents and solvents were purchased from Sigma-Aldrich, Acros Organics, or TCI Europe, 
and used as received. Reactions were monitored by thin-layer chromatography on TLC aluminum 
sheets (Macherey-Nagel, Alugram Sil G/UV254) with detection by spraying with a solution of 
(NH4)6Mo7O24·4H2O (25 g/L) and (NH4)4Ce(SO4)4·2H2O (10 g/L) in H2SO4 (10%) or KMnO4 (20 g/L) and 
K2CO3 (10 g/L) in water followed by charring, or Ninhydrin (2% in ethanol). Column chromatography 
was performed manually with 60 Å silica gel (Grace, Davisil, 40-63 µm) and/or automatically on a 
Grace Reveleris X2 flash system equipped with disposable silica gel cartridges (Grace, Reveleris). LC-
MS analyses were carried out on a Waters Alliance 2695 XE separation Module by using a 
Phenomenex Luna reversed-phase C18 column (1002.00 mm, 3 μm) and a gradient system of 
HCOOH in H2O (0.1 %, v/v)/HCOOH in CH3CN (0.1 %, v/v) at a flow rate of 0.4 mL/min. High-resolution 
spectra were recorded on a Waters LCT Premier XE Mass spectrometer. 1H and 13C NMR spectra were 
measured on a Varian Mercury-300BB (300/75 MHz) spectrometer. NMR solvents were purchased 
from Euriso-top. Chemical shifts () are given in ppm relative to tetramethylsilane (1H NMR) or CDCl3, 
CD3OD or SO(CD3)2 (
13C NMR) as internal standards. Coupling constants are given in Hz. Preparative 
TLC purification was carried out on glass-backed Uniplate TLC plates (Analtech, Silica gel GF, UV254, 
2020 cm, 2000 µm). Preparative HPLC purifications were carried out by using a Laprep preparative 
RP-HPLC system equipped with a Phenomenex Luna C18 column (21.20250 mm, 5 μm) with a 
gradient system of HCOOH in H2O (0.2 %, v/v)/CH3CN at a flow rate of 17.5 mL/min. Microwave 
experiments were performed using a Milestone Microsynth under fiberoptic internal temperature 
control. 
 
-Azido,-deoxyhexa(ethylene glycol) (25): Triethylamine (8.4 mL, 60.4 mmol) and TsCl (5.62 g, 29.5 
mmol) were added to an ice-cooled solution of hexa(ethylene glycol) (9.58 g, 33.9 mmol) in 
anhydrous CH2Cl2 (150 mL). This solution was stirred overnight, and the temperature was allowed to 
rise to RT. The reaction mixture was concentrated in vacuo, and the crude tosylate was taken up in 
DMF (250 mL). Sodium azide (6.71 g, 103.2 mmol) was added, and the mixture was vigorously stirred 
overnight at 60°C. The mixture was concentrated in vacuo, and the residue was purified by silica gel 
chromatography (MeOH/CH2Cl2 2:98, v/v) to yield the title compound (5.80 g, 18.9 mmol, 64%) as a 
pale yellow viscous liquid. 1H NMR (300 MHz, CDCl3)  = 3.74-3.69 (m, 2H), 3.69-3.64 (m, 18H), 3.62-
3.58 (m, 2H), 3.39 (t, J = 5.0 Hz, 2H), 3.05 ppm (br s, 1H); 13C NMR (75 MHz, CDCl3)  = 72.5, 70.5-70.3 
(wide peak), 70.2, 69.9, 61.5, 50.5 ppm; HRMS: calcd. for C12H25N3O6Na: 330.1636 [M+Na]
+, found: 
330.1649. 
 
-Azido,-deoxy,-p-toluenesulfonylhexa(ethylene glycol) (26): Alcohol 25 (1.53 g, 5.0 mmol) was 
dissolved in anhydrous CH2Cl2 (25 mL), and the solution was cooled on ice. Triethylamine (2.1 mL, 
15.1 mmol) and TsCl (2.38 g, 12.5 mmol) were added. The resulting mixture was stirred overnight, 
and the temperature was allowed to rise to RT. The mixture was concentrated in vacuo, and the 
residue was purified by silica gel chromatography (MeOH/CH2Cl2 1-3%, v/v) to yield the title 
compound (2.10 g, 4.5 mmol, 91%) as a brownish-yellow viscous liquid. 1H NMR (300 MHz, CDCl3)  = 
7.79 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 8.4 Hz, 2H), 4.15 (t, J = 5.0 Hz, 2H), 3.70-3.56 (m, 20H), 3.37 (t, J = 
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5.0 Hz, 2H), 2.44 ppm (s, 3H); 13C NMR (75 MHz, CDCl3)  = 144.6, 132.8, 129.7, 127.7, 70.5-70.2 (wide 
peak), 69.8, 69.1, 68.4, 50.4, 21.4 ppm; HRMS: calcd. for C19H35N4O8S: 479.2170 [M+NH4]
+, found: 
479.2176. 
 
First-generation TMP-N3 reagent (27): K2CO3 (138 mg, 1.00 mmol) and PEG linker 26 (369 mg, 0.80 
mmol) were added to a solution of phenol 28 (138 mg, 0.50 mmol) in acetone (5 mL). The resulting 
mixture was refluxed at 75°C for 60 h with vigorous stirring. After being cooled to RT, the mixture 
was concentrated in vacuo. The residue was repeatedly purified by silica gel chromatography 
(MeOH/CH2Cl2 0-15%, v/v) to give a semipure product, which was further purified to homogeneity by 
preparative RP-HPLC (10-100% MeCN) to yield the title compound (111.2 mg, 197 µmol, 39%) as a 
clear, colorless oil. 1H NMR (300 MHz, CD3OD)  = 7.35 (s, 1H), 6.54 (s, 2H), 4.05 (t, J = 4.8 Hz, 2H), 
3.79 (s, 6H), 3.77-3.71 (m, 2H), 3.71-3.60 (m, 20H), 3.35 ppm (t, J = 5.0 Hz, 2H); 13C NMR (75 MHz, 
CD3OD)  = 164.9, 161.3, 154.8, 151.8, 136.4, 136.0, 108.8, 106.9, 73.4, 71.5-71.4 (wide peak), 71.34, 
71.27, 71.0, 56.6, 51.8, 34.3 ppm; LC-HRMS: tR = 5.90 min (10-100% MeCN, 15 min run); HRMS: calcd. 
for C25H40N7O8: 566.2933 [M+H]
+, found: 566.2919. 
 
TMP-OH (28): The synthetic procedure was adapted from Long et al.[17] A large scale synthesis was 
initiated from 100 g commercially available trimethoprim, subdivided into four equal, sequential 
synthesis batches. In brief, trimethoprim (25 g, 86.1 mmol) was taken up in aq. HBr (311 mL, 48%, 
w/w) and heated to 100°C under vigorous stirring. After maintaining this temperature for 28 min, the 
solution was immediately quenched with ice-cooled aq. NaOH (75 mL, 50%, w/w). The resulting 
mixture was allowed to cool to RT to give fine precipitates, which were filtered, washed with Et2O (2 
x 75 mL) and dried overnight under high vacuum. Subsequently, the crude precipitates from the four 
batches were combined and taken up in ice-cooled water (600 mL), after which the pH was adjusted 
to 7 by the addition of NaOH (4M). The resulting mixture was redissolved by heating to 125°C for 15 
min under vigorous stirring. After this time, the solution was allowed to cool for only 5 min at RT and 
the freshly formed precipitates were directly filtered and dried overnight under high vacuum. This 
recrystallization procedure was twice more repeated to yield the title compound (28.2 g, 102.1 
mmol, 30%) as an off white solid. 1H NMR (300 MHz, SO(CD3)2)  = 8.16 (br s, 1H), 7.47 (s, 1H), 6.49 (s, 
2H), 6.07 (s, 2H), 5.71 (s, 2H), 3.70 (s, 6H), 3.48 ppm (s, 2H); 13C NMR (75 MHz, SO(CD3)2)  = 162.23, 
162.16, 155.4, 147.9, 133.8, 130.0, 106.2, 106.1, 56.0, 32.8 ppm; HRMS: calcd. for C13H17N4O3: 
277.1295 [M+H]+, found: 277.1297. 
 
First-generation tamoxifen TFC (29a): Azide 27 (166.5 mg, 294 µmol, 2.3 eq.) was taken up in 
H2O/tBuOH (2.5 mL, 1:1, v/v), and alkyne-functionalized tamoxifen (50.0 mg, 126 µmol, 1.0 eq.), 
CuSO4 (50.4 µL, 0.5M, 0.2 eq.), and Na ascorbate (252 µL, 0.5M, 1.0 eq.) were added. The resulting 
mixture was charged with a catalytic amount of TBTA[31] and heated to 80°C for 16 h with vigorous 
stirring. After being cooled to RT, the solution was concentrated in vacuo. The residue was purified 
by preparative RP-HPLC (10-100% MeCN) to yield the title compound (90.9 mg, 95 µmol, 75%) as a 
white amorphous solid. LC-HRMS: tR = 6.96 min (10-100% MeCN, 15 min run); HRMS: calcd. for 
C53H70N8O9: 481.2627 [M+2H]
2+, found: 481.2622. 
 
First-generation reversine TFC (29b): Azide 27 (67.9 mg, 120 µmol, 1.7 eq.) was taken up in 
H2O/tBuOH (2.1 mL, 1:1, v/v), and alkyne-functionalized reversine (30.3 mg, 70 µmol, 1.0 eq.), CuSO4 
(28.0 µL, 0.5M, 0.2 eq.), and Na ascorbate (140 µL, 0.5M, 1.0 eq.) were added. The resulting mixture 
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was charged with a catalytic amount of both Et3N and TBTA
[31] and heated to 80°C with vigorous 
stirring. Upon completion of the reaction (88 h), the solution was cooled to RT and concentrated in 
vacuo. The residue was purified by preparative RP-HPLC (10-100% MeCN) to yield the title compound 
(36.6 mg, 37 µmol, 53%) as a white amorphous solid. LC-HRMS: tR = 5.30 min (10-100% MeCN, 15 
min run); HRMS: calcd. for C49H72N15O8: 332.8557 [M+3H]
3+, found: 332.8524. 
 
First-generation simvastatin TFC (29c): Azide 27 (84.8 mg, 150 µmol, 1.5 eq.) was taken up in 
H2O/DMF (3.3 mL, 1:1, v/v), and alkyne-functionalized simvastatin (42.9 mg, 100 µmol, 1.0 eq.), 
CuSO4 (40.0 µL, 0.5M, 0.2 eq.), and Na ascorbate (200 µL, 0.5M, 1.0 eq.) were added. The resulting 
mixture was charged with a catalytic amount of TBTA[31] and heated to 75°C for 16 h with vigorous 
stirring. After being cooled to RT, the solution was concentrated in vacuo. The residue was purified 
by preparative RP-HPLC (30-50% MeCN) to yield the title compound (16.7 mg, 17 µmol, 17%) as a 
white amorphous solid. LC-HRMS: tR = 7.39 min (10-100% MeCN, 15 min run); HRMS: calcd. for 
C51H77N7O13: 497.7784 [M+2H]
2+, found: 497.7700. 
 
Monacolin J (30): The synthetic procedure was adapted from Sorensen et al.[21] In brief, lovastatin 
(12.0 g, 29.7 mmol) was suspended in aq. LiOH (600 mL, 1M) and refluxed overnight under vigorous 
stirring. After being cooled to RT, the pH was adjusted to 1-2 by the addition of HCl (12M). The acidic 
solution was extracted with CH2Cl2 (3 x 600 mL) and the organic fractions were pooled, dried over 
Na2SO4 and concentrated in vacuo to give 12.7 g crude residue. Next, the latter was dissolved in 
toluene (700 mL) and lactonized by refluxing with a CaH2 Soxhlet apparatus for 1 h. After being 
cooled to RT, the reaction mixture was concentrated in vacuo and the residue was purified by silica 
gel chromatography (EtOAc/hexane 75-80%, v/v). The thus obtained semi pure product was purified 
further by precipitation (EtOAc/hexane) yielding the title compound (4.2 g, 13.2 mmol, 44%) as a 
white solid. 1H NMR (300 MHz, CD3OD)  = 5.95 (d, 1H, J = 9.6 Hz), 5.75 (dd, 1H, J = 9.6 Hz, J = 6.0 Hz), 
5.49-5.44 (m, 1H), 4.77-4.62 (m1 H), 4.29-4.20 (m, 2H), 2.73 (dd, 1H, J = 17.7 Hz, J = 4.5 Hz), 2.53 
(ddd, 1H, J = 17.7 Hz, J = 3.3 Hz, J = 1.7 Hz), 2.45-2.32 (m, 2H), 2.14 (dd, 1H, J = 12.0 Hz, J = 2.7 Hz), 
2.02-1.73 (m, 7H), 1.64-1.48 (m, 1H), 1.48-1.33 (m, 1H), 1.19 (d, 3H, J = 7.5 Hz), 0.90 ppm (d, 3H, J = 
7.2 Hz); 13C NMR (75 MHz, CD3OD)  = 173.7, 133.9, 133.0, 130.7, 130.1, 78.3, 65.7, 63.3, 39.6, 39.2, 
37.5, 37.1, 36.6, 34.0, 32.1, 29.1, 25.1, 23.6, 14.3 ppm; HRMS: calcd. for C19H29O4: 321.2060 [M+H]
+, 
found: 321.2060. 
 
tert-Butyldimethylsilyloxymonacolin J (31): The synthetic procedure was adapted from Sorensen et 
al.[21] In brief, to a solution of compound 30 (1.60 g, 5.0 mmol) and imidazole (1.70 g, 25.0 mmol) in 
DMF (70 mL), tert-butyldimethylsilyl chloride (TBDMSCl) (1.88 g, 12.5 mmol) was added and the 
resulting reaction mixture was stirred overnight at RT. The solution was poured into water (140 mL) 
and transferred to a separation funnel. The aqueous fraction was extracted with Et2O (3 x 250 mL) 
and the organic fractions were pooled, dried over Na2SO4 and concentrated in vacuo. The residue 
was purified by silica gel chromatography (EtOAc/toluene 15:85, v/v) to yield the title compound 
(2.03 g, 4.67 mmol, 93%) as a white solid. 1H NMR (300 MHz, CDCl3)  = 5.98 (d, 1H, J = 9.6 Hz), 5.80 
(dd, 1H, J = 9.6 Hz, J = 6.0 Hz), 5.57-5.51 (m, 1H), 4.73-4.61 (m, 1H), 4.33-4.26 (m, 1H), 4.26-4.20 (m, 
1H), 2.62 (dd, 1H, J = 17.4 Hz, J = 4.2 Hz), 2.55 (ddd, 1H, J = 17.4 Hz, J = 3.6 Hz, J = 1.3 Hz), 2.50-2.31 
(m, 2H), 2.17 (dd, 1H, J= 12.0 Hz, J = 2.7 Hz), 1.96-1.63 (m, 7H), 1.57-1.43 (m, 2H), 1.37 (br s, 1H), 1.19 
(d, 3H, J = 7.5 Hz), 0.90 (d, 3H, J = 7.2 Hz), 0.884 (s, 9H), 0.078 (s, 3H), 0.073 ppm (s, 3H); 13C NMR (75 
MHz, CDCl3)  = 170.6, 133.8, 131.5, 130.2, 128.6, 76.6, 65.4, 63.7, 39.5, 39.0, 37.1, 36.6, 36.0, 33.2, 
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31.0, 27.5, 25.8, 24.5, 24.0, 18.1, 14.1, -4.7 ppm; HRMS: calcd. for C25H43O4Si: 435.2925 [M+H]
+, 
found: 435.2941. 
 
TBS-protected alkyne-functionalized simvastatin (32): To an ice-cooled solution of 2,2-
dimethylpent-4-ynoic acid 37 (278 mg, 2.20 mmol) in CH2Cl2 (5 mL), PPh3 (1.44 g, 5.5 mmol) and NBS 
(0.63 g, 3.5 mmol)  were added. The resulting reaction mixture was allowed to stir for 30 min at RT. 
After this time, the mixture was cooled on ice again and N,N-dimethylaniline (0.3 mL, 2.38 mmol) and 
compound 31 (869 mg, 2.00 mmol) were added. The resulting solution was stirred overnight letting 
the temperature rise to RT. The reaction mixture was successively washed with 1.0M HCl, water, sat. 
NaHCO3, water and brine (20 mL), dried over Na2SO4 and concentrated in vacuo. The residue was 
purified by silica gel chromatography (EtOAc/toluene 10-12.5%, v/v) to yield the title compound (624 
mg, 1.15 mmol, 58%, 80% based on recovered starting material) as a pale yellowish oil. 1H NMR (300 
MHz, CDCl3)  = 5.98 (d, 1H, J = 9.6 Hz), 5.77 (dd, 1H, J = 9.6 Hz, J = 6.0 Hz), 5.53-5.49 (m, 1H), 5.38-
5.33 (m, 1H), 4.65-4.54 (m, 1H), 4.33-4.27 (m, 1H), 2.62 (dd, 1H, J = 17.4 Hz, J = 4.5 Hz), 2.54 (ddd, 1H, 
J = 17.4 Hz, J = 3.3 Hz, J = 1.2 Hz), 2.46-2.39 (m, 3H), 2.39-2.32 (m, 1H), 2.27 (dd, 1H, J = 12.0 Hz, J = 
2.7 Hz), 2.06-1.91 (m, 3H), 1.91-1.79 (m, 2H), 1.74-1.59 (m, 2H), 1.54-1.29 (m, 3H), 1.26 (s, 3H), 1.25 
(s, 3H), 1.08 (d, 3H, J = 7.5 Hz), 0.890 (d, 3H, J = 6.9 Hz), 0.885 (s, 9H), 0.084 (s, 3H), 0.081 ppm (s, 3H); 
13C NMR (75 MHz, CDCl3)  = 176.1, 170.1, 132.9, 131.5, 129.6, 128.3, 81.0, 76.3, 70.7, 68.7, 63.5, 
42.2, 39.2, 37.4, 36.77, 36.75, 33.0, 32.6, 30.6, 29.4, 27.2, 25.7, 24.7, 24.4, 24.1, 23.1, 17.9, 13.8, -
4.91, -4.92 ppm; HRMS: calcd. for C32H51O5Si: 543.3500 [M+H]
+, found: 543.3502. 
 
Alkyne-functionalized simvastatin (33): To an ice-cooled solution of compound 32 (390 mg, 0.72 
mmol) in a mixture of THF and 1,4-dioxane (7 mL, 95:5, v/v), concentrated HCl (482 µL) was added 
and the resulting reaction mixture was stirred for 5 h at RT. The solution was poured into sat. 
NaHCO3 (30 mL) and transferred to a separation funnel. The aqueous fraction was extracted with 
CH2Cl2 (3 x 30 mL) and the organic fractions were pooled, dried over Na2SO4 and concentrated in 
vacuo. The residue was purified by silica gel chromatography (EtOAc/toluene 1:1, v/v) yielding the 
title compound (234 mg, 0.55 mmol, 76%) as a yellowish/beige foam. 1H NMR (300 MHz, CDCl3)  = 
5.99 (d, 1H, J = 9.6 Hz), 5.78 (dd, 1H, J = 9.6 Hz, J = 6.0 Hz), 5.53-5.49 (m, 1H), 5.40-5.35 (m, 1H), 4.69-
4.58 (m, 1H), 4.41-4.33 (m, 1H), 2.74 (dd, 1H, J = 17.6 Hz, J = 5.0 Hz), 2.62 (ddd, 1H, J = 17.6 Hz, J = 3.8 
Hz, J = 1.5 Hz), 2.49-2.41 (m, 3H), 2.39-2.33 (m, 1H), 2.27 (dd, 1H, J = 12.0 Hz, J = 2.7 Hz), 2.05 (t, 1H, J 
= 2.7 Hz), 2.01-1.93 (m, 3H), 1.90-1.77 (m, 2H), 1.76-1.64 (m, 2H), 1.55-1.30 (m, 3H), 1.26 (s, 3H), 1.25 
(s, 3H), 1.08 (d, 3H, J = 7.2 Hz), 0.89 ppm (d, 3H, J = 6.9 Hz); 13C NMR (75 MHz, CDCl3)  = 176.6, 170.6, 
133.1, 131.6, 129.8, 128.5, 81.3, 76.5, 71.0, 69.0, 62.8, 42.5, 38.8, 37.6, 36.8, 36.2, 33.1, 32.9, 30.8, 
29.7, 27.4, 24.9, 24.7, 24.5, 23.3, 14.0 ppm; HRMS: calcd. for C26H36O5Na: 451.2455 [M+Na]
+, found: 
451.2466. 
 
Simvastatin-MFC (34): The earlier prepared -tert-butylester protected MTX-PEG6-N3 reagent 6a 
(160 mg, 0.2 mmol) was taken up in a mixture of TFA and CH2Cl2 (5 mL, 1:1, v/v) and stirred for 40 
min at RT. The reaction mixture was then taken to dryness, coevaporated twice with toluene and 
concentrated under high vacuum for 1 h. The residue was dissolved in 2.8 mL of DMF, taken up in a 
mixture of water and DMF (3 mL, 1:1, v/v) and alkyne 33 (43 mg, 0.1 mmol), CuSO4 (400 μL, 0.05M, 
0.2 eq.) and Na ascorbate (200 μL, 0.5M, 1.0 eq.) were added. Finally, the resulting reaction mixture 
was charged with a catalytic amount of both Et3N and TBTA
[31] and heated to 150°C for 15 min 
(microwave). After being cooled to RT, the solution was concentrated in vacuo. The residue was 
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purified by preparative RP-HPLC (10-70% MeCN) yielding the title compound (51 mg, 44 μmol, 44%) 
as a pale yellow amorphous solid. LC-HRMS: tR = 4.69 min (30-100% MeCN, 15 min run); HRMS: calcd. 
for C58H84N12O14: 586.3110 [M+2H]
2+, found: 586.3058. 
 
Methyl 2,2-dimethylpent-4-ynoate (36): To a stirred solution of diisopropylamine (14.7 mL, 104.0 
mmol) in anhydrous THF (50 mL) under a nitrogen atmosphere at -78°C was added dropwise n-BuLi 
(56.2 mL, 1.6M in n-hexane, 89.9 mmol). The resulting solution was warmed to 0°C, stirred for 20 min 
and then cooled to -78°C. To this solution of LDA was added dropwise methyl isobutyrate (35) (9.87 
mL, 86.1 mmol) at -78°C. This mixture was next brought to 0°C, stirred for 20 min and cooled to -78°C 
again. Finally, propargyl bromide (10.2 mL, 80% in toluene, 94.4 mmol) was added and the resulting 
solution was stirred overnight letting the temperature rise to RT. The reaction mixture was poured 
into brine (20 mL) and transferred to a separation funnel. The aqueous fraction was extracted with 
Et2O (3 x 40 mL) and the organic fractions were pooled, dried over Na2SO4 and filtered. Vacuum 
distillation of the filtrate yielded the title compound (8.57 g, 61.1 mmol, 71%) as a colorless liquid. 1H 
NMR (300 MHz, CDCl3)  = 3.70 (s, 3H), 2.44 (d, 2H, J = 2.6 Hz), 2.01 (t, 1H, J = 2.6 Hz), 1.28 ppm (s, 
6H); 13C NMR (75 MHz, CDCl3)  = 177.2, 81.1, 70.6, 52.2, 42.2, 29.7, 24.6 ppm. 
 
2,2-Dimethylpent-4-ynoic acid (37): An ice-cooled solution of ester 36 (8.57 g, 61.1 mmol) in MeOH 
(100 mL) was treated with NaOH (30 mL, 4.0M). The resulting reaction mixture was warmed to RT 
and subsequently heated to 50°C overnight under vigorous stirring. After being cooled to RT, the 
mixture was acidified to pH 1 by addition of 4M HCl. The acidic solution was next extracted with 
EtOAc (3 x 250 mL) and the organic fractions were pooled, dried over Na2SO4 and concentrated in 
vacuo to yield the title compound (7.21 g, 57.2 mmol, 94%) as a pale yellowish oil. 1H NMR (300 MHz, 
CDCl3)  = 11.60 (br s, 1H), 2.47 (d, 2H, J = 2.6 Hz), 2.04 (t, 1H, J = 2.6 Hz), 1.32 ppm (s, 6H); 
13C NMR 
(75 MHz, CDCl3)  = 183.7, 80.8, 70.9, 42.1, 29.3, 24.4 ppm. HRMS: calcd. for C7H9O2: 125.0608 [M-H]
-
, found: 125.0594. 
 
Ethyl 5-(p-trimethoprimoxy)valerate (38): Cs2CO3 (11.80 g, 36.2 mmol, 2.0 eq.) and ethyl 5-
bromovalerate (2.87 mL, 18.1 mmol, 1.0 eq.) were added to a solution of phenol 28 (5.00 g, 18.1 
mmol, 1.0 eq.) in DMF (250 mL). The resulting solution was heated to 70°C for 7 h. After being cooled 
to RT, the mixture was concentrated in vacuo, and the residue was purified by silica gel 
chromatography (MeOH/CH2Cl2 0-13%, v/v) to yield the title compound (4.81 g, 11.9 mmol, 66%) as 
an off white solid. 1H NMR (300 MHz, CD3OD)  = 7.51 (s, 1H), 6.50 (s, 2H), 4.11 (q, J = 7.1 Hz, 2H), 
3.89 (t, J = 6.0 Hz, 2H), 3.76 (s, 6H), 3.62 (s, 2H), 2.38 (t, J = 7.2 Hz, 2H), 1.87-1.75 (m, 2H), 1.75-1.64 
(m, 2H), 1.23 ppm (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CD3OD)  = 175.5, 164.4, 163.1, 155.8, 154.8, 
136.7, 136.2, 108.1, 106.7, 73.6, 61.4, 56.5, 34.7, 34.5, 30.4, 22.7, 14.6 ppm; HRMS: calcd. for 
C20H29N4O5: 405.2133 [M+H]
+, found: 405.2113. 
 
5-(p-Trimethoprimoxy)valeric acid (39): A solution of ester 38 (370 mg, 0.92 mmol, 1.0 eq.) in MeOH 
(9 mL) was treated with NaOH (1.0 mL, 4.0M). The resulting mixture was stirred overnight at RT, then 
neutralized by the addition of HCl (1.33 mL, 3.0M); this gave fine precipitates. The latter were 
filtered, washed with a minimal amount of cold MeOH and dried overnight under high vacuum to 
afford the title compound (317 mg, 0.84 mmol, 92%) as an off white solid. 1H NMR (300 MHz, 
SO(CD3)2)  = 7.51 (s, 1H), 6.54 (s, 2H), 6.09 (s, 2H), 5.71 (s, 2H), 3.77 (t, J = 6.0 Hz, 2H), 3.71 (s, 6H), 
3.52 (s, 2H), 2.26 (t, J = 6.9 Hz, 2H), 1.71-1.54 ppm (m, 4H); 13C NMR (75 MHz, SO(CD3)2)  = 174.8, 
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162.23, 162.18, 155.6, 152.9, 135.7, 134.8, 105.85, 105.76, 71.9, 55.8, 33.8, 33.0, 29.1, 21.3 ppm; 
HRMS: calcd. for C18H23N4O5: 375.1674 [M-H]
-, found: 375.1669. 
 
Second-generation TMP-N3 reagent (40): TPTU (2.72 g, 9.2 mmol, 1.2 eq.) and Et3N (10.6 mL, 76.3 
mmol) were added to a solution of acid 39 (2.87 g, 7.6 mmol, 1.0 eq.) in DMF (33.5 mL). The resulting 
preactivation mixture was stirred for 5 min at RT. Subsequently, a solution of spacer 4b (1.58 g, 7.2 
mmol, 0.95 eq.) and Et3N (10.6 mL, 76.3 mmol) in DMF (4.5 mL) was added dropwise to this mixture. 
The resulting reaction mixture was stirred for 5 h at RT, then concentrated in vacuo, and the residue 
was purified by silica gel chromatography (MeOH/CH2Cl2 0-12%, v/v) to yield the title compound 
(3.27 g, 5.7 mmol, 78%) as a beige oil. 1H NMR (300 MHz, CD3OD)  = 7.29 (s, 1H), 6.55 (s, 2H), 3.92 (t, 
J = 6.2 Hz, 2H), 3.80 (s, 6H), 3.68-3.57 (m, 12H), 3.54 (t, J = 5.6 Hz, 2H), 3.40-3.32 (m, 4H), 2.28 (t, J = 
7.2 Hz, 2H), 1.87-1.65 ppm (m, 4H); 13C NMR (75 MHz, CD3OD)  = 176.1, 164.9, 160.8, 154.9, 150.9, 
136.8, 135.4, 109.0, 106.9, 73.8, 71.50, 71.49, 71.4, 71.2, 71.0, 70.5, 56.6, 51.7, 40.3, 36.6, 34.2, 30.5, 
23.6 ppm; HRMS: calcd. for C26H41N8O7: 577.3093 [M+H]
+, found: 577.3090. 
 
Second-generation tamoxifen TFC (41): Azide 40 (132.6 mg, 230 µmol, 2.3 eq.) was taken up in 
H2O/tBuOH (1.6 mL, 1:1, v/v), and alkyne-functionalized tamoxifen (39.6 mg, 100 µmol, 1.0 eq.), 
CuSO4 (40 µL, 0.5M, 0.2 eq.), and Na ascorbate (200 µL, 0.5M, 1.0 eq.) were added. The resulting 
mixture was charged with a catalytic amount of TBTA[31] and heated to 80°C for 16 h with vigorous 
stirring. After being cooled to RT, the solution was concentrated in vacuo. The residue was purified 
by preparative RP-HPLC (10-100% MeCN) to yield the title compound (54.6 mg, 56 µmol, 56%) as a 
white amorphous solid. LC-HRMS: tR = 6.98 min (10-100% MeCN, 15 min run); HRMS: calcd. for 
C54H71N9O8: 486.7707 [M+2H]
2+, found: 486.7708. 
 
BODIPY MFC (42): The earlier prepared -tert-butylester protected MTX-PEG6-N3 reagent 6a (79.9 
mg, 100 µmol) was taken up in TFA/CH2Cl2 (2.2 mL, 1:1, v/v), and the solution was stirred for 40 min 
at RT. The mixture was then evaporated, coevaporated twice with toluene, and concentrated under 
high vacuum for 1 h. The residue was taken up in H2O/DMF (2.6 mL, 1:1, v/v), and CuSO4 (120 µL, 
0.5M, 0.6 eq.), Na ascorbate (600 µL, 0.5M, 3.0 eq.), and a catalytic amount of TBTA[31] were added. 
Finally, the pH of the resulting reaction mixture was adjusted to 8 by the addition of Et3N (168 µL, 12 
eq.), and BODIPY-alkyne[27] (108.3 mg, 330 µmol, 3.3 eq.) was added. The reaction mixture was 
stirred for 24 h at RT and concentrated in vacuo. The residue was purified by preparative RP-HPLC 
(10-100% MeCN) to yield the title compound (63.7 mg, 59 µmol, 59%) as an orange amorphous solid. 
LC-HRMS: tR = 7.08 min (10-100% MeCN, 15 min run); HRMS: calcd. for C51H71N14O9BF2: 536.2789 
[M+2H]2+, found: 536.2791. 
 
BODIPY TFC (43): Azide 40 (57.7 mg, 100 µmol, 1.0 eq.) was taken up in H2O/DMF (2.6 mL, 1:1, v/v), 
and BODIPY-alkyne[27] (75.5 mg, 230 µmol, 2.3 eq.), CuSO4 (80 µL, 0.5M, 0.4 eq.), and Na ascorbate 
(400 µL, 0.5M, 2.0 eq.) were added. The resulting mixture was charged with a catalytic amount of 
TBTA,[31] stirred for 29 h at RT, and concentrated in vacuo. The residue was purified by preparative 
TLC (MeOH/CH2Cl2 1:4, v/v with 1.0% NH4OH) to yield the title compound (37.0 mg, 41 µmol, 41%) as 
an orange amorphous solid. LC-HRMS: tR = 7.22 min (10-100% MeCN, 15 min run); HRMS: calcd. for 
C45H65N10O7BF2: 453.2544 [M+2H]
2+, found: 453.2533. 
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4-(((TBDMS)oxy)methyl)benzyl alcohol (45): To a solution of 1,4-benzenedimethanol (44) (14.00 g, 
101.33 mmol, 1.45 eq.) in DMF (500 mL) were added imidazole (6.81 g, 100.03 mmol, 1.43 eq.) and 
TBDMSCl (10.55 g, 70.00 mmol, 1.0 eq.). The resulting reaction mixture was stirred at RT for 16 h and 
then concentrated in vacuo. To the residue were added water (400 mL) and Et2O (400 mL) and the 
biphasic mixture was agitated until the residue was completely dissolved and transferred to a 
separation funnel. The organic layer was separated and the aqueous fraction was washed with Et2O 
(2 x 200 mL). All Et2O fractions were pooled, dried on Na2SO4 and taken to dryness. The residue was 
purified by silica gel chromatography (EtOAc/hexane, 2:8 v/v) yielding the title compound (6.70 g, 
26.54 mmol, 38%) as a colorless oil. 
Furthermore, the double silylated product, i.e. 1,4-bis(((TBDMS)oxy)methyl)benzene, was isolated as 
well, and subsequently mono-deprotected as follows. To a solution of this bis-silyl-protected diol 
(8.06 g, 21.98 mmol, 1.0 eq.) in THF (200 mL) was added tetra-n-butylammonium fluoride (TBAF) 
(10.1 mL, 1.0M in THF). The resulting reaction mixture was stirred at RT for 1 h and then 
concentrated in vacuo. The residue was purified by silica gel chromatography (EtOAc/hexane 2:8, 
v/v) yielding additional compound 45 (0.78 g, 3.09 mmol, 31%) as a colorless oil. Taken together, 
starting from 14.0 g 1,4-benzenedimethanol, 7.48 g (29.63 mmol) of the title compound was 
obtained in 42% overall yield. 1H NMR (300 MHz, CDCl3)  = 7.25 (d, 2H, J = 8.4 Hz), 7.21 (d, 2H, J = 8.4 
Hz), 4.69 (s, 2H), 4.48 (s, 2H), 3.32 (br s, 1H), 0.94 (s, 9H), 0.09 ppm (s, 6H); 13C NMR (75 MHz, CDCl3)  
= 140.5, 139.7, 127.0, 126.2, 64.9, 64.7 (weak), 26.0, 18.4, -5.2 ppm; HRMS: calcd. for C14H23OSi: 
235.1513 [M+H-H2O]
+, found: 235.1519. 
 
4-(((TBDMS)oxy)methyl)benzyl iodide (46): To a solution of triphenylphosphine (5.90 g, 22.50 mmol, 
1.5 eq.) and imidazole (2.00 g, 30.0 mmol, 2.0 eq.) in a mixture of Et2O/MeCN (84 mL, 3:1, v/v) was 
added diiodine (I2) (5.70 g, 22.50 mmol, 1.5 eq.) and vigorous stirring was continued until a yellow 
suspension formed. A solution of benzyl alcohol 45 (3.84 g, 15.00 mmol, 1.0 eq.) in 16 mL of the same 
solvent mixture was then added. The resulting reaction mixture was stirred for 1 h at RT, filtered and 
concentrated in vacuo. To the residue were added Et2O (100 mL) and a saturated sodium thiosulfate 
solution (100 mL) and the biphasic mixture was agitated until the residue was completely dissolved 
and transferred to a separation funnel. The organic layer was separated and the aqueous fraction 
was washed with Et2O (2 x 100 mL). All Et2O fractions were pooled, dried on Na2SO4 and taken to 
dryness. The residue was purified by silica gel chromatography (EtOAc/hexane 5:95, v/v) yielding the 
title compound (4.28 g, 11.81 mmol, 79%) as a reddish-pink oil. 1H NMR (300 MHz, CDCl3)  = 7.34 (d, 
2H, J = 8.0 Hz), 7.24 (d, 2H, J = 8.0 Hz), 4.70 (s, 2H), 4.46 (s, 2H), 0.94 (s, 9H), 0.10 ppm (s, 6H); 13C 
NMR (75 MHz, CDCl3)  = 141.5, 138.0, 128.8, 126.6, 64.8, 26.1, 18.6, 6.0, -5.1 ppm. 
 
-Azido,-deoxy,-4-(((TBDMS)oxy)methyl)benzylhexa(ethylene glycol) (47): Azido spacer 25 (3.63 
g, 11.8 mmol, 1.05 eq.) was dissolved in DMF (100 mL), and the solution was cooled on ice under 
nitrogen. Sodium hydride (60% dispersion in mineral oil, 450 mg, 11.25 mmol, 1.0 eq.) was added to 
this solution, and the mixture was stirred for 10 min. A solution of compound 46 (4.28 g, 11.8 mmol, 
1.05 eq.) in DMF (20 mL) was then added, and the resulting mixture was stirred overnight; the 
temperature was allowed to rise to RT. The mixture was then concentrated in vacuo, resuspended in 
EtOAc (300 mL), and filtered. The filtrate was concentrated in vacuo, and the residue was purified by 
silica gel chromatography (MeOH/CH2Cl2 0-8%, v/v) to yield the title compound (3.58 g, 6.6 mmol, 
59%) as a clear, colorless oil. 1H NMR (300 MHz, CDCl3)  = 7.30 (br s, 4H), 4.73 (s, 2H), 4.55 (s, 2H), 
3.69-3.59 (m, 22H), 3.38 (t, J = 5.0 Hz, 2H), 0.94 (s, 9H), 0.09 ppm (s, 6H); 13C NMR (75 MHz, CDCl3)  = 
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140.8, 136.9, 127.7, 126.1, 73.1, 70.7-70.5 (wide peak), 70.0, 69.3, 64.8, 50.7, 26.0, 18.4, -5.2 ppm; 
HRMS: calcd. for C26H51N4O7Si: 559.3522 [M+NH4]
+, found: 559.3511. 
 
-Azido,-deoxy,-4-(hydroxymethyl)benzylhexa(ethylene glycol) (48): A hydrogen fluoride-
pyridine complex (HF·pyr; 0.9 mL, 38.5M, 34.7 mmol, 16.6 eq.) was added dropwise to a solution of 
compound 47 (1.13 g, 2.1 mmol, 1.0 eq.) in anhydrous THF (30 mL) in a plastic flask. The resulting 
mixture was gently stirred at RT for 6 h, then neutralized with NaOH (10 mL, 4.0M). The basic 
solution was concentrated in vacuo, resuspended in MeOH (40 mL), and filtered. The filtrate was 
dried over Na2SO4, concentrated in vacuo, and finally coevaporated twice with toluene to remove 
any traces of pyridine. The residue was purified by silica gel chromatography (MeOH/CH2Cl2 0-8%, 
v/v) to yield the title compound (716 mg, 1.68 mmol, 80%) as a clear, colorless oil. 1H NMR (300 MHz, 
CDCl3)  = 7.30 (br s, 4H), 4.60 (s, 2H), 4.52 (s,2H), 3.67-3.57 (m, 22H), 3.34 (t, J = 5.0 Hz, 2H), 3.20 
ppm (br s, 1H); 13C NMR (75 MHz, CDCl3)  = 140.6, 137.1, 127.6, 126.6, 72.7,70.4-70.2 (wide peak), 
69.7, 69.1, 64.3, 50.4 ppm; HRMS: calcd. for C20H37N4O7: 445.2657 [M+NH4]
+, found: 445.2673. 
 
1-(2-Aminopurin-6-yl)-1-methylpyrrolidinium chloride (50): 6-Chloroguanine (49) (5.0 g, 29.5 mmol) 
was suspended in DMF (200 mL) and stirred for 1 h at RT. Next, 1-methylpyrrolidine (9.2 mL, 88.5 
mmol) was added and the resulting reaction mixture was stirred for two days at RT. After this time, 
acetone (100 mL) was added to precipitate the product. The solution was filtered and the solid was 
washed with acetone and dried under high vacuum to yield the title compound (4.72 g, 18.6 mmol, 
63%) as an off white solid. 1H NMR (300 MHz, SO(CD3)2)  = 13.34 (br s, 1H), 8.34 (s, 1H), 7.10 (s, 2H), 
4.65-4.54 (m, 2H), 4.02-3.90 (m, 2H), 3.65 (s, 3H), 2.33-2.15 (m, 2H), 2.15-1.98 ppm (m, 2H); 13C NMR 
(75 MHz, D2O)  = 158.9, 157.9, 151.9, 143.5, 116.3, 64.9, 51.8, 21.3 ppm; HRMS: calcd. for C10H15N6: 
219.1353 [M]+, found: 219.1347. 
 
BG-PEG6-N3 reagent (51): Benzyl alcohol 48 (711 mg, 1.66 mmol, 1.0 eq.) was dissolved in DMF (4.2 
mL) under nitrogen. KOtBu (746 mg, 6.65 mmol, 4.0 eq.) was added to this solution, and the mixture 
was stirred for 30 min at RT, turning dark red. After this time, compound 50 (423 mg, 1.66 mmol, 1.0 
eq.) was added slowly, and the resulting mixture was stirred for 22 h at RT. The mixture was 
concentrated in vacuo, and the residue was purified by silica gel chromatography (MeOH/CH2Cl2 0-
10%, v/v) to yield the title compound (227 mg, 0.41 mmol, 25%) as a pale yellow oil. 1H NMR (300 
MHz, SO(CD3)2)  = 7.82 (br s, 1H), 7.48 (d, J = 7.8 Hz, 2H), 7.35 (d, J = 7.8 Hz, 2H), 6.27 (br s, 2H), 5.48 
(s, 2H), 4.50 (s, 2H), 3.61-3.48 ppm (m, 22H); 13C NMR (75 MHz, SO(CD3)2)  = 159.9 (weak), 159.7, 
155.2 (weak), 138.4, 137.8 (weak), 135.9, 128.4, 127.5, 113.5 (weak), 71.7, 69.86-69.78 (wide peak), 
69.70, 69.2, 69.1, 66.5, 50.0 ppm; LC-HRMS: tR = 6.47 min (10-100% MeCN, 15 min run); HRMS: calcd. 
for C25H37N8O7: 561.2780 [M+H]
+, found: 561.2735. 
 
Tamoxifen BGFC (52): Azide 51 (227.3 mg, 405 µmol, 3.2 eq.) was taken up in H2O/tBuOH (2.5 mL, 
1:1, v/v), and alkyne-functionalized tamoxifen (50.0 mg, 126 µmol, 1.0 eq.), CuSO4 (50.4 µL, 0.5M, 0.2 
eq.), and Na ascorbate (252 µL, 0.5M, 1.0 eq.) were added. The resulting mixture was charged with a 
catalytic amount of TBTA[31] and heated to 80°C for 16 h with vigorous stirring. After being cooled to 
RT, the solution was concentrated in vacuo. The residue was purified by preparative RP-HPLC (30-
100% MeCN) to yield the title compound (58.1 mg, 61 µmol, 48%) as an off white amorphous solid. 
LC-HRMS: tR = 7.89 min (10-100% MeCN, 15 min run); HRMS: calcd. for C53H67N9O8: 478.7551 
[M+2H]2+, found: 478.7526. 
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IV.4.2. Molecular biology 
 
Performed by the Cytokine Receptor Laboratory, Department of Medical Protein Research, VIB, Ghent 
& Department of Biochemistry, Faculty of Medicine and Health Sciences, Ghent University (Prof. Jan 
Tavernier, Dr. Sam Lievens). 
 
Plasmid constructs: The CR-eDHFR chimeric protein consisting of the full-size mouse leptin receptor 
F3 mutant fused to E. coli DHFR is encoded by the pCLL-eDHFR plasmid described previously.[10] The 
pCLG-hAGT plasmid encodes the CR-hAGT fusion protein, which is made up of the extracellular, 
transmembranal, and membrane-proximal portions of the mouse leptin receptor tethered to a 
mutant hAGT protein. This plasmid was generated by amplifying the hAGT coding sequence of the 
pSNAPf vector (New England Biolabs) by using forward primer 5’-CCCGA GCTCA ATGGA CAAAG 
ACTGC GAAAT G-3’ and reverse primer 5’-GGGGC GGCCG CTTAA CCCAG CCCAG GCTTG CCCAG-3’ to 
introduce a stop codon downstream of hAGT. The amplicon was cloned into the pCLG vector 
backbone, which has been described previously,[32] by using SacI and NotI restriction enzymes. The 
ER1 prey, consisting of full-size ER1 fused N-terminally to a gp130 receptor fragment containing 
multiple STAT3 recruitment sites, was generated by Gateway recombinatorial cloning (Invitrogen) 
into a Gateway-compatible pMG1C vector. To generate this destination vector, first the pMet7-Flag 
Gateway destination vector was made by amplifying the Gateway cassette from the Gateway-
compatible pMG1 vector[32] by using forward primer 5’-CCCCA ATTGA CAAGT TTGTA CAAAA AAGC-3’ 
and reverse primer 5’-GGGTC TAGAC TACTT ATCGT CGTCA TCCTT GTAAT CTTTA ATTAA AACCA CTTTG 
TACAA GAAAG C-3’ (the latter containing the Flag epitope coding sequence), and inserting this 
amplicon into the pMet7 expression vector[7] by ligation of the MfeI-XbaI restriction enzyme product 
into the EcoRI-XbaI cut pMet7 vector. Next, the gp130 coding sequence of the pMG1 vector[32] was 
amplified by using forward primer 5’-CCCTT AATTA ACGGA GGGAG TATCT CGACC GTGGT ACACA 
GTG-3’ and reverse primer 5’-GGGTT AATTA ACCCC TGAGG CATGT AGCCG C-3’, which was inserted 
into the PacI site of the pMet7-Flag Gateway destination vector. Finally, the ER1 open reading frame 
was transferred into the pMG1C destination vector from the ER1 entry clone of the hORFeome 
collection.[33] The pMG1-TTK prey plasmid encoding the C-terminal fusion of full-size TTK to the 
gp130 fragment[10] and the pMG1-HMGCR plasmid coding for the C-terminal fusion of the statin-
binding cytoplasmic domain to the gp130 fragment[20] have been described elsewhere, as has the 
STAT3-dependent firefly luciferase reporter pXP2d2-rPAPI-luciferase.[7] 
 
MASPIT assays: HEK293T cells were cultured in 96-well microtiter plates in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal calf serum, incubated at 37°C, under 8% CO2, and 
transfected with pCLL-eDHFR or pCLG-hAGT CR fusion protein plasmid (10 ng per 96 wells), pMG1C-
ER1, pMG1-TTK, or pMG1-HMGCR prey plasmid (100 ng per 96 wells) and pXP2d2-rPAPI-luciferase (5 
ng per 96 wells) by applying a standard calcium phosphate transfection method, as described 
earlier.[32] Twenty-four hours after transfection, cells were stimulated with leptin (100 ng/mL final 
concentration) alone or in combination with the indicated concentration of fusion compound. After 
another 24 h, luciferase activity was measured by using the Luciferase Assay System kit (Promega) on 
an Envision plate reader (PerkinElmer). Luciferase data are the average of three technical replicates, 
error bars indicate standard deviation. 
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Fluorescence measurement: The fluorescence of the MTX- and TMP-BODIPY fluorophores was 
measured by preparing a serial dilution of the molecules in PBS in 96-well microtiter plates, and 
analyzing the plates in an Envision plate reader equipped with a FITC filter set. Fluorescence data are 
the average of three replicates, error bars indicate standard deviation. The curve in Figure IV.4A was 
fit by using four-parameter nonlinear regression in GraphPad Prism. 
 
FACS analysis: HEK293T cells at a density of 107/mL were incubated with propidium iodide (3 µM), 
and the indicated concentration of MTX- or TMP-BODIPY (1 µM final concentration in the kinetic 
experiment in Figure IV.4C) for the indicated time (15 min in the dose-response experiment in Figure 
IV.4B). Samples were analyzed by using a FACSCalibur instrument (BD Biosciences), measuring mean 
BODIPY fluorescence of the viable cells (propidium iodide negative). 
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V. The Photocrosslinker Approach: Towards Covalency on the Bait-End of the Dimerizers 
 
V.1. Introduction 
 
Further optimization efforts to stabilize the ternary complex (CR-CID-Prey) were aimed at introducing 
covalent bonding on the bait-end of the dimerizer starting from TMP as immobilizing anchor moiety. 
For this purpose, we envisioned that photoactivatable crosslinkers would be particularly suitable for 
capturing transient and low-affinity bait-prey interactions (Figure V.1). Indeed, such 
photocrosslinkers convert upon photoactivation to highly reactive species, capable of introducing 
covalent bonds between interacting molecules.[1] In the context of the MASPIT assay, this strategy 
thus might give rise to increased signal output. However, a potential disadvantage of the approach 
includes undesired or detrimental nonspecific crosslinking events with cellular components. To the 
best of our knowledge, no prior literature data on the implementation of photocrosslinkers in the 
context of three-hybrid systems for compound profiling exists. 
 
 
 
Figure V.1: Schematic representation of the photocrosslinker optimization approach. Upon interaction with a 
bait, covalent immobilization of a prey chimera on the TMP fusion compound could be attained by activation of 
the photocrosslinker (h) with light of the appropriate wavelength. 
 
The initial report in the field of photoaffinity labeling (PAL) was published in 1962 by Westheimer and 
colleagues, describing the use of a singlet carbene species, generated by photolysis of a diazoacetyl 
group, to inactivate chymotrypsin.[2] Since then substantial research on the development of novel 
photogenerated reagents has been conducted,[3],[4] yet the current panel of photocrosslinking groups 
that has demonstrated utility in cellular systems is rather limited. These comprise benzophenones, 
aryl azides and diazirines (Figure V.2), whose characteristics and photochemistry will be discussed in 
the following subsections.[1],[5] 
 
 
 
Figure V.2: Chemical structures of photocrosslinking functional groups for use in biological systems. Figure 
adapted from: Molecular Biosystems 2008, 4 (6), 473-480. 
 
In order to function in a cellular context, photocrosslinkers must meet a number of 
requirements.[1],[5] First, the photochemical precursors must be stable under the various conditions of 
the cellular environment, while being bioorthogonal to all functional groups present in the sample. 
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Furthermore, they should only be activated upon irradiation with the appropriate wavelength of 
light, which should not damage cellular components, i.e. act > 300 nm. Second, the lifetime of the 
generated reactive species needs to be shorter than that of the studied macromolecular complexes 
so as to limit nonspecific labeling. However, this desired specificity of short-lived active species is 
often at the expense of their crosslinking efficiency and vice versa. Additionally, the photogenerated 
species preferably react with any chemical entity in close proximity, regardless of its nature, thereby 
forming stable covalent adducts. Finally, to minimize perturbation of the studied interaction, a 
relatively small photophore is required. Taken together, the relative importance of each of these 
criteria can be anticipated to be application-specific. 
 
V.1.1. Benzophenone (BP) 
 
The chemistry of benzophenones after photolysis is outlined in Scheme V.1.[1],[5] Upon activation by 
350-365 nm light, benzophenones (53) reversibly convert to a triplet state benzhydril diradical (54). 
In the absence of an appropriate reaction partner, this reactive species can persist for as long as 120 
µs before relaxing back to its ground state. The triplet diradical abstracts in a first slow step a 
hydrogen radical from a neighboring X-H bond. In general, C-H bonds are more prone to react than 
O-H bonds, especially those that form stabilized carbon radicals, such as benzylic positions, tertiary 
carbon centers, and amino acid -positions (55). In particular, benzophenones have been shown to 
exhibit a strong preference for methionine -H’s.[6] Hydrogen abstraction by the diradical affords a 
ketyl (56) and an alkyl radical (57), which subsequently recombine in a second fast step to obtain the 
final benzhydrol covalent adduct (58). In the case of glycine, water can be eliminated from the 
benzhydrol yielding the corresponding cross-conjugated olefin 61. Another side reaction that can 
occur is the homodimerization of ketyl 56 resulting in the formation of benzopinacol 60. However, 
typically only trace amounts of the latter are retrieved, given the significant relative difference in 
kinetics for the tandem abstraction and recombination reactions. Finally, the reactive diradical 
species (54) can be quenched by the insertion of water, which is omnipresent in a cellular 
environment, giving the corresponding hydrate (59). Yet, the latter swiftly dehydrates to the 
thermodynamically favored ketone (53), which can ultimately recover the diradical after UV 
irradiation. 
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Scheme V.1: Possible reaction pathways of benzophenones after photolysis. Scheme adapted from: Topics in 
Current Chemistry 2012, 324, 85-113. 
 
This ‘recycling’ capability represents one of the major assets of the benzophenone moiety in terms of 
crosslinking efficiency, yet concomitantly increases the change of nonspecific labeling (cf. supra).[5] 
The latter event is also facilitated by the relative bulkiness of this photocrosslinker, as the resulting 
steric hindrance can lead to discrimination between reaction sites. Moreover, its relatively large size 
can also directly cause a detrimental perturbation of binding events. On the other hand, 
benzophenones benefit from the fact that their photogenerated species are more reactive towards 
C-H bonds compared to nitrenes, and less prone to intramolecular rearrangements than carbenes (cf. 
infra).[5] Additionally, this photophore can be excited at relatively long wavelengths of 350-365 nm 
(i.e., well above the earlier mentioned 300 nm cutoff), hence minimizing the incidence of nucleic acid 
or protein damage.[7],[1] However, the photolysis often requires more prolonged time (> 30 min) to 
attain reasonable crosslinking efficiency.[8] 
 
V.1.2. Aryl azide (AA) 
 
Aryl azides (62) are photoactivated by irradiation with 250 nm light, which triggers the initial 
formation of a singlet nitrene (63) upon release of molecular nitrogen (N2) (Scheme V.2.).
[5] 
Displaying electrophilic properties, this nitrene species readily undergoes insertion reactions with 
nearby C-H bonds to yield a covalent adduct (66). However, due to its highly energetic and reactive 
character, the singlet nitrene has a short lifetime (0.1 ms) and it is rapidly converted into other, 
lower-energy intermediates such as the corresponding triplet nitrene (64) and benzazirine (69).[3],[9] 
The former is generated by intersystem crossing and reacts analogous to activated benzophenones 
(cf. Section V.1.1) as a diradical via a two-step hydrogen radical abstraction-recombination cascade 
to afford the same adduct 66. The benzazirine can further rearrange into dehydroazepine (71), and 
both species can react, as long-lived electrophiles, only with nucleophiles to obtain addition products 
70 and 72, respectively. Therefore, these rearrangements are typically associated with losses in 
crosslinking efficiency and increase the risk of nonspecific labeling events.[1] Two alternative side 
reactions might take place upon application of aryl azides in a biological context, i.e. triplet nitrene 
scavenging by molecular oxygen (a notorious triplet quencher), giving the corresponding nitro 
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species (68);[10] and reduction of the starting material (62) to the amine (67) by thiols (e.g. 
dithiothreitol).[11]    
 
 
 
Scheme V.2: Possible reaction pathways of the reactive intermediates formed after photolysis of aryl azides.  
DTT, dithiothreitol; ISC, intersystem crossing; NuH, nucleophile. Scheme adapted from: Topics in Current 
Chemistry 2012, 324, 85-113. 
 
Clearly, the main benefits of the aryl azide moiety include its relatively small size and ease of 
incorporation into various PAL probes. However, the biocompatibility of this photocrosslinker is 
hampered by its maximal absorption at a wavelength below 300 nm (i.e., 250 nm for plain phenyl 
azide).[1] Hence, in an attempt to improve its photochemical properties, considerable research has 
been focused on the development of substituted aryl azides. Most notably, it has been shown that 
electron-withdrawing substituents (e.g., nitro, hydroxyl, and acyl groups) both increase the molar 
absorptivity and red-shift the absorption maximum (up to 400 nm).[12],[13] In this respect, most 
substituents ortho to the azide should be avoided since they might give rise to undesired cyclizations 
after photoexcitation.[5] Additionally, (per)fluorinated aryl azides were found to rearrange more 
slowly from the singlet nitrene to the benzazirine (cf. Scheme V.2.), thereby enhancing the efficiency 
of insertion reactions.[14] Nevertheless, crosslinking yields for aryl azides are often low (i.e. < 30%) 
given the diverse fates, including capturing by the solvent, of their reactive photogenerated 
intermediates.[5]  
 
V.1.3. Diazirine (DZ) 
 
Irradiation of diazirines (73/74) at 350-380 nm results in molecular nitrogen loss and the generation 
of a singlet carbene species (75) (Scheme V.3.).[5] However, competitively, the starting material is 
considerably (> 30%) photoisomerized to the linear diazo compound (76), which in turn can give 
access to the singlet carbene (75) upon photoexcitation, albeit this conversion is relatively sluggish at 
the latter activation wavelengths.[15] Hence, the diazo isomer is reasonably long-lived and, given its 
generally high sensitivity towards nucleophilic attack, one of the root causes for either nonspecific 
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labeling or decreased crosslinking efficiency.[1] Brunner et al. largely circumvented this issue by 
introducing in the -position the strong electron-withdrawing trifluoromethyl substituent (as in 74), 
which stabilizes the diazo isomer and renders it fairly resistant towards undesired ‘dark’ side 
reactions.[16] Singlet carbenes (75) are highly reactive crosslinkers with typical nanosecond half-lives, 
giving fast insertion reactions into any adjacent C-H or heteroatom-H bond.[17] Generally, insertions 
into hydroxyl groups (83) are more efficient compared to C-H insertions (84).[18] Reactions with 
primary or secondary amines yield a covalent adduct (79), from which HF can be readily eliminated 
to afford an enamine (80). The latter is in equilibrium with imine 81 and both species can be 
hydrolyzed (e.g., in a biological context) to the corresponding ketone (82), entailing unwanted loss of 
the captured binding partner.[18] Via intersystem crossing the singlet carbene can be transformed into 
its triplet state congener (77), which reacts as a typical diradical (cf. supra) with C-H bonds to give the 
same insertion product (84). However, in this respect, two quenching side reaction can occur, i.e. 
aerobic oxidation (cf. supra) to the corresponding ketone (78); and reduction (86) via two sequential 
hydrogen radical abstractions.[13] Finally, as illustrated in the inset of Scheme V.3, unsubstituted 3-
alkyl-3H-diazirines are less suitable as their photogenerated singlet carbenes are likely to rearrange 
to olefins via hydride shift.[19] 
 
 
 
Scheme V.3: Possible reaction pathways of the reactive intermediates formed after photolysis of 3-aryl-3H-
diazirines. The inset shows hydride shift of a singlet carbene derivative of unsubstituted 3-alkyl-3H-diazirines 
resulting in olefin formation. ISC, intersystem crossing. Scheme adapted from: Topics in Current Chemistry 
2012, 324, 85-113. 
 
Diazirines offer a number of important advantages over aryl azides, including their stability towards 
strongly acidic/basic conditions, as well as various oxidating/reducing agents.[5] More importantly, 
their maximum absorption wavelength (350-380 nm) is well above 300 nm, thus causing no 
significant damage to the biological sample under analysis. On the other hand, trifluoromethyl 
phenyl diazirines are quite bulky, despite the relatively small size of the diazirine heterocycle itself. 
Two other disadvantages of the diazirine photophore, contributing to reduced crosslinking efficiency, 
comprise its substantial (> 30%) conversion to the diazo isomer upon photoactivation (cf. supra) and 
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scavenging of the corresponding singlet carbene species by water due to its intrinsic efficient 
reactivity towards O-H bonds.[1],[5] 
 
In conclusion, the ‘ideal photocrosslinker’ does not exist. Rather, the optimal crosslinker type is likely 
to be application-specific due to the differences in reaction site preferences as well as the nature of 
the photogenerated reactive species. Additionally, it might be worthwhile to screen a panel of 
different photophores so as to obtain complementary insights into a particular binding event.[13],[5]   
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V.2. Synthesis of heterotrimeric PAL probes 
 
As a starting point, the second-generation TMP-N3 reagent 40
 was equipped with a double ligation 
handle originating from (S)-6-amino-2-azidohexanoic acid.[20] Toward this end, azide 40 was 
hydrogenated and subsequently condensed with acid 92[20] using TPTU reagent. Acidic Boc removal 
readily afforded the desired building block 89, which consists of both an azide for CuAAC with alkyne-
functionalized tamoxifen 7 and a terminal amine for subsequent amide coupling with NHS esterified 
photoaffinity labels 94a-c.[21],[22],[23] Following a one pot sequential protocol, heterotrimeric probes 
90a-c, comprising TMP, TAM and a benzophenone/aryl azide/trifluoromethyl phenyl diazirine 
photocrosslinker, were successfully obtained after HPLC purification in 30%, 24% and 34% yield, 
respectively (Scheme V.4). 
 
 
 
Scheme V.4: Synthesis of the heterotrimeric TMP-TAM-PAL probes. [i] H2, Pd/C, H2O/dioxane, 90%; [ii] 92, 
TPTU, Et3N, DMF, 69%; [iii] TFA, CH2Cl2, quant.; [iv] first alkyne-functionalized tamoxifen 7, Na ascorbate, 
CuSO4, Et3N, TBTA, DMF; then 94a-c, (a 30%; b 24%; c 34%); [v] first NaN3, Tf2O, CH2Cl2/H2O; then K2CO3, CuSO4, 
MeOH/H2O, 79%; [vi] NHS, EDC.HCl, DMAP, DMF, 0°C to RT, (a 65%; b 85%; c 94%). 
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V.3. Biological evaluation of heterotrimeric PAL probes 
 
Previously, in a standard MASPIT cell array screen against a 10,000 ORF prey collection, we identified 
eight novel candidate interaction partners of tamoxifen using the second-generation tamoxifen-TFC 
(41), in addition to the known estrogen receptor  (ER1) target (Figure V.3A).[24] Interestingly, at least 
four of these newly identified target proteins cluster in a putative complex that is functionally 
relevant with respect to a potentially novel mechanism of action for this 40-year-old drug. The 
heterotrimeric PAL probes 90a-c were first evaluated for binding to this panel of putative tamoxifen 
target proteins without UV irradiation and their resulting target protein profile was compared to the 
one obtained for 41 (Figure V.3). 
 
Although the small-molecule bait and photophore are separated by a flexible methylene spacer, 
comparison of the screening profiles revealed that the unactivated photocrosslinkers seem to 
sterically interfere with the binding of tamoxifen to its target proteins. Indeed, in the case of the 
bulky benzophenone moiety, as much as six out of nine binding partners are lost (Figure V.3B), 
whereas for the aryl azide and diazirine probe only four interactions are retained (Figure V.3C and 
3D, respectively). Nevertheless, we initially estimated that this loss of signal output might be 
compensated for by successful covalent crosslinking of the target preys following photoactivation. 
 
 
 
Figure V.3. Target protein profile of the second-generation tamoxifen-TFC and heterotrimeric PAL probes. A) 
TAM-TFC (41); B) TMP-TAM-benzophenone (90a); C) TMP-TAM-aryl azide (90b); D) TMP-TAM-diazirine (90c). 
Luciferase signals are expressed as fold induction relative to a control sample treated with cytokine without 
fusion compound. 1-8, confidential anonymized newly identified potential target preys. 
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However, establishing covalent immobilization of the prey chimeras with the aim of increasing the 
MASPIT readout turned out to be less straightforward than anticipated based on success stories from 
the chemical proteomics field.[5],[25] Upon extensive testing of PAL probes 90a-c against a panel of 
target preys in MASPIT, no relative increase in luciferase signal was observed after photoexcitation, 
as exemplified below for candidate target protein ‘2’ (Figure V.4). In this respect, variation of the 
irradiation time (BP probe 90a: 4 min - 2 h; AA probe 90b: 15 sec - 1 min; DZ probe 90c: 5 - 40 min), 
cell culture medium (DMEM vs. phenol red free DMEM, i.e. to rule out potential quenching of the UV 
irradiation) and of the UV lamp-microtiter plate distance had no additional beneficial effects on the 
signal output and in fact indicated that the desired crosslinking failed. 
 
Rather, a clear decrease in luciferase activity after photoactivation was observed, which might be 
attributed to degradation of either the PAL probes or of the biological system. In the latter case, the 
detrimental effects might originate from two different routes: first, the UV irradiation itself may 
directly damage the cellular environment (e.g. 254 nm); second, the photogenerated species could 
nonspecifically bind to essential cellular components and perturb their function (e.g. cell-cycle 
proteins). Another potential limiting factor includes quenching of the activating UV irradiation 
through intrinsic absorption by the PAL probes. To investigate this option, the UV absorption spectra 
of PAL probes 90a-c were assessed from their corresponding LC-DAD-MS spectra (Figure V.5). For the 
benzophenone and diazirine probe no significant absorption is detected at their activation 
wavelength of 365 nm (Figure V.5A and V.5C, respectively). On the other hand, the aryl azide probe 
90b displays partial absorption at 254 nm, hence potentially impeding efficient photoexcitation 
(Figure V.5B).  
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Figure V.4. Evaluation of the interaction of the second-generation tamoxifen-TFC and the PAL probes with 
candidate target protein ‘2’ in MASPIT, in the absence and presence of UV irradiation. A) TMP-TAM-
benzophenone (90a); B) TMP-TAM-aryl azide (90b); C) TMP-TAM-diazirine (90c). For each probe the irradiation 
time and wavelength is indicated. Luciferase signals are expressed as fold induction relative to a control sample 
treated with cytokine without fusion compound. 
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Figure V.5: UV absorption profiles (190-400 nm) of the PAL probes extracted from their corresponding LC-
DAD-MS spectra. A) TMP-TAM-benzophenone (90a); B) TMP-TAM-aryl azide (90b); C) TMP-TAM-diazirine (90c).  
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Finally, besides functional testing in MASPIT, a more direct evaluation approach was explored using 
Western blot (WB) analysis. Inspired by a report of the Cornish group on the development of a 
covalent TMP-tag,[26] we envisioned that successful labeling of target preys with low molecular 
weight, such as ER1 (86 kDa) or candidate target protein ‘8’ (37 kDa), with the photoactivated PAL 
probes 90a-c (1.3 kDa), would yield a detectable shift of the corresponding protein bands in the 
WB. However, also in this setup no proof of effective photocrosslinking could be provided.  
 
V.4. Taking a short cut: a test system based on EGFR kinase inhibitors 
 
As we might have set the bar a bit too high for the pilot PAL probes, we decided to take a step back 
and explore a test system that would enable the assessment of the actual contribution of a covalent 
linkage on the bait-end of the dimerizers with respect to the MASPIT readout, before undertaking 
any further empirical optimization efforts regarding design and technological aspects of the 
photocrosslinker approach. 
 
 
 
Figure V.6: Outline of the EGFR kinase inhibitor-based test system. For each inhibitor, the functional group 
selected as conjugation site is highlighted in red. The acrylamide/alkylamide moiety of afatinib/dihydro-afatinib 
is highlighted in green. 
 
Toward this end, we were inspired by the trend observed in the epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitor (TKI) field, evolving over the past decades from reversible to 
irreversible covalent inhibitors to tackle mutant kinases, which developed resistance toward the 
early generation inhibitors. More specifically, we focused on a panel of three TKIs, including the 
recently approved afatinib; its closely related analogue BI 37781, which we coined dihydro-afatinib; 
and the prototypic gefitinib (Figure V.6).[27] By comparing the irreversible, covalent binding afatinib 
with its ,-saturated congener, which lacks the covalent reactivity while maintaining binding affinity 
(Ki (EGFR
WT kinase) = 0.8 nM vs. 0.5 nM for afatinib),[27] we estimated that this test system would 
allow assessment of the contribution of covalent bonding with respect to the MASPIT signal output. 
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However, since the dihydro-afatinib analogue represents a rather artificial reversible binder, we 
decided to also incorporate the natural reversible first-generation TKI gefitinib in our analysis, 
providing a positive control and setting at the same time a reference point for the readout attainable 
solely based on reversible interactions. 
 
In the following subsections some background on the mechanism of action and binding mode of 
these TKIs is provided as well as our rationale for the selection of the conjugation site on these baits 
allowing their incorporation into appropriate TFCs. 
 
V.4.1. MOA of gefitinib and afatinib 
 
Gefitinib, a 4-anilinoquinazoline derivative, is the first reversible, ATP-competitive EGFR tyrosine 
kinase inhibitor that was approved by the FDA in 2003 for the treatment of non-small-cell lung 
carcinoma (NSCLC).[28] EGFR/ErbB-1/HER1 together with the closely related ErbB-2/HER2, ErbB-
3/HER3 and ErbB-4/HER4 constitute the ErbB (proto-oncogene B of the avian erythroblastosis virus 
AEV-H strain) family of tyrosine kinase receptors.[29] Structurally, each receptor is composed of an 
extracellular ligand-binding domain, a transmembrane domain, and an intracellular part containing 
the catalytic tyrosine kinase (TK) domain, except for ErbB3 which lacks intrinsic TK activity.[30] 
Deregulation of the ErbB receptor network is well recognized as an oncogenic driver in a variety of 
epithelial malignancies, making this protein kinase family an attractive drug target.[31],[32] 
 
Yet, the ability of gefitinib to treat NSCLC patients effectively is short-lived as it is seen that such 
patients typically relapse within 6-8 months of treatment.[33] This observation is partly attributed to 
acquired drug resistant mutations in EGFR, which affect approximately 50% of the treated 
population.[34],[35] One of these secondary mutations, accounting for about half of all resistance to 
gefitinib, involves substitution of the threonine gatekeeper residue 790 with methionine (T790M). 
This point mutation confers resistance by increasing the affinity for the competing physiologic 
substrate (ATP), rather than by interfering with specific inhibitor binding.[36] As such, T790M 
substitution tends to cause resistance to any ATP-competitive inhibitor, designating it as a ‘generic’ 
resistance mutation. An additional postulated mechanism of acquired resistance to gefitinib 
comprises increased internalization of ligand-bound EGFR, as observed in drug resistant tumor cell 
lines.[37] In fact, significant EGF-dependent signaling is thought to occur during the process of 
internalization,[38] and such alterations in receptor trafficking may be correlated with dissociation of 
the reversible gefitinib-EGFR complex at the low pH of intracellular vesicles. 
  
Both resistance mechanisms may be circumvented by irreversible EGFR-TK inhibitors such as afatinib, 
which was approved by the FDA in 2013 for the first-line treatment of NSCLC in patients bearing 
activating oncogenic mutations.[39] Afatinib relies on an electrophilic acrylamide Michael acceptor 
grafted onto its anilinoquinazoline pharmacophore to form a covalent bond with conserved cysteine 
residues within the catalytic domains of EGFR (Cys797), HER2 (Cys805) and ErbB-4 (Cys803) (Figure 
V.7).[27] In fact, this Michael addition enables a greater occupancy of the ATP-binding site and 
prolonged time of exposure compared to gefitinib, thus ensuring irreversible inhibition of the 
enzymatic activity of these ErbB family kinases. As a result, afatinib is no longer in a competitive, 
reversible equilibrium with ATP and hence capable of overcoming T790M resistance. Moreover, 
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Kwak et al. assumed that irreversible inhibition of EGFR would be unaffected by alterations in 
receptor trafficking.[37]  
 
 
  
Figure V.7: Covalent binding mode of afatinib to conserved cysteine residues within the catalytic domains of 
ErbB receptor family members. The electrophilic acrylamide Michael acceptor and ATP-competitive 4-
anilinoquinazoline moiety of afatinib are highlighted in red and green, respectively. Figure adapted from: The 
Journal of Pharmacology and Experimental Therapeutics 2012, 343 (2), 342-350. 
 
V.4.2. SAR and conjugation site selection 
 
Apart from the covalent bonding aspect, the binding modes of afatinib and gefitinib in the kinase 
domain of human wild-type EGFR are strikingly similar (PDB codes: 4G5J, 2ITY; Figures V.8,V.9, 
respectively).[27],[40] For either inhibitor, the quinazoline ring is positioned in the back of the ATP-
binding pocket where its orientation is governed by a critical hydrogen bond between its N1 and the 
amide nitrogen of Met793 at the hinge region. Further down the ATP-binding cleft, the 3-chloro-4-
fluoro aniline substituent extends into a hydrophobic pocket. 
 
In the case of afatinib (Figure V.8), the crystal structure unambiguously proves the formation of a 
covalent bond between Cys797 at the edge of the active site and the -carbon of the acrylamide 
moiety installed at the 6 position of the heterocycle. Hence, so as not to disturb this crucial covalent 
bonding mechanism, we selected the 7 position of the quinazoline to introduce an alkyne ligation 
handle. This strategy was based on a report by Kobus et al., describing an afatinib analogue bearing a 
18F label at the 7 position that was successfully installed following a CuAAC approach.[41] 
Encouragingly, profiling of this conjugate against a panel of 117 kinases revealed that it retained high 
binding affinities for its primary targets, EGFR and ErbB4. 
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Figure V.8: Binding mode of afatinib in the active site of human wild-type EGFR (PDB code: 4G5J). A) The 
structure of the whole EGFR kinase domain. B) A close-up of the hinge region illustrating the covalent C-S bond 
(1.82 Å) formed between Cys797 at the edge of the active site and the -carbon of the acrylamide Michael 
acceptor moiety of afatinib. The red dashed line represents a hydrogen bond (3.3 Å) between the amide 
nitrogen of Met793 at the hinge region and N
1
 of the quinazoline core of the inhibitor. Figure from: The Journal 
of Pharmacology and Experimental Therapeutics 2012, 343 (2), 342-350. 
 
Continuing along the same line, the 7 position of the quinazoline ring of gefitinib was explored as 
derivatization site. Although the methoxy group in this position is in van der Waals contact with 
Gly796, we anticipated that its substitution for an alkynoxy moiety would not significantly influence 
overall binding affinity. To the best of our knowledge, no literature data on the conjugation of 
gefitinib at this specific site exists. Rather, the 6-propylmorpholino group has received more 
attention, as structural data revealed that it is poorly ordered and extends into the solvent (Figure 
V.9).[40] These findings are in agreement with the reported SAR for gefitinib, since this substituent 
was exclusively implemented to improve the pharmacokinetic profile of this kinase inhibitor.[28] 
Hence, by exchanging the morpholine for a piperazine, a strategy previously described in Chapter 3 
for the reversine bait, an appropriate ligation handle might be attached, as exemplified by Hill et 
al.[42] Nevertheless, in order to allow optimal comparison between either interaction mode (covalent 
vs. reversible), we decided to keep the substituent at the 6 position of the quinazoline intact (as in 
the case of afatinib) and to focus our ligation efforts on the 7 position, enabling a synthetic route 
starting from the commercially available drug. 
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Figure V.9: Binding mode of gefitinib in the active site of human wild-type EGFR (PDB code: 2ITY). Key side 
chains are labeled. The black dashed line represents a hydrogen bond between the amide of Met793 at the 
hinge region and N
1
 of the quinazoline core of the inhibitor. Figure from: Cancer Cell 2007, 11 (3), 217-227. 
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V.5. Synthesis of EGFR kinase inhibitor TFCs 
 
The alkyne-functionalized afatinib 102a and its ,-saturated analogue, dihydro-afatinib 102b, were 
synthesized based on a protocol by Kobus et al.[41] with modifications (Scheme V.5). Both alkynes 
were derived from a common 6-aminoquinazoline precursor 98, which was obtained from 7-fluoro-6-
nitroquinazolin-4(3H)-one (95) in 3 steps. The latter was first chlorinated and subsequently 
substituted with 3-chloro-4-fluoroaniline to give 96. In a next substitution step, the alkyne ligation 
handle was attached using 4-pentynol, after which selective tin(II) mediated aromatic nitro 
reduction[43] afforded the desired aniline building block 98. Furthermore, the divergent side chains 
101a-b were prepared from methyl 4-bromocrotonate (99a) and ethyl 4-bromobutyrate (99b), 
respectively. Substitution of these esters with dimethylamine, followed by saponification with 
concomitant acidification, provided the acid hydrochlorides 101a-b. 
 
Ultimately, these acids were condensed with aniline 98 in the presence of Mukaiyama’s reagent (2-
chloro-1-methylpyridinium iodide)[44] to yield the final alkyne-functionalized analogues 102a-b in 30% 
and 53% yield, respectively. Alternative methods for this amide condensation, including HATU-
mediated coupling and (in situ) acid chloride formation using oxalyl chloride[41] or Ghosez’s reagent 
(tetramethyl--chloroenamine) followed by treatment with the aniline, were unsuccessful.  
 
 
 
Scheme V.5: Synthesis of alkyne-functionalized (dihydro)-afatinib. [i] first SOCl2, DMF, ; then 3-chloro-4-
fluoroaniline, Et3N, iPrOH, , 92%; [ii] 4-pentynol, NaH, DMF, 82%; [iii] SnCl2, EtOH, , 73%; [iv] NH(Me)2, THF, 
0°C to RT, (a 91%; b 21%); [v] first NaOH, MeOH, 50°C; then HCl, (a 32%; b quant.); [vi] Mukaiyama’s reagent, 
Et3N, CH2Cl2/DMF, , (a 30%; b 53%).   
 
The desired afatinib TFC 103a and dihydro-afatinib TFC 103b (Figure V.10) were constructed by 
conjugating alkynes 102a-b with the second-generation TMP-N3 reagent (40) via CuAAC in 56% and 
69% yield, respectively, after HPLC purification. 
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Figure V.10: Chemical structures of (dihydro)-afatinib TFCs.  
 
To acquire an alkyne-functionalized analogue of gefitinib, the latter was first selectively 
demethylated using pyridinium chloride under melt conditions[45] (Scheme V.6). The same pentynol-
based ligation handle as in the case of afatinib was next grafted onto the resulting 7-
hydroxyquinazoline 104 via Mitsunobu reaction[45] to afford the final terminal alkyne 105 in 
satisfactory yield. 
 
 
 
Scheme V.6: Synthesis of alkyne-functionalized gefitinib. [i] pyridinium chloride, 170°C, 76%; [ii] 4-pentynol, 
DBAD, PPh3, THF, 0°C to 70°C, 57%. 
 
The alkyne-functionalized gefitinib 105 was analogously click-coupled to the TMP-N3 reagent 40 to 
generate the desired TFC 106 in 74% yield after HPLC purification (Figure V.11). 
 
 
Figure V.11: Chemical structure of gefitinib TFC.  
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V.6. Biological evaluation of EGFR kinase inhibitor TFCs 
 
The (dihydro)-afatinib and gefitinib TFCs (103a-b and 106) were first evaluated in MASPIT for binding 
to their primary target protein, EGFR. Given the transmembrane nature of this ErbB family receptor, 
two MASPIT-compatible target prey constructs were prepared (see Experimental Section), i.e. the 
entire cytoplasmic tail of EGFR (cyt) and its protein kinase domain (kinase), comprising amino acid 
residues 696-1022 (analogous to the domain applied in the reported cocrystal structures of these 
TKIs, PDB codes: 4G5J, 2ITY). Unexpectedly, for both constructs only a signal for the covalently 
binding afatinib TFC 103a was obtained, despite the comparable binding affinities of unfunctionalized 
afatinib and gefitinib toward wild-type EGFR (KD = 0.25 nM and 1 nM, respectively)
[46] (Figure V.12). 
 
 
 
Figure V.12: Evaluation of EGFR kinase inhibitor TFCs 103a-b and 106 for binding to their primary target 
protein in MASPIT. Cyt and kinase denote the cytoplasmic and kinase domain of EGFR, respectively. Luciferase 
signals are expressed as fold induction relative to a control sample treated with cytokine without fusion 
compound. 
 
Therefore, in a next step we set out to elucidate the hypothesis that modification of these kinase 
inhibitors might result in significant loss in binding affinity to their primary target. Toward this end, 
the cellular activity of the alkynylated analogues (102a-b and 105) and their final TMP conjugates 
(103a-b and 106) was assessed using a functional WB-based assay, monitoring the phosphorylation 
status of ERK1/2 (extracellular signal-regulated kinase), one of the main downstream signaling 
molecules within the EGFR signaling pathway. 
 
This signaling cascade is initiated by extracellular binding of the EGF (epidermal growth factor) ligand, 
which triggers a conformational change in the extracellular domain of this receptor, thereby allowing 
its homodimerization and/or heterodimerization with other ErbB family members. In such dimers, 
one monomer allosterically activates the intrinsic intracellular catalytic tyrosine kinase activity of the 
partnered receptor. As a result, specific tyrosine residues within the C-terminal tail segment of the 
activating partner become transphosphorylated, thus providing a scaffold for the recruitment of 
adaptor and effector proteins. The latter are responsible for onward transmission of the signal via 
stimulation of their corresponding signaling cascades, including the KRAS-BRAF-MEK-ERK pathway, 
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PI3K-AKT-mTOR pathway, JAK-STAT pathway, and the PLC-PKC pathway. Ultimately, this leads to cell 
proliferation, angiogenesis, migration and anti-apoptosis (Figure V.13).[47],[48],[27],[49] 
 
 
 
Figure V.13: Schematic outline of the epidermal growth factor receptor (EGFR) signaling pathway. Ligand-
induced homodimerization of EGFR results in activation of the intracellular kinase domain and subsequent 
phosphorylation of tyrosine residues in the C-terminal regulatory domains, which serve as docking sites for 
signaling molecules that engage multiple signaling cascades including the KRAS-BRAF-MEK-ERK pathway (see 
text for more details). BRAF, B-rapidly accelerated fibrosarcoma; ERK, extracellular signal-regulated kinase; 
KRAS, Kirsten rat sarcoma; MEK, MAPK/ERK kinase. Figure from: Nature Reviews Cancer 2009, 9 (7), 489-499. 
 
Thus, stimulation of intact MASPIT HEK293T cells, which endogenously express the EGF receptor, 
with human EGF results in phosphorylation of the downstream ERK1/2 kinases, as observed in the 
WB below (see Experimental Section; Figure V.14, lane 2). Accordingly, functional binding and cellular 
activity of an appropriate EGFR inhibitor can be read out as inhibition of ERK phosphorylation, as in 
the case of unfunctionalized gefitinib, serving as a positive control. Likewise, all alkyne-functionalized 
analogues (102a-b and 105) clearly showed cellular activity, thereby validating our rationale for the 
selection of the conjugation site on these baits. However, as deduced from the intense pERK bands, 
even at concentrations up to 10 µM, no functional response for all corresponding TFCs (103a-b and 
106) was observed. 
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Figure V.14: Functional Western blot-based analysis determining the cellular activity of the alkyne-
functionalized EGFR inhibitors (102a-b and 105) and their corresponding TMP conjugates (103a-b and 106). 
For each of the applied compound concentrations, the corresponding amount of pure DMSO was taken along 
as control. cpd, compound; dh, dihydro; EGF, epidermal growth factor.  
 
The latter conflicting results lead us to the following two assumptions. First, despite the fact that 
implementation of the alkyne ligation handle seems to be well-tolerated, coupling to the TMP-N3 
reagent might affect overall binding affinity of the final conjugates. Second, although 
counterintuitive, the TMP fusion compounds might suffer from intrinsic cell permeability issues. 
  
To explore the first postulation, we decided to determine and compare the potency of the 
alkynylated analogues and final TFCs using an in vitro (cell-free) radiometric kinase assay. The latter 
was performed by CEREP - Eurofins Pharma Discovery Services UK Limited (Dundee, UK), employing 
full-length human EGFR, -33P-ATP, a poly(Glu, Tyr) 4:1 peptide substrate and unmodified gefitinib as 
control compound. Biochemical IC50 values resulting from these competition experiments are 
summarized below (Table V.1). 
 
Table V.1: Potency of the alkyne-functionalized EGFR inhibitors (102a-b and 105) and their 
corresponding TMP conjugates (103a-b and 106) in a radiometric kinase assay. 
 
 
Compound 
EGFR inhibition 
IC50 (nM) 
gefitinib 3 
alkyne-gefitinib (105) 5 
TMP-gefitinib (106) 7 
  
alkyne-afatinib (102a) 3 
TMP-afatinib (103a) 4 
  
alkyne-dh-afatinib (102b) 4 
TMP-dh-afatinib (103b) 6 
 
Abbreviations used: dh, dihydro. 
 
In agreement with the gefitinib control, all tested compounds exhibited single digit nanomolar IC50 
values, and no significant differences among alkyne-functionalized analogues and their 
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corresponding TMP conjugates were observed. Hence, yet contradictory to the pERK WB analysis, 
these data demonstrate that coupling of the TMP anchor moiety does not hamper overall binding of 
the TFCs to EGFR. Moreover, these data clearly validate our rationale and pioneering work regarding 
the conjugation of gefitinib at the 7 position of the quinazoline ring (see Section V.4.2). 
 
To evaluate the possibility that a lack of cellular permeability of the TMP conjugates is causing the 
observed absence of effect in the cellular assays, the cellular uptake of the (dihydro)-afatinib and 
gefitinib TFCs (103a-b and 106) was indirectly determined by means of a MASPIT-based competition 
experiment strategy (see Experimental Section). Toward this end, we reasoned that increasing 
concentrations of cell-permeable competing small-molecule fusion compounds would enable the 
gradual disruption of an established three-hybrid interaction in MASPIT, thereby yielding a decrease 
in reporter readout following a sigmoidal inhibition curve. In fact, considering the interaction 
between the CR-eDHFR chimeric anchor protein, the second-generation tamoxifen TFC (41) and the 
ER1 target prey, two competition interfaces can be distinguished (Figure V.15). 
 
 
 
Figure V.15: Schematic outline of the competition experiment strategy to indirectly asses cell permeability of 
EGFR kinase inhibitor TFCs. The two competition interfaces on the target prey and anchor protein side are 
indicated, as well as the control interaction between RNF41 (ring finger protein 41) and JAK2 (Janus kinase 2). 
 
First, focusing on the target prey side, the interaction between 41 and ER1 was effectively disrupted 
using unmodified tamoxifen as a positive control (Figure V.16A). Additionally, in order to further 
validate the competition approach at this specific interface, simvastatin was taken along as negative 
control compound. As anticipated, since the latter lacks binding affinity toward ER1, no competition 
effect was observed, resulting in a flat inhibition curve (Figure V.16C). 
 
Similarly, we studied interference with the chemically-induced dimerization and proximity events, 
underlying successful MASPIT signaling, on the eDHFR anchor protein side starting with an 
unfunctionalized trimethoprim control (Figure V.16B). The inhibition curve and corresponding IC50 
value obtained for TMP nicely complement our earlier findings reflecting the excellent cell 
permeability properties of this DHFR inhibitor (see Chapter 4). Moreover, the first-generation 
simvastatin TFC (29c) convincingly demonstrated that this type of competition is attainable with 
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appropriate TMP-based fusion compounds as well (Figure V.16D). Markedly, all EGFR kinase inhibitor 
TFCs (103a-b and 106) displayed clear inhibition profiles and comparable IC50 values, which seems to 
indicate that these compounds are indeed effectively taken up by the HEK cells, thereby excluding 
our second assumption. (Figure V.16E-G). 
 
 
 
Figure V.16: Inhibition curves resulting from  MASPIT competition experiments based on the CR-eDHFR/TMP-
TAM/ER1 three-hybrid interaction. A) tamoxifen; B) trimethoprim; C) simvastatin; D) simvastatin TFC (29c); E) 
afatinib TFC (103a); F) dihydro-afatinib TFC (103b); G) gefitinib TFC (106). For each inhibition curve, the 
corresponding IC50 value of the evaluated compound is indicated. JAK2, Janus kinase 2; RNF41, ring finger 
protein 41. 
 
Of note, all competition experiments described above were run in parallel with control experiments 
based on the RNF41-JAK2 interaction. As schematically depicted in Figure V.15, the RNF41 prey 
directly binds the associated JAK2 kinases of the activated CR-eDHFR chimeric receptor, thereby 
short-circuiting the MASPIT signaling cascade and inducing luciferase reporter gene expression. 
Hence, any (concentration-dependent) detrimental direct or indirect effect of the evaluated 
compounds on this interaction, could be attributed to either toxicity or interference with the MASPIT 
system, which might erroneously influence interpretation of the actual inhibition data. However, as 
for each competition experiment in this setup an overall flat line is observed, this does not seem to 
be the case. 
 
In conclusion, currently we are facing a clear discrepancy between the results obtained from the 
radiometric kinase assay/competition experiments on the one hand, and the MASPIT/pERK WB 
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assays on the other. Whereas the first two analyses clearly demonstrate the high in vitro 
potency/effective cellular uptake of the EGFR kinase inhibitor TFCs, the latter curiously fail to show 
any MASPIT activity for the reversible inhibitor probes/any cellular functional effects for all TMP 
conjugates. 
 
Therefore, future research will be focused on the evaluation of the interaction of these kinase 
inhibitor probes with alternative targets in MASPIT. As a starting point, the other two ErbB family 
members, HER2 and HER4, for which the same Michael addition-based covalent binding mode with 
afatinib is described, will be tested (see Figure V.7). Furthermore, based on a comprehensive analysis 
by Davis et al.,[46] we plan to analyze all additional (cytosolic) target kinases for which afatinib 
displays a KD value below 250 nM, which is currently the estimated cutoff of the MASPIT system 
(Table V.2).  
 
Table V.2: Highest affinity target kinases of afatinib and gefitinib.  
 
Compound Kinase KD (nM) 
Afatinib EGFR 0.25 
ErbB2 5 
ErbB4 6.3 
GAK 79 
BLK 220 
IRAK1 240 
Gefitinib EGFR 1 
GAK 13 
IRAK1 69 
YSK4 240 
 
Table adapted from: Nature Biotechnology 2011, 29 (11), 1046-1051. 
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V.7. Experimental Section 
 
V.7.1. Synthesis 
 
General: All reactions were performed under nitrogen and at ambient temperature, unless stated 
otherwise. Reagents and solvents were purchased from Sigma-Aldrich, Acros Organics, TCI Europe, 
Apollo Scientific, Carbosynth, or Activate Scientific, and used as received. Reactions were monitored 
by thin-layer chromatography on TLC aluminum sheets (Macherey-Nagel, Alugram Sil G/UV254) with 
detection by spraying with a solution of (NH4)6Mo7O24·4H2O (25 g/L) and (NH4)4Ce(SO4)4·2H2O (10 g/L) 
in H2SO4 (10%) or KMnO4 (20 g/L) and K2CO3 (10 g/L) in water followed by charring. Column 
chromatography was performed on a Grace Reveleris X2 flash system equipped with disposable silica 
gel cartridges (Grace, Reveleris). LC-MS analyses were carried out on a Waters Alliance 2695 XE 
Separation Module by using a Phenomenex Luna reversed-phase C18 column (1002.00 mm, 3 μm) 
and a gradient system of HCOOH in H2O (0.1 %, v/v)/HCOOH in CH3CN (0.1 %, v/v) at a flow rate of 
0.4 mL/min. High-resolution spectra were recorded on a Waters LCT Premier XE Mass spectrometer. 
1H and 13C NMR spectra were measured on a Varian Mercury-300BB (300/75 MHz) spectrometer. 
NMR solvents were purchased from Euriso-top. Chemical shifts () are given in ppm relative to 
tetramethylsilane (1H NMR) or CDCl3, CD3OD or SO(CD3)2 (
13C NMR) as internal standards. Coupling 
constants are given in Hz. Preparative HPLC purifications were carried out by using a Laprep 
preparative RP-HPLC system equipped with a Phenomenex Luna C18 column (21.20250 mm, 5 μm) 
with a gradient system of HCOOH in H2O (0.2 %, v/v)/CH3CN at a flow rate of 17.5 mL/min.  
 
TMP-NH2 (87): The second-generation TMP-N3 reagent 40
 (386 mg, 0.67 mmol) was dissolved in 
H2O/1,4-dioxane (44 mL, 10:1, v/v), and the system was purged with nitrogen for 10 min. 
Subsequently, the solution was charged with a catalytic amount of palladium on activated charcoal 
(Pd/C, 10% Pd basis,  50 mg) after which hydrogen was bubbled through the reaction mixture for 1 
h (1 atm, RT). Next, the system was flushed again with nitrogen for 10 min and the mixture was 
filtered. The filtrate was concentrated in vacuo, redissolved in H2O (20 mL) and lyophilized to yield 
the title compound (331 mg, 0.60 mmol, 90%) as a white amorphous solid. 1H NMR (300 MHz, 
CD3OD)  = 7.51 (s, 1H), 6.52 (s, 2H), 3.90 (t, 2H, J = 6.0 Hz), 3.77 (s, 6H), 3.68-3.57 (m, 12H), 3.53 (t, 
2H, J = 5.6 Hz), 3.37 (t, 2H, J = 5.6 Hz), 3.07 (t, 2H, J = 5.0 Hz), 2.27 (t, 2H, J = 7.4 Hz), 1.86-1.64 ppm 
(m, 4H); 13C NMR (75 MHz, CD3OD)  = 176.3, 164.5, 162.8, 155.1, 154.8, 136.6, 136.2, 108.3, 106.8, 
73.9, 71.42, 71.41, 71.12, 71.11, 70.6, 68.7, 56.6, 40.9, 40.2, 36.7, 34.4, 30.5, 23.6 ppm; HRMS: calcd. 
for C26H44N6O7 [M+2H]
2+: 276.1630, found: 276.1619. 
 
TMP-N3-Lys(Boc) (88): TPTU (680 mg, 2.29 mmol, 1.97 eq.) and Et3N (338 µL, 2.43 mmol, 2.09 eq.) 
were added to a solution of acid 92[20] (557 mg, 2.05 mmol, 1.77 eq.) in DMF (1.9 mL). The resulting 
preactivation mixture was stirred for 5 min at RT. Subsequently, a solution of amine 87 (638 mg, 1.16 
mmol, 1.0 eq.) and Et3N (1.92 mL, 13.79 mmol, 11.89 eq.) in DMF (8.9 mL) was added dropwise to 
this mixture. The resulting reaction mixture was stirred for 29 h at RT, then concentrated in vacuo, 
and the residue was purified by silica gel chromatography (MeOH/CH2Cl2 0-10%, v/v with 0.1% 
NH4OH) yielding the title compound (640 mg, 0.80 mmol, 69%) as a white foam. 
1H NMR (300 MHz, 
CD3OD)  = 7.45 (s, 1H), 6.52 (s, 2H), 3.91 (t, 2H, J = 6.2 Hz), 3.83-3.80 (m, 1H), 3.78 (s, 6H), 3.65-3.57 
(m, 10H), 3.56-3.51 (m, 4H), 3.41-3.33 (m, 4H), 3.03 (t, 2H, J = 6.8 Hz), 2.28 (t, 2H, J = 7.2 Hz), 1.88-
1.65 (m, 6H), 1.55-1.35 ppm (m, 13H); 13C NMR (75 MHz, CD3OD)  = 176.2, 172.5, 164.9, 161.6, 
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158.5, 154.9, 152.4, 136.9, 135.7, 108.8, 106.9, 79.9, 73.9, 71.6, 71.3, 70.6, 70.4, 64.2, 56.6, 41.1, 
40.4, 40.3, 36.7, 34.4, 32.5, 30.5, 28.8, 23.9, 23.7 ppm; HRMS: calcd. for C37H61N10O10 [M+H]
+: 
805.4567, found: 805.4577. 
 
TMP-N3-Lys (89): Compound 88 (627 mg, 0.78 mmol) was taken up in TFA/CH2Cl2 (20 mL, 1:1, v/v), 
and the solution was stirred for 40 min at RT. The reaction mixture was then evaporated, 
coevaporated twice with toluene, and concentrated under high vacuum for 1 h. The residue was 
redissolved in H2O (40 mL), after which the pH was adjusted to 10 by the addition of Amberlite IRA-
400 hydroxide form. The resin was next filtered, and the filtrate lyophilized to yield the title 
compound (549 mg, 0.78 mmol, quant.) as a white solid. 1H NMR (300 MHz, CD3OD)  = 7.51 (s, 1H), 
6.51 (s, 2H), 3.90 (t, 2H, J = 6.2 Hz), 3.85 (dd, 1H, J = 7.5 Hz, J = 6.0 Hz), 3.78 (s, 6H), 3.65-3.57 (m, 
10H), 3.57-3.50 (m, 4H), 3.42-3.33 (m, 4H), 2.77 (t, 2H, J = 7.4 Hz), 2.28 (t, 2H, J = 7.4 Hz), 1.87-1.65 
(m, 6H), 1.65-1.36 ppm (m, 4H); 13C NMR (75 MHz, CD3OD)  = 176.2, 172.3, 164.4, 163.2, 156.0, 
154.9, 136.7, 136.4, 108.1, 106.8, 73.9, 71.6, 71.3, 71.2, 70.6, 70.3, 64.2, 56.6, 41.4, 40.4, 40.3, 36.7, 
34.5, 32.4, 30.8, 30.5, 23.8, 23.7 ppm; HRMS: calcd. for C32H54N10O8 [M+2H]
2+: 353.2058, found: 
353.2050. 
 
TMP-TAM-benzophenone (90a): Azide 89 (70.5 mg, 100 µmol, 1.0 eq.) was taken up in DMF (1.13 
mL), and alkyne-functionalized tamoxifen 7 (59.3 mg, 150 µmol, 1.5 eq.), CuSO4 (40 μL, 0.5M, 0.2 
eq.), Na ascorbate (200 μL, 0.5M, 1.0 eq.), and Et3N (14 µL, 100 µmol, 1.0 eq.) were added. The 
resulting mixture was charged with a catalytic amount of TBTA[50] and vigorously stirred at RT. Upon 
completion of the reaction (1 h, based on HRMS analysis), NHS ester 94a[21] (38.8 mg, 120 µmol, 1.2 
eq.) was added to the crude mixture, which was stirred for another 16 h in the dark. The solution was 
next concentrated in vacuo and the residue was purified by preparative RP-HPLC (30-80% MeCN) 
yielding the title compound (39.6 mg, 30 μmol, 30%) as a white amorphous solid. LC-HRMS: tR = 6.13 
min (35-60% MeCN, 15 min run); HRMS: calcd. for C74H91N11O11 [M+2H]
2+: 654.8444, found: 
654.8440. 
 
TMP-TAM-aryl azide (90b): Azide 89 (84.6 mg, 120 µmol, 1.2 eq.) was taken up in DMF (1.13 mL), 
and alkyne-functionalized tamoxifen 7 (39.6 mg, 100 µmol, 1.0 eq.), CuSO4 (40 μL, 0.5M, 0.2 eq.), Na 
ascorbate (200 μL, 0.5M, 1.0 eq.), and Et3N (14 µL, 100 µmol, 1.0 eq.) were added. The resulting 
mixture was charged with a catalytic amount of TBTA[50] and vigorously stirred at RT. Upon 
completion of the reaction (2 h, based on HRMS analysis), NHS ester 94b[22] (37.5 mg, 144 µmol, 1.4 
eq.) was added to the crude mixture, which was stirred for another 16 h in the dark. The solution was 
next concentrated in vacuo and the residue was purified by preparative RP-HPLC (30-80% MeCN) 
yielding the title compound (29.9 mg, 24 μmol, 24%) as a white amorphous solid. LC-HRMS: tR = 5.52 
min (35-60% MeCN, 15 min run); HRMS: calcd. for C67H86N14O10 [M+2H]
2+: 623.3320, found: 
623.3311. 
 
TMP-TAM-diazirine (90c): Azide 89 (70.5 mg, 100 µmol, 1.0 eq.) was taken up in DMF (1.13 mL), and 
alkyne-functionalized tamoxifen 7 (42.4 mg, 107 µmol, 1.1 eq.), CuSO4 (40 μL, 0.5M, 0.2 eq.), Na 
ascorbate (200 μL, 0.5M, 1.0 eq.), and Et3N (14 µL, 100 µmol, 1.0 eq.) were added. The resulting 
mixture was charged with a catalytic amount of TBTA[50] and vigorously stirred at RT. Upon 
completion of the reaction (6 h, based on HRMS analysis), NHS ester 94c[23] (49.1 mg, 150 µmol, 1.5 
eq.) was added to the crude mixture, which was stirred for another 21 h in the dark. The solution was 
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next concentrated in vacuo and the residue was purified by preparative RP-HPLC (30-80% MeCN) 
yielding the title compound (45.1 mg, 34 μmol, 34%) as a white amorphous solid. LC-HRMS: tR = 6.84 
min (30-80% MeCN, 15 min run); HRMS: calcd. for C69H86F3N13O10 [M+2H]
2+: 656.8281, found: 
656.8282. 
 
(S)-2-azido-6-((tert-butoxycarbonyl)amino)hexanoic acid (92): Preparation of triflyl azide (TfN3) 
solution (Caution: TfN3 is explosive when not in solvent and should always be used as a solution!): 
To an ice-cooled solution of sodium azide (7.0 g, 107.7 mmol) in H2O/CH2Cl2 (40 mL, 1:1, v/v), triflic 
anhydride (Tf2O) (4.0 mL, 23.8 mmol) was added dropwise and the resulting biphasic mixture was 
vigorously stirred for 2 h at RT. The reaction mixture was transferred to a separation funnel and the 
organic layer was separated. The aqueous fraction was backwashed with CH2Cl2 (10 mL) and the two 
organic fractions were pooled. 
To a solution of H-Lys(Boc)-OH (91) (2.50 g, 10.15 mmol, 1.0 eq.) and K2CO3 (2.4 g, 17.0 mmol) in 
H2O/MeOH (100 mL, 1:1, v/v) was added a solution of CuSO4 (150 mg) in H2O (1 mL). To the resulting 
dark blue mixture, the freshly prepared TfN3 solution and water (20 mL) were added. The reaction 
mixture was homogenized by the addition of a minimal amount of MeOH and vigorously stirred at RT 
for 24 h. After this time, the resulting dark green solution was partly concentrated in vacuo to 
remove all CH2Cl2, MeOH and part of the water. The aqueous residue was redissolved in water (150 
mL) and the pH was adjusted to 2.5-3 by the addition of HCl (1.0M). The acidic solution was extracted 
with EtOAc (4 x 200 mL) and the organic fractions were pooled, dried over Na2SO4 and concentrated 
in vacuo. The residue was purified by silica gel chromatography (MeOH/CH2Cl2 0-10%, v/v with 0.1% 
HOAc), and coevaporated with dichloroethane and chloroform to yield the title compound (2.18 g, 
8.00 mmol, 79%) as a colorless oil. 1H NMR (300 MHz, CD3OD)  = 3.94 (dd, 1H, J = 8.1 Hz, J = 4.8 Hz), 
3.04 (t, 2H, J = 6.6 Hz), 1.91-1.78 (m, 1H), 1.78-1.62 (m, 1H), 1.55-1.39 ppm (m, 13H); 13C NMR (75 
MHz, CD3OD)  = 173.8, 158.5, 79.9, 63.1, 41.0, 32.1, 30.4, 28.8, 24.0 ppm; HRMS: calcd. for 
C11H19N4O4 [M-H]
-: 271.1412, found: 271.1407. 
 
N-succinimidyl 4-benzoylbenzoate (94a): The synthetic procedure was adapted from Olivo et al.[21] In 
brief, to a solution of 4-benzoylbenzoic acid (93a) (1.13 g, 5.0 mmol) and DMAP (31 mg, 5 mol%) in 
anhydrous CH2Cl2 (50 mL) were added N-hydroxysuccinimide (NHS) (0.86 g, 7.5 mmol) and EDC.HCl 
(1.44 g, 7.5 mmol). The resulting reaction mixture was stirred overnight at RT in the dark under 
nitrogen. The mixture was washed with water (10 mL) and brine (10 mL), dried over Na2SO4, and 
concentrated in vacuo. The thus obtained semi pure product was purified further by precipitation 
(CH2Cl2/hexane) yielding the title compound (1.05 g, 3.25 mmol, 65%) as white crystals. 
1H NMR (300 
MHz, CDCl3)  = 8.26 (d, 2H, J = 8.6 Hz), 7.90 (d, 2H, J = 8.6 Hz), 7.84-7.77 (m, 2H), 7.69-7.60 (m, 1H), 
7.56-7.47 (m, 2H), 2.94 ppm (br s, 4H); 13C NMR (75 MHz, CDCl3)  = 195.7, 169.2, 161.4, 143.2, 136.7, 
133.4, 130.7, 130.3, 130.1, 128.7, 128.2, 25.8 ppm. 
 
N-succinimidyl 4-azidobenzoate (94b): The synthetic procedure was adapted from Dcona et al.[22] In 
brief, to an ice-cooled solution of 4-azidobenzoic acid (93b) (500 mg, 3.065 mmol) in DMF (10 mL) 
were added NHS (423 mg, 3.678 mmol) and EDC.HCl (705 mg, 3.678 mmol). The resulting reaction 
mixture was stirred overnight in the dark under nitrogen, allowing the temperature to rise to RT. The 
mixture was concentrated in vacuo and the residue was resuspended in EtOAc (50 mL), washed with 
water (3 x 20 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by silica 
gel chromatography (EtOAc/toluene 0-25%, v/v) yielding the title compound (674 mg, 2.59 mmol, 
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85%) as a white solid. 1H NMR (300 MHz, SO(CD3)2)  = 8.11 (d, 2H, J = 8.9 Hz), 7.37 (d, 2H, J = 8.9 Hz), 
2.90 ppm (s, 4H); 13C NMR (75 MHz, SO(CD3)2)  = 170.3, 161.1, 146.8, 132.0, 120.5, 120.1, 25.5 ppm; 
HRMS: calcd. for C22H16N8O8Na [2M+Na]
+: 543.0983, found: 543.0982. 
 
N-succinimidyl 4-(3-(trifluoromethyl)-3H-diazirinyl) benzoate (94c): The synthetic procedure was 
adapted from Pourcelle et al.[23] In brief, to an ice-cooled solution of 4-(3-(trifluoromethyl)-3H-
diazirinyl) benzoic acid (93c) (230 mg, 1.0 mmol) and NHS (138 mg, 1.2 mmol) in DMF (2.5 mL) was 
added dropwise a suspension of EDC.HCl (230 mg, 1.2 mmol) and DMAP (6 mg, 5mol%) in DMF (5.5 
mL). The resulting reaction mixture was stirred overnight in the dark under nitrogen, allowing the 
temperature to rise to RT. The mixture was concentrated in vacuo and the residue was resuspended 
in EtOAc (40 mL), washed with water (3 x 15 mL), dried over Na2SO4, and concentrated in vacuo. The 
residue was purified by silica gel chromatography (EtOAc/toluene 0-12%, v/v) yielding the title 
compound (308 mg, 0.94 mmol, 94%) as a white solid. 1H NMR (300 MHz, CDCl3)  = 8.17 (d, 2H, J = 
8.6 Hz), 7.32 (d, 2H, J = 8.6 Hz), 2.91 ppm (br s, 4H); 13C NMR (75 MHz, CDCl3)  = 169.1, 161.1, 136.0, 
131.0, 126.9, 126.4, 121.8 (q, JC-F = 273.3 Hz), 28.5 (q, JC-F = 40.9 Hz), 25.8 ppm; HRMS: calcd. for 
C15H12F3N4O4 [M+MeCN+H]
+: 369.0805, found: 369.0801. 
 
4-(3-Chloro-4-fluorophenylamino)-7-fluoro-6-nitroquinazoline (96): 7-Fluoro-6-nitroquinazolin-
4(3H)-one (95) (627 mg, 3.00 mmol) was suspended in thionyl chloride (15 mL), charged with a 
catalytic amount of DMF (50 µL), and refluxed for 4 h. After being cooled to RT, the mixture was 
concentrated in vacuo, and coevaporated with toluene (4 × 10 mL) to remove traces of thionyl 
chloride. The resulting crude 4-chloro substitution product and 3-chloro-4-fluoroaniline (437 mg, 
3.00 mmol) were next taken up in iPrOH (20 mL). Triethylamine (1.5 mL, 10.8 mmol) was added and 
the reaction mixture was refluxed for 4 h. After being cooled to RT, the mixture was concentrated in 
vacuo. To the residue were added EtOAc (15 mL) and sat. NaHCO3 (15 mL) and the biphasic mixture 
was agitated until the residue was completely dissolved and transferred to a separation funnel. The 
aqueous layer was separated and the organic fraction was washed with sat. NaHCO3 (2 × 15 mL), 
dried over Na2SO4 and concentrated in vacuo. The residue was purified by silica gel chromatography 
(EtOAc/toluene 0-20%, v/v) yielding the title compound (929 mg, 2.76 mmol, 92%) as a bright orange 
solid. 1H NMR (300 MHz, SO(CD3)2)  = 10.50 (s, 1H), 9.57 (d, 1H, JH-F = 8.1 Hz), 8.73 (s, 1H), 8.13 (dd, 
1H, JH-F = 6.8 Hz, J = 2.6 Hz), 7.85 (d, 1H, JH-F = 12.6 Hz), 7.80 (ddd, 1H, J = 9.0 Hz, JH-F = 4.2 Hz, J = 2.6 
Hz), 7.49 ppm (dd, 1H, J = JH-F = 9.0 Hz); 
13C NMR (75 MHz, SO(CD3)2)  = 158.2, 158.0, 156.2 (JC-F = 
249.6 Hz), 153.9 (JC-F = 13.8 Hz), 153.8 (JC-F = 242.7 Hz), 135.4 (JC-F = 3.5 Hz), 135.2 (JC-F = 10.4 Hz), 
124.2, 123.9, 122.6 (JC-F = 6.9 Hz), 118.9 (JC-F = 18.3 Hz), 116.5 (JC-F = 21.8 Hz), 115.0 (JC-F = 19.5 Hz), 
111.0 ppm; HRMS: calcd. for C14H8ClF2N4O2 [M+H]
+: 337.0298, found: 337.0288. 
 
4-(3-Chloro-4-fluorophenylamino)-6-nitro-7-(4-pentynoxy)quinazoline (97): A flask was charged 
with 4-pentynol (19 mL, 204 mmol), and cooled on ice under nitrogen. To the dry material sodium 
hydride (60% dispersion in mineral oil, 0.75 g, 18.8 mmol, 2.2 eq.) was added, and the mixture was 
stirred for 45 min, turning dark yellow while the temperature was allowed to rise to RT. Compound 
96 (2.87 g, 8.5 mmol, 1.0 eq.) and DMF (6 mL) were added to this suspension, and the resulting 
reaction mixture was stirred overnight at RT, turning dark red. The mixture was subsequently poured 
in EtOAc (300 mL) and washed with water (2 × 50 mL) and brine (50 mL). The combined aqueous 
phases were next backwashed with EtOAc (750 mL), after which all EtOAc fractions were pooled, 
dried over Na2SO4 and concentrated in vacuo. The oily residue was further concentrated under high 
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vacuum for 1 h to remove excess of 4-pentynol. The crude material was purified by silica gel 
chromatography (EtOAc/toluene 0-20%, v/v) yielding the title compound (2.80 g, 7.0 mmol, 82%) as a 
yellowish-orange solid. 1H NMR (300 MHz, SO(CD3)2)  = 9.99 (s, 1H), 9.13 (s, 1H), 8.59 (s, 1H), 8.11 
(dd, 1H, JH-F = 6.8 Hz, J = 2.6 Hz), 7.78 (ddd, 1H, J = 9.0 Hz, JH-F = 4.5 Hz, J = 2.6 Hz), 7.40 (dd, 1H, J = JH-F 
= 9.0 Hz), 7.35 (s, 1H), 4.31 (t, 2H, J = 6.0 Hz), 2.85 (t, 1H, J = 2.7 Hz), 2.40 (dt, 2H, J = 7.2 Hz, J = 2.7 
Hz), 2.04-1.93 ppm (m, 2H); 13C NMR (75 MHz, SO(CD3)2)  = 157.6, 157.2, 153.6, 153.5 (JC-F = 242.8 
Hz), 153.2, 138.5, 135.9 (JC-F = 3.5 Hz), 123.4, 122.1 (JC-F = 6.8 Hz), 121.9, 118.8 (JC-F = 18.3 Hz), 116.4 
(JC-F = 21.8 Hz), 110.0, 107.8, 83.3, 71.7, 68.1, 27.4, 14.4 ppm; HRMS: calcd. for C19H15ClFN4O3 [M+H]
+: 
401.0811, found: 401.0811. 
 
6-Amino-4-(3-chloro-4-fluorophenylamino)-7-(4-pentynoxy)quinazoline (98): Compound 97 (2.39 g, 
6.0 mmol) and SnCl2 (11.3 g, 60 mmol) were taken up in EtOH (90 mL). The resulting reaction mixture 
was refluxed for 5 h under vigorous stirring. After being cooled to RT, the pH was made slightly basic 
(pH 7-8) by slow addition of sat. Na2CO3. The alkaline solution was transferred to a separation funnel 
and the aqueous fraction was extracted with EtOAc (3 × 300 mL). All EtOAc fractions were pooled, 
dried over Na2SO4 and concentrated in vacuo. The residue was purified by silica gel chromatography 
(MeOH/CH2Cl2 0-4%, v/v with 0.1% NH4OH) yielding the title compound (1.64 g, 4.4 mmol, 73%) as a 
light greenish-brown solid. 1H NMR (300 MHz, SO(CD3)2)  = 9.39 (s, 1H), 8.37 (s, 1H), 8.19 (dd, 1H, JH-F 
= 6.9 Hz, J = 2.7 Hz), 7.81 (ddd, 1H, J = 9.0 Hz, JH-F = 4.3 Hz, J = 2.7 Hz), 7.39 (dd, 1H, J = JH-F = 9.0 Hz), 
7.38 (s, 1H), 7.08 (s, 1H), 5.41 (s, 2H), 4.22 (t, 2H, J = 5.9 Hz), 2.84 (t, 1H, J = 2.7 Hz), 2.47 (dt, 2H, J = 
7.1 Hz, J = 2.7 Hz), 2.06-1.95 ppm (m, 2H); 13C NMR (75 MHz, SO(CD3)2)  = 155.0, 152.6 (JC-F = 240.5 
Hz), 151.9, 150.2, 144.7, 138.6, 137.5 (JC-F = 2.3 Hz), 122.4, 121.4 (JC-F = 6.9 Hz), 118.6 (JC-F = 17.2 Hz), 
116.4 (JC-F = 20.6 Hz), 110.4, 106.3, 100.8, 84.0, 71.6, 66.7, 27.5, 14.7 ppm; HRMS: calcd. for 
C19H17ClFN4O [M+H]
+: 371.1069, found: 371.1071. 
 
Methyl 4-(dimethylamino)crotonate (100a): Dimethylamine (62.8 mL, 2.0M in THF, 125.6 mmol, 3 
eq.) was added dropwise to a solution of methyl 4-bromocrotonate (99a) (5.0 mL, 41.8 mmol) in THF 
(60 mL) at 0°C under nitrogen in the dark. The reaction mixture was stirred for 4 h, allowing the 
temperature to rise to RT, and subsequently concentrated in vacuo. The residue was dissolved in 
CH2Cl2 (40 mL) and washed with sat. NaHCO3 (10 mL). The aqueous phase was next backwashed with 
CH2Cl2 (40 mL), after which all CH2Cl2 fractions were pooled, dried over Na2SO4, and concentrated in 
vacuo to yield the title compound (5.42 g, 37.9 mmol, 91%) as a yellowish-orange oil. 1H NMR (300 
MHz, CDCl3)  = 6.95 (dt, 1H, J = 15.7 Hz, J = 6.2 Hz), 5.98 (dt, 1H, J = 15.7 Hz, J = 1.6 Hz), 3.74 (s, 3H), 
3.07 (dd, 2H, J = 6.2 Hz, J = 1.6 Hz), 2.25 ppm (s, 6H); 13C NMR (75 MHz, CDCl3)  = 166.6, 145.9, 122.6, 
60.4, 51.5, 45.4 ppm; HRMS: calcd. for C7H14NO2 [M+H]
+: 144.1019, found: 144.1016. 
 
Ethyl 4-(dimethylamino)butyrate (100b): Dimethylamine (31.5 mL, 2.0M in THF, 63 mmol, 3 eq.) was 
added dropwise to a solution of ethyl 4-bromobutyrate (99b) (3.0 mL, 21.0 mmol) in THF (25 mL) at 
0°C under nitrogen. The reaction mixture was stirred for 2 h, allowing the temperature to rise to RT, 
and subsequently concentrated in vacuo. The residue was dissolved in EtOAc (40 mL) and washed 
with sat. NaHCO3 (10 mL). The aqueous phase was next backwashed with EtOAc (40 mL), after which 
all EtOAc fractions were pooled, dried over Na2SO4, and concentrated in vacuo. The residue was 
purified by silica gel chromatography (EtOH/CH2Cl2 0-20%, v/v with 0.1% NH4OH) yielding the title 
compound (688 mg, 4.32 mmol, 21%) as an off white oil. 1H NMR (300 MHz, CDCl3)  = 4.13 (q, 2H, J = 
7.1 Hz), 2.52 (t, 2H, J = 7.7 Hz), 2.39 (s, 6H), 2.38 (t, 2H, J = 7.4 Hz), 1.95-1.84 (m, 2H), 1.26 ppm (t, 3H, 
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J = 7.1 Hz); 13C NMR (75 MHz, CDCl3)  = 173.1, 60.4, 58.3, 44.7, 31.7, 22.1, 14.2 ppm; HRMS: calcd. 
for C8H18NO2 [M+H]
+: 160.1332, found: 160.1329. 
 
4-(Dimethylamino)crotonic acid hydrochloride (101a): A solution of sodium hydroxide (856 mg, 21.4 
mmol) in water (6.3 mL) was added to a solution of methyl ester 100a (3.07 g, 21.4 mmol) in MeOH 
(25 mL). The resulting reaction mixture was heated to 50°C for 1 h. After being cooled to RT, the 
solution was acidified with hydrochloric acid (5.0M) to pH 1-2 and concentrated in vacuo to a thick 
oil. Anhydrous ethanol (25 mL) was added and the white precipitate of sodium chloride was removed 
by filtration. The filtrate was concentrated in vacuo and product precipitation was induced by the 
addition of iPrOH (13 mL) and overnight storing at -20°C. The resulting precipitate was filtered and 
dried under high vacuum to afford the title compound (1.12 g, 6.8 mmol, 32%) as an off white solid. 
1H NMR (300 MHz, D2O)  = 6.97-6.84 (m, 1H), 6.31 (d, 1H, J = 15.6 Hz), 3.99 (d, 2H, J = 7.2 Hz), 2.94 
ppm (s, 6H); HRMS: calcd. for C6H12NO2 [M+H]
+: 130.0863, found: 130.0857. 
 
4-(Dimethylamino)butyric acid hydrochloride (101b): A solution of ethyl ester 100b (627 mg, 3.94 
mmol) in MeOH (5 mL) was treated with sodium hydroxide (4 mL, 4.0M). The resulting reaction 
mixture was heated to 50°C for 6 h. After being cooled to RT, the solution was acidified with 
hydrochloric acid (4.0M) to pH 1-2 and concentrated in vacuo. The residue was coevaporated with 
toluene (3 × 10 mL) and dried overnight under high vacuum to afford the title compound (3.94 mmol, 
considered quant.) as a white solid. 1H NMR (300 MHz, D2O)  = 3.23 (t, 2H, J = 8.3 Hz), 2.94 (s, 6H), 
2.55 (t, 2H, J = 7.2 Hz), 2.11-2.00 ppm (m, 2H); HRMS: calcd. for C6H14NO2 [M+H]
+: 132.1019, found: 
132.1023. 
 
Alkyne-functionalized afatinib (102a): 2-Chloro-1-methylpyridinium iodide (Mukaiyama’s reagent) 
(618 mg, 2.42 mmol) and Et3N (642 µL, 4.61 mmol) were added to a solution of acid 101a (381 mg, 
2.30 mmol) in CH2Cl2 (3.5 mL). The resulting preactivation mixture was refluxed for 25 min. 
Subsequently, a solution of aniline 98 (142 mg, 0.383 mmol) in DMF (2 mL) was added to this mixture 
and stirring was continued for 50 h at 60°C. After being cooled to RT, the reaction mixture was 
concentrated in vacuo. To the residue were added EtOAc (10 mL) and sat. NaHCO3 (10 mL) and the 
biphasic mixture was agitated until the residue was completely dissolved and transferred to a 
separation funnel. The aqueous layer was separated and next backwashed with EtOAc (20 mL), after 
which all EtOAc fractions were pooled, dried over Na2SO4, and concentrated in vacuo. The residue 
was purified by preparative RP-HPLC (15-30% MeCN) yielding the title compound (55.2 mg, 115 
μmol, 30%) as a pale yellow amorphous solid. 1H NMR (300 MHz, SO(CD3)2)  = 9.80 (s, 1H), 9.49 (s, 
1H), 8.91 (s,1H), 8.53 (s, 1H), 8.14 (dd, 1H, JH-F = 6.9 Hz, J = 2.4 Hz), 7.81 (ddd, 1H, J = 9.0 Hz, JH-F = 4.3 
Hz, J = 2.4 Hz), 7.42 (dd, 1H, J = JH-F = 9.0 Hz), 7.28 (s, 1H), 6.81 (dt, 1H, J = 15.4 Hz, J = 5.9 Hz), 6.57 (d, 
1H, J = 15.4 Hz), 4.28 (t, 2H, J = 6.2 Hz), 3.10 (d, 2H, J = 5.9 Hz), 2.84 (t, 1H, J = 2.6 Hz), 2.45 (dt, 2H, J = 
7.1 Hz, J = 2.6 Hz), 2.19 (s, 6H), 2.08-1.97 ppm (m, 2H); LC-HRMS: tR = 5.64 min (10-100% MeCN, 15 
min run); HRMS: calcd. for C25H26ClFN5O2 [M+H]
+: 482.1754, found: 482.1748. 
 
Alkyne-functionalized dihydro-afatinib (102b): 2-Chloro-1-methylpyridinium iodide (Mukaiyama’s 
reagent) (368 mg, 1.44 mmol) and Et3N (482 µL, 3.46 mmol) were added to a solution of acid 101b 
(290 mg, 1.73 mmol) in CH2Cl2 (3.0 mL). The resulting preactivation mixture was refluxed for 45 min. 
Subsequently, a solution of aniline 98 (142 mg, 0.383 mmol) in DMF (1.5 mL) was added to this 
mixture and stirring was continued for 19 h at 60°C. After being cooled to RT, the reaction mixture 
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was concentrated in vacuo. To the residue were added EtOAc (10 mL) and sat. NaHCO3 (10 mL) and 
the biphasic mixture was agitated until the residue was completely dissolved and transferred to a 
separation funnel. The aqueous layer was separated and next backwashed with EtOAc (20 mL), after 
which all EtOAc fractions were pooled, dried over Na2SO4, and concentrated in vacuo. The residue 
was purified by silica gel chromatography (MeOH/CH2Cl2 0-6%, v/v with 0.1% NH4OH) yielding the 
title compound (97.8 mg, 202 µmol, 53%) as a white amorphous solid. 1H NMR (300 MHz, CDCl3)  = 
9.02 (s, 1H), 8.63 (s, 1H), 8.47 (s, 1H), 7.89 (dd, 1H, JH-F = 6.6 Hz, J = 2.7 Hz), 7.78 (s, 1H), 7.51 (ddd, 1H, 
J = 9.0 Hz, JH-F = 4.2 Hz, J = 2.7 Hz), 7.24 (s, 1H), 7.11 (dd, 1H, J = JH-F = 9.0 Hz), 4.32 (t, 2H, J = 6.2 Hz), 
2.58 (t, 2H, J = 7.2 Hz), 2.51-2.42 (m, 4H), 2.30 (s, 6H), 2.21-2.11 (m, 2H), 2.11 (t, 1H, J = 2.7 Hz), 2.01-
1.90 ppm (m, 2H); 13C NMR (75 MHz, CDCl3)  = 172.0, 156.8, 154.8 (JC-F = 245.0 Hz), 154.5, 152.1, 
148.4, 135.3 (JC-F = 3.5 Hz), 128.1, 124.2, 121.8 (JC-F = 6.9 Hz), 121.0 (JC-F = 19.5 Hz), 116.5 (JC-F = 21.8 
Hz), 109.7, 109.4, 107.6, 83.0, 69.9, 68.1, 58.2, 45.3, 35.5, 27.6, 22.9, 15.6 ppm; LC-HRMS: tR = 5.42 
min (10-100% MeCN, 15 min run); HRMS: calcd. for C25H29ClFN5O2 [M+2H]
2+: 242.5991, found: 
242.5984. 
 
Afatinib TFC (103a): The second-generation TMP-N3 reagent 40
 (21.6 mg, 37.5 µmol, 1.5 eq.) was 
taken up in DMF (760 µL), and alkyne 102a (12.1 mg, 25 µmol, 1.0 eq.), CuSO4 (100 μL, 0.05M, 0.2 
eq.), Na ascorbate (50 μL, 0.5M, 1.0 eq.), and Et3N (10.5 µL, 75 µmol, 3.0 eq.) were added. The 
resulting mixture was charged with a catalytic amount of TBTA[50] and vigorously stirred at RT for 16 
h. The solution was concentrated in vacuo and the residue was purified by preparative RP-HPLC (10-
100% MeCN) yielding the title compound (15.1 mg, 14 μmol, 56%) as an off white amorphous solid. 
LC-HRMS: tR = 5.23 min (10-100% MeCN, 15 min run); HRMS: calcd. for C51H68ClFN13O9 [M+3H]
3+: 
353.4973, found: 353.4913. 
 
Dihydro-afatinib TFC (103b): The second-generation TMP-N3 reagent 40 (42.4 mg, 73.5 µmol, 1.5 eq.) 
was taken up in DMF (1.5 mL), and alkyne 102b (23.5 mg, 49 µmol, 1.0 eq.), CuSO4 (196 μL, 0.05M, 
0.2 eq.), Na ascorbate (98 μL, 0.5M, 1.0 eq.), and Et3N (20.5 µL, 147 µmol, 3.0 eq.) were added. The 
resulting mixture was charged with a catalytic amount of TBTA[50] and vigorously stirred at RT for 16 
h. The solution was concentrated in vacuo and the residue was purified by preparative RP-HPLC (10-
100% MeCN) yielding the title compound (35.8 mg, 34 μmol, 69%) as an off white amorphous solid. 
LC-HRMS: tR = 5.24 min (10-100% MeCN, 15 min run); HRMS: calcd. for C51H70ClFN13O9 [M+3H]
3+: 
354.1692, found: 354.1663. 
 
4-(3-Chloro-4-fluorophenylamino)-7-hydroxy-6-(3-morpholinopropoxy)quinazoline (104): Gefitinib 
(1.00 g, 2.24 mmol) was added batchwise to neat liquid pyridinium chloride (3.88 g, 33.6 mmol) at 
170°C over 10 min and the resulting reaction mixture was gently stirred at 170°C for 3 h. After being 
cooled to RT, the resulting solid was taken up in water (30 mL) and the pH was increased to 7 using 
ammonium hydroxide. The neutral solution was concentrated in vacuo and the residue was purified 
by silica gel chromatography (MeOH/CH2Cl2 0-20%, v/v) yielding the title compound (742 mg, 1.71 
mmol, 76%) as a brown foam. 1H NMR (300 MHz, SO(CD3)2)  = 10.42 (br s, 1H), 8.55 (s, 1H), 8.28 (s, 
1H), 8.23 (d, 1H, JH-F = 5.1 Hz), 7.98-7.86 (m, 1H), 7.45 (dd, 1H, J = JH-F = 8.7 Hz), 7.22 (s, 1H), 4.41-4.27 
(m, 2H), 3.96-3.84 (m, 4H), 3.40-3.13 (m, 6H), 2.36-2.21 ppm (m, 2H); HRMS: calcd. for C21H23ClFN4O3 
[M+H]+: 433.1437, found: 433.1423. 
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Alkyne-functionalized gefitinib (105): A solution of di-tert-butyl azodicarboxylate (DBAD) (213 mg, 
924 µmol, 4.0 eq.) in THF (1.0 mL) was added dropwise to a solution of phenol 104 (100 mg, 231 
µmol, 1.0 eq.), 4-pentynol (54 µL, 578 µmol, 2.5 eq.), and triphenylphosphine (242 mg, 924 µmol, 4.0 
eq.) in THF (1.5 mL) at 0°C over 5 min. The resulting reaction mixture was allowed to warm to RT and 
subsequently heated to 70°C for 21 h. After being cooled to RT, the solution was concentrated in 
vacuo and the residue was purified by silica gel chromatography (MeOH/CH2Cl2 0-5%, v/v with 0.1% 
NH4OH) yielding the title compound (65.3 mg, 131 µmol, 57%) as a white amorphous solid. 
1H NMR 
(300 MHz, CDCl3)  = 8.65 (s, 1H), 7.87 (dd, 1H, JH-F = 6.6 Hz, J = 2.7 Hz), 7.54 (ddd, 1H, J = 8.9 Hz, JH-F = 
4.1 Hz, J = 2.7 Hz), 7.40 (s, 1H), 7.25 (s, 1H), 7.15 (dd, 1H, J = JH-F = 8.9 Hz), 7.11 (s, 1H), 4.23 (t, 2H, J = 
6.2 Hz), 4.14 (t, 2H, J = 6.5 Hz), 3.74 (t, 4H, J = 4.7 Hz), 2.57 (t, 2H, J = 7.1 Hz), 2.49 (t, 4H, 4.7 Hz), 2.46 
(dt, 2H, J = 6.9 Hz, J = 2.7 Hz), 2.16-2.02 (m, 4H), 1.99 ppm (t, 1H, J = 2.7 Hz); 13C NMR (75 MHz, CDCl3) 
 = 156.2, 154.9 (JC-F = 245.0 Hz), 154.8, 153.5, 149.5, 147.7, 135.4 (JC-F = 3.5 Hz), 124.2, 121.8 (JC-F = 
6.8 Hz), 121.2 (JC-F = 18.4 Hz), 116.7 (JC-F = 21.8 Hz), 108.99, 108.91, 100.9, 83.1, 69.4, 67.7, 67.2, 67.1, 
55.6, 53.9, 27.9, 26.3, 15.3 ppm; HRMS: calcd. for C26H29ClFN4O3 [M+H]
+: 499.1907, found: 499.1912. 
 
Gefitinib TFC (106): The second-generation TMP-N3 reagent 40
 (43.2 mg, 75 µmol, 1.5 eq.) was taken 
up in DMF (1.5 mL), and alkyne 105 (24.9 mg, 50 µmol, 1.0 eq.), CuSO4 (200 μL, 0.05M, 0.2 eq.), Na 
ascorbate (100 μL, 0.5M, 1.0 eq.), and Et3N (20.9 µL, 150 µmol, 3.0 eq.) were added. The resulting 
mixture was charged with a catalytic amount of TBTA[50] and vigorously stirred at RT for 16 h. The 
solution was concentrated in vacuo and the residue was purified by preparative RP-HPLC (10-100% 
MeCN) yielding the title compound (40.2 mg, 37 μmol, 74%) as an off white amorphous solid. LC-
HRMS: tR = 5.29 min (10-100% MeCN, 15 min run); HRMS: calcd. for C52H71ClFN12O10 [M+3H]
3+: 
359.1691, found: 359.1676. 
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V.7.2. Molecular biology 
 
Performed by the Cytokine Receptor Laboratory, Department of Medical Protein Research, VIB, Ghent 
& Department of Biochemistry, Faculty of Medicine and Health Sciences, Ghent University (Prof. Jan 
Tavernier, Dr. Sam Lievens). 
 
Plasmid constructs: The pCLL-eDHFR and pCLG-eDHFR plasmids expressing a fusion of the partial 
leptin receptor fused to the E. coli dihydrofolate reductase enzyme have been described 
previously,[51] as have the pMG1C-ER1,[52] and pMG1-RNF41[53] prey plasmids. Other prey constructs 
encoding C-terminal fusions of a protein (domain) of interest with a gp130 receptor fragment 
containing functional STAT3 recruitment sites were generated by Gateway mediated transfer of the 
corresponding entry clones in the Gateway-compatible pMG1 prey destination vector as reported 
earlier.[54] Gateway entry vectors harboring partial sequences corresponding to human EGFR were 
produced by PCR amplifying the region C-terminal of AA669 (for the cytoplasmic domain; primers 
used were 5’-GGGGACAACTTTGTACAAAAAAGTTGGCACCATGCGAAGGCGCCACATCGTTCG-3’ and 5’-
GGGGACAACTTTGTACAAGAAAGTTGGCAATGCTCCAATAAATTCACTGC-3’) or covering AA696-AA1022 
(for the kinase domain; primers used were 5’-GGGGACAACTTTGTACAAAAAAGTTGGCACCATGGGAGA-
AGCTCCCAACCAAGC-3’ and 5’-GGGGACAACTTTGTACAAGAAAGTTGGCAAGCCCTGCTGTGGGATGAGG-
TAC-3’) and Gateway BP recombination into the pDONR223 vector, as reported.[55] All other prey 
constructs were derived from full size human ORF entry clones available in the hORFeome v8.1 
collection.[55] Also the STAT3-dependent firefly luciferase reporter pXP2d2-rPAPI-luciferase has been 
described before.[56] 
 
MASPIT assays: For standard MASPIT assays, HEK293T cells were cultured in 96-well microtiter plates 
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal calf serum, incubated 
at 37°C, under 8% CO2, and transfected with pCLL-eDHFR or pCLG-eDHFR fusion protein plasmid (10 
ng per well), either of the prey plasmids (100 ng per well) and pXP2d2-rPAPI-luciferase (5 ng per well) 
by applying a standard calcium phosphate transfection method, as described earlier.[54] Twenty-four 
hours after transfection, cells were stimulated with leptin (100 ng/mL final concentration) alone or in 
combination with the indicated concentration of fusion compound. After another 24 h, luciferase 
activity was measured by using the Luciferase Assay System kit (Promega) on an Envision plate 
reader (PerkinElmer). Luciferase data represent the average of three technical replicates; error bars 
indicate standard deviation. 
A similar procedure was followed in the MASPIT UV irradiation experiment, except for the following 
modifications: twenty-four hours after transfection, media was changed for serum-supplemented 
DMEM lacking phenol red and cells were treated with the fusion compound in the absence of leptin; 
another 24 h later, cells were irradiated with UV at 245nm or 365nm for the indicated time (Benda 
NU-8 KL handheld UV lamp; 2x8W), after which media was changed for serum-supplemented DMEM 
containing phenol red and additionally supplemented with leptin (100 ng/mL final concentration); 
luciferase activity was measured another 24 h later. 
In MASPIT competition assays, cells were transfected according to the protocol described above, 
with a combination of the pCLG-eDHFR fusion protein plasmid (10 ng per well), either pMG1-RNF41 
or pMG1C-ER1 (10 ng per well), and the luciferase reporter plasmid (5 ng per well). Twenty-four 
hours after transfection, cells were treated with a combination of either leptin alone (100 ng/mL final 
concentration) or leptin combined with TMP-tamoxifen (0,1 µM final concentration) and the 
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indicated concentration of the competing molecule (tamoxifen, trimethoprim, simvastatin, TMP-
simvastatin, TMP-afatinib, TMP-dihydro-afatinib or TMP-gefitinib). Luciferase activity was measured 
another 24h later, as described above. 
 
ERK phosphorylation assay: HEK293T cells were seeded at 200.000 cells/well in 6-well plates in 
DMEM supplemented with 10% fetal calf serum and grown as in the case of the MASPIT assays. 
Forty-eight hours after seeding, medium was replaced by DMEM supplemented with 1% fetal calf 
serum and cells were treated with the indicated small molecule concentration, all diluted from 
10mM 100% DMSO stocks. For each of the applied concentrations, the corresponding amount of 
pure DMSO was taken along as control. Sixteen hours later, cells were stimulated with human EGF 
(50 ng/mL final concentration) for 5 minutes. Next, cells were rinsed with PBS and lysed in Laemmli 
lysis buffer at 4°C. Lysates were cleared by centrifugation, heated for 5 min at 95°C and subjected to 
SDS/PAGE on a 12% gel. After blotting, total and phosphorylated ERK1/2 were revealed using mouse 
anti-ERK1/2 (Cell Signaling Technologies #4696) and rabbit anti-phospho-ERK1/2 (Cell Signaling 
Technologies #9101) antibodies combined with appropriately infrared dye-labeled secondary 
antibodies on a LiCor Odyssey infrared imager. 
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VI. General Conclusion 
 
As a starting point, we developed a scalable synthesis of a versatile MTX reagent comprising a tetra-, 
hexa-, or octa(ethylene glycol) linker and an azide ligation handle (6a-c) that enabled rapid -selective 
generation of MFCs from alkyne-functionalized small-molecule baits (such as tamoxifen, reversine, 
FK506 and simvastatin) using CuAAC (Figure VI.1, panel A). This modular strategy allowed swift 
access to various MFCs, thereby minimizing the number of chemical manipulations for each 
construct. In analytical mode, MASPIT was able to give concentration-dependent reporter signals for 
the established target proteins of these model baits. Furthermore, we demonstrated that the 
sensitivity obtained with the newly developed MTX reagent was significantly stronger than that of a 
previously used non-regiomeric conjugate mixture. 
 
 
 
Figure VI.1: Schematic overview of strategies and building blocks applied to the synthesis of chemical 
dimerizers for the optimization of MASPIT. 
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Although the optimal spacer length may be determined by the nature of the prey and no significant 
differences in readout were observed upon evaluation of tamoxifen MFCs comprising the linkers 
mentioned above, we decided to apply the intermediate PEG6 throughout our different optimization 
approaches. Likewise, a comparable reporter activity pattern was obtained for an alternative 
tamoxifen-based MFC synthesized via amide conjugation. Finally, in a pilot cellular array screen, 
FKBP12 was selectively identified as an interaction partner of FK506, thereby validating the MASPIT 
system. 
 
Subsequently, evaluation of first-generation TMP fusion compounds with tamoxifen, reversine, and 
simvastatin as model baits, resulted in dose-response curves shifted towards lower EC50 values than 
those of their MTX congeners. Hence, these data clearly implied a successful improvement in the 
MASPIT system’s sensitivity by introducing TMP as an alternative immobilizing anchor moiety. 
Furthermore, a scalable second-generation TMP-azido reagent (40) was synthesized that displayed a 
similar improvement in sensitivity, possibly owing to increased membrane permeability relative to 
the MTX anchor, as assessed by the differential cellular uptake of TMP- vs. MTX-linked BODIPY 
fluorophores (Figure VI.1, panel B). Moreover, next to its superior behavior in the MASPIT assay, 40 
offered a number of important advantages over the existing MTX anchor from a chemical 
perspective. 
 
Applying the SNAP-tag approach to stabilize the ternary complex via introduction of covalent 
bonding on the CR-hAGT chimeric anchor protein side, on the other hand, produced an inferior 
readout than in the MTX- or TMP-tag based assay. Additionally, the required BG-PEG6-N3 reagent (51) 
suffered from intrinsic thermal degradation issues, making it less attractive than the optimized TMP 
reagent. 
 
Furthermore, MASPIT evaluation of the heterotrimeric PAL probes, comprising TMP, TAM and a 
BP/AA/DZ photophore, aimed at establishing covalent immobilization on the bait-end of the 
dimerizer, turned out to be less straightforward than anticipated (Figure VI.1, panel C). Upon 
extensive testing of these photocrosslinkers against a panel of target preys in MASPIT, no increase in 
luciferase signal was detected after photoexcitation, and clear-cut proof of effective 
photocrosslinking remained forthcoming.  
 
Finally, we experienced some unexpected difficulties upon evaluating the EGFR kinase inhibitor-
based test system that would enable the assessment of the actual contribution of a covalent linkage 
on the bait-end of the dimerizers with respect to the MASPIT readout. As yet, we faced a clear 
discrepancy between the results obtained from the radiometric kinase assay/competition 
experiments on the one hand, and the MASPIT/pERK WB assays on the other. Whereas the first two 
analyses clearly demonstrated the high in vitro potency/effective cellular uptake of the EGFR kinase 
inhibitor TFCs, the latter curiously failed to show any MASPIT activity for the reversible inhibitor 
probes/any cellular functional effects for all TMP conjugates. Therefore, the interaction of these 
kinase inhibitor probes with alternative targets in MASPIT will be explored. 
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VII. Broader International Context, Relevance, and Future Perspectives 
 
VII.1. Context: Target Deconvolution and Drug Discovery 
 
To date, merely approximately 2% of all predicted human proteins have been successfully targeted 
with small-molecule drugs, whereas the fraction of druggable proteins is estimated at 10-15%.[1] 
Likewise, it is sobering to consider that most new drugs are directed toward a small number of 
targets, representing only selected protein classes - the so-called ‘usual suspects’ - i.e. G protein-
coupled receptors (GPCRs), kinases, proteases and ion channels.[2] Hence, it is believed that many 
potential therapeutic targets probably remain untapped. Ironically, the discovery of such novel, 
validated targets is currently an important bottleneck in drug discovery research, since a generally 
applicable methodology is still lacking.[1],[3] 
 
Undoubtedly, there is a clear rationale for identifying the target spectrum of bioactive small 
molecules. For instance, target profiling technologies contribute to deciphering the mechanism of 
action (MOA) of leads, thereby supporting chemical optimization programs while providing a 
polypharmacological framework[4] for anticipating potential efficacy or toxicity-related later-stage 
attrition. Alternatively, these methods also allow to identify potential novel therapeutic applications 
of established drugs within the scope of drug repositioning projects.[5]  
 
At present, the most frequently employed strategies to protein target identification include genomic 
(gene expression-based), genetic (short hairpin RNA and ORF screening), and proteomic 
approaches.[6],[7],[1] Classical mass spectrometry-based proteomics, analyzing relative protein 
abundance in a drug-treated versus control cell sample, accounts for both protein expression and 
degradation, hence making this approach particularly valuable in drug target discovery.[8] In this 
respect, the recently disclosed Functional Identification of Target by Expression Proteomics (FITExP) 
method might have the potential of becoming an important tool in small-molecule target 
deconvolution.[9] 
 
In practice, chemical proteomics-based techniques, which mainly comprise a compound-centric 
approach and activity-based protein profiling (ABPP), are far more widely applied compared to 
elaborated genetic methods.[10],[1] An important limitation of ABPP with respect to target 
identification is its inherent restriction to the detection of members of a specific class of enzymes 
(such as proteases, glycosidases, hydrolases, phosphatases) that are active under certain conditions, 
for example in a particular disease state. Compound-centric chemical proteomics (CCCP), on the 
other hand, consists of classical affinity chromatography (pulldown) combined with high-resolution 
mass spectrometric (MS) analysis, followed by protein database mining and further bioinformatics 
for subsequent identification of binding partners.  
 
Despite significant technological advances in quantitative MS approaches,[11],[12] affinity-based 
proteomics however continues to be labor-intensive, time-consuming and prone to artifacts, as it 
often fails to reveal physiologically relevant interactions. In fact, significant triage and additional 
(de)validation is required to identify the actual target(s) from the extensive list of candidates (often 
exceeding 500) typically resulting from such experiments.[13] In addition, sensitivity can be an 
important limiting factor, for instance, if the small molecule exhibits low binding affinity for its target 
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protein or if the target of interest is endogenously expressed at low levels. In these cases, the target 
protein is lost during the stringent washing steps, or its binding is obscured by the presence of highly 
abundant (non-specifically binding) background proteins.[14] Furthermore, the target proteins might 
suffer from stability issues under the classical in vitro conditions of chemical proteomics experiments, 
possibly resulting in the loss of their three-dimensional structure.[1] More than that, the protein 
target might be missing owing to the nature as well as the preparation conditions of the cell or tissue 
lysate.[13] Finally, although seemingly straightforward, the required immobilization of the small 
molecule of interest onto the solid support is a challenging task and represents one of the major 
disadvantages of pulldown approaches.  
 
As a result, there has been an interest in the development of label-free chemical proteomics 
techniques, not necessitating any chemical modification of the small molecule of interest. Two such 
strategies, DARTS (drug affinity responsive target stability)[15] and SPROX (stability of proteins from 
rates of oxidation),[16] are based upon changes in thermodynamic stability resulting from a small 
molecule-target protein interaction. More specifically, DARTS relies on the concept that a target 
protein bound to a small molecule is more resistant to proteolysis compared to its unbound state.[17] 
SPROX, on the other hand, exploits chemical denaturant-dependent oxidation rates of methionine 
residues to study protein-ligand interactions. The approach is based on the finding that ligand-bound 
proteins are less susceptible to oxidation, hence requiring higher concentrations of denaturant to 
afford the same oxidation state as compared to non-binders.[18] Consequently, the application scope 
of the SPROX methodology is inherently restricted to proteins that contain methionine residues in 
their ligand-binding site. Moreover, both techniques might be limited by the binding affinity of the 
drug to its target, target protein abundance and sensitivity of detection by MS, as in the case of 
affinity chromatography. 
 
Hence, to circumvent these limitations, several expression-cloning-based methods, such as yeast[19] 
and mammalian[20] three-hybrid systems, phage display,[21] and mRNA display[22] have been 
developed in the last decades. Collectively, these functional cloning technologies exploit the artificial 
overexpression of target proteins from cDNA libraries to overcome the above-mentioned potential 
sensitivity issues related to endogenous expression levels in proteomic methods. The last two display 
technologies have a number of features in common with classical pulldown approaches, including 
exposure of a target protein collection to the immobilized small-molecule drug, affinity-based target 
binding, washing of non-binders and elution of specific interaction partners. In the case of phage 
display, a cDNA library is fused to a phage coat protein encoding gene, so as to display candidate 
target proteins on the phages’ surface.[21] Alternatively, in mRNA display, potential target proteins 
are expressed as a fusion to their corresponding mRNAs via a DNA-puromycin linker.[22] 
 
Both phage and mRNA display benefit from the iterative amplification steps (by transfection into a 
bacterial host or by PCR, respectively), thus enabling the identification of low-abundance targets and 
of targets of low-affinity ligands.[14] Disadvantages include the lack of post-translational modifications 
(PTMs) and the potentially inefficient expression of the target proteins or their improper folding. 
Furthermore, a prerequisite for phage display is that the coding sequence of the target protein is in-
frame with the one of the phage coat protein.[1] Alternatively, mRNA display might suffer from 
inefficient mRNA fusion or from the generation of short-length transcripts leading to the 
identification of protein fragments instead of full-length polypeptides.[14] In general, phage display is 
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more widely adopted[23],[24],[25],[26] compared to its mRNA congener, which hasn’t been applied since 
its initial proof-of-concept study[22] more than a decade ago. 
 
Rather than the in vitro pulldown and display techniques, three-hybrid systems operate in the 
physiologically relevant context of an intact cell. In the case of mammalian three-hybrid assays, this 
can be a human cell, which is the native background of the targeted protein(s) and the context in 
which the future drug will operate. Consequently, normal protein conformation is conserved and 
furthermore this might reveal potential effects of PTMs of the target or of the target’s association 
with additional proteins or other intracellular molecules on small molecule binding. Another 
advantage of 3H systems includes their generality since they function regardless of the nature of 
both the small-molecule drug and the candidate target proteins. Moreover, 3H systems comprise 
unbiased screening approaches, which are not restricted to a limited panel of related proteins but 
cover a broad area of the human proteome.  
 
Additionally, once a target protein for a small molecule of interest is identified, 3H systems provide 
an interesting binary small molecule-target assay, which allows for the evaluation of structural 
variations of either partner. More specifically, focusing first on the small molecule side, structure-
activity relationships can be delineated, e.g. during lead optimization, based on the side-by-side 
comparison of analogue series via competition experiments. Hence, unfused small molecules can be 
ranked with respect to their in cell target binding affinity, as exemplified earlier for a series of 
antiplasmodial fumarranol analogues (see Chapter 1).[27] Alternatively, by creating and screening a 
systematic collection of target protein point mutants against a specific small-molecule bait, their 
interaction interface can be carefully mapped. This might provide additional structural information 
facilitating medicinal chemistry and drug design campaigns. 
 
A final specific asset of the MASPIT screening platform includes its high throughput, which ensures 
rapid turnaround times (screen and hit validation in four weeks’ time) and flexibility with regard to 
parallel screens (up to ten per week) or iterative rounds of screening compound analogues during a 
hit or lead optimization process.  
 
However, as for every other target identification methodology, 3H approaches display some inherent 
limitations. For example, a major disadvantage of 3H methods includes the necessity to derivatize 
the small molecule of interest, as in the case of most chemical proteomics-based methods. Toward 
this end, extensive knowledge of the structure-(phenotypic) activity relationship (SAR) of the 
compound is needed and the process often requires elaborate chemistry efforts to identify a 
conjugation site on the molecule that tolerates modification without significant loss in binding 
affinity to the target protein(s). Additionally, the application of 3H systems is hampered in case the 
conjugated small-molecule drug exhibits variable or limited cellular uptake. Furthermore, most 3H 
methods, including MASPIT, are not compatible with the detection of (full size) transmembrane 
proteins. 
 
A limitation that specifically applies to MASPIT is that compounds which exhibit affinity for any of the 
proteins involved in the JAK/STAT pathway might compromise the assay readout and hence are not 
compatible with the approach (e.g. a broad spectrum kinase inhibitor might inhibit JAK2 kinase 
activity). Additional disadvantages of MASPIT relate to the current target protein collection, which is 
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not complete (15,000 human ORFs versus 22,000 human genes defined) and contains only one 
splice variant for the majority of genes. 
 
VII.2. Relevance 
 
Although the number of published reports describing the application of three-hybrid systems in an 
actual drug discovery context is rather confined, these papers clearly demonstrate the potential of 
three-hybrid approaches to uncover the molecular targets of drugs and lead compounds. Major 
contributions to the field have been made by the Kley,[28],[20] Cornish,[29] and Johnsson[30],[31] groups. 
Undoubtedly, these successful de novo small-molecule target identification studies opened up 
intriguing insights into the mechanisms of action of both drug candidates and clinically approved 
drugs, thereby potentially providing explanations for off-target-related side effects and suggesting 
new or improved therapeutic applications. Moreover, 3H systems should prove useful for uncovering 
yet unidentified targets that contribute to the efficacy of known drugs. 
 
For example, the discovery that sulfasalazine interferes with BH4 metabolism might explain some of 
its adverse effects related to changes in the concentration of neurotransmitters dependent on this 
cofactor.[30] Accordingly, this realization allows to set up hypotheses to alleviate these side effects, 
for instance by adjunct therapy with agents that would restore a correct neurotransmitter balance. 
Furthermore, considering sulfasalazine’s specific inhibition of BH4 biosynthesis, this drug might be 
qualified for repurposing for other therapeutic applications, such as the suppression of chronic pain 
in cancer patients. Other examples highlighting the utility of 3H screening in drug MOA studies 
include the work by Caligiuri et al. and Odell et al.[32],[33] In the former study, the authors applied Y3H 
to explore the pharmacological properties and therapeutic potential of compounds derived from a 
trisubstituted pyrazolopyrimidinone CDK kinase inhibitor scaffold. Odell et al. recently used a Y3H 
screen to study the proteins and mechanisms involved in stage conversion in T. gondii, ultimately 
aiming at the development of new approaches to prevent the establishment of chronic infection. 
 
Y3H screenings are also being offered as a commercial compound profiling service, e.g. by the 
company Hybrigenics Services[34] who acquired the three-hybrid activities of Dualsystems Biotech AG, 
which had formerly significantly contributed to the field.[29],[35] Also our research group has offered 
small molecule-target protein profiling services applying the MASPIT human cell array screening 
platform. The chemistry that was developed in this project has been applied to both internal drug 
repositioning projects with academic partners, and to fee-for-service collaborations with pharma 
companies. 
 
VII.3. Recommendations and Contributions 
 
While methotrexate-eDHFR has been the most extensively applied CID pair in the 3H field, currently 
two other prominent anchor moieties serve as useful starting points for compound profiling 
campaigns. First, based on our own experience in the design and synthesis of CIDs for the 
optimization of MASPIT, trimethoprim comprises a valuable alternative for MTX and in fact offers a 
number of important advantages over the latter, including significantly higher membrane 
permeability, increased solubility as well as compatibility with various reaction conditions, and lack of 
chirality (see Chapter 4). Second, the introduction of O6-benzylguanine-hAGT (SNAP-tag) by the 
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Johnsson group, enabling screening of covalently anchored small-molecule baits, has proven a 
significant advance in the field.[30],[36]  
 
Taken together, in this work we contributed to enriching the toolbox of chemical dimerizers for 
three-hybrid applications with two innovations. First, we introduced scalable syntheses of versatile 
methotrexate- and trimethoprim-azido reagents that allow for the modular and practical generation 
of CIDs compatible with DHFR-based 3H systems from any alkyne-functionalized small molecule of 
interest using click chemistry. Second, we were the first to explore the concept of photocrosslinking 
in the 3H field with the aim of introducing covalent bonding on the bait-end of the CID using 
heterotrimeric PAL probes.  
 
VII.4. Future Perspectives 
 
We anticipate that in the near future, the 3H field will further focus on the implementation of ligand-
receptor CID pairs that enable establishing covalent immobilization of bait small molecules, following 
a trend that has also been seen for chemical protein labeling techniques. In the following two 
subsections alternative suggestions for anchor moieties and conjugation methodologies are 
discussed (Figure VII.1). 
 
VII.4.1. Anchor moieties 
 
Next to the ligand-receptor pairs used in three-hybrid systems to date (see Chapter 1), a number of 
alternative anchor moieties might be considered as suitable immobilization reagents (Figure VII.1). 
These predominantly originate from a limited number of irreversible, orthogonal covalent chemical 
tags, which were introduced in recent years. In order to render the TMP-tag covalent, the Cornish 
group designed an eDHFR variant (eDHFR:L28C) with a unique cysteine nucleophile positioned just 
outside the TMP-binding pocket to react with an acrylamide electrophile installed on the TMP-probe 
(A-TMP) via a proximity-induced Michael addition.[37],[38],[39] Furthermore, the substrate scope of the 
SNAP-tag labeling technology implemented in 3H systems could be extended to O4-benzyl-2-amino-
6-chloropyrimidine (CP) conjugates, which have shown higher cell permeability compared to the 
corresponding benzylguanine derivatives.[40] Alternatively, the specific labeling of fusion proteins 
based on the irreversible reaction of O2-benzylcytosine (BC) derivatives with an engineered AGT 
mutant, coined CLIP-tag, might be explored.[41] Finally, yet another modular protein tagging system, 
i.e. HaloTag, should prove useful for covalently immobilizing small molecules of interest, originally 
attached to a chloroalkane linker, onto a modified haloalkane dehalogenase chimera.[42] Lastly, one 
could rely on biotin-based heterodimerizers and their quasi irreversible interaction with streptavidin 
(SA) fusions, which implies a reciprocal setup as described by Muddana et al.[43] or a comparable 
approach to the alternative Y3H system by Athavankar et al.[44] (see Chapter 1). 
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Figure VII.1: Alternative suggestions for anchor moieties and conjugation methodologies. Schematic non-
comprehensive overview of anchor moieties and conjugation methods applicable to the synthesis of chemical 
dimerizers as exemplified by TMP-TAM 40. All anchor moieties and conjugation methods (except for hydrazone 
ligation) listed, represent alternative examples that have not been applied in the context of three-hybrid 
studies to date. Anchor proteins are in brackets. SA, streptavidin. 
 
VII.4.2. Conjugation methodologies 
 
Besides the frequently employed conjugation chemistries described in Chapter 1, a range of 
alternative click-type modular fusion reactions could be applied (Figure VII.1). For instance, the 
toolbox of thiol-click reactions[45] (such as thiol-ene, thiol-yne, thiol-Michael) or (hetero-)Diels-Alder 
ligations,[46] encompassing [4+2] cycloadditions, might be exploited. Furthermore, one could envision 
the use of carbonyl-condensation reactions of the ‘non-aldol’ type, such as imine-, oxime- and 
hydrazone-bond formation.[47] An interesting recent example of the successful application of the 
latter conjugation reaction is provided by Moser and Johnsson,[31] describing the synthesis of BG 
derivatized rifampicin, among others, for target identification using an adapted SNAP-tag-based Y3H 
system (see Chapter 1). Finally, alternative amidation reactions, such as the Staudinger-Bertozzi 
ligation[48] or thio acid/sulfonyl azide amidation,[49] also denoted as sulfo-click,[50] could be 
appropriate for chemoselective CID construction. 
 
It is clear that three-hybrid systems have a great potential, both for de novo identification of small-
molecule targets and for analysis of specific compound-protein interactions. As more tools have 
become available that increase sensitivity and efficiency of 3H-based platforms, there is no doubt 
that this potential will materialize in important contributions to drug discovery. 
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